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Abstract 
Toward Understanding the Metabolic Pathway of Hydrogen Sulfide 
Scott L. Melideo 
Mentor: Marilyn Schuman Jorns, PhD  
 
 
 
 
 Hydrogen sulfide (H2S) is the most recently identified member of a small family 
of labile biological signaling molecules, termed gasotransmitters, which includes nitric 
oxide and carbon monoxide. H2S is the only gasotransmitter that is enzymatically 
metabolized a process that occurs in the mitochondria. H2S needs to be tightly regulated 
because it is toxic at high concentrations and leads to physiological defects at low 
concentrations. For example, a genetic defect that affects the metabolic pathway of H2S is 
ethylmalonic encephalopathy, a fatal disorder that is characterized by extremely high 
levels of H2S. On the other hand, animal model studies provide compelling evidence for a 
functional association between abnormally low levels of H2S and cardiovascular disease. 
In light of H2S’s critical role, the goal of this thesis was to identify and characterize two 
human enzymes that are proposed to comprise part of the metabolic pathway of H2S in 
mammals: Sulfide:quinone oxidoreductase (SQOR) and thiosulfate:glutathione 
sulfurtransferase (TST). 
 The present study postulates that human sulfide:quinone oxidoreductase (SQOR), 
a membrane-bound enzyme, catalyzes the first step in the mitochondrial metabolism of 
H2S. The reaction involves a two-electron oxidation of H2S to S0 (sulfane sulfur) and uses 
coenzyme Q as an electron acceptor. The fact that SQOR is a membrane-associated 
! xv!
protein has made its expression and isolation challenging. We successfully purified and 
characterized human SQOR. Cyanide, sulfite, or sulfide can act as the sulfane sulfur 
acceptor in reactions that produce thiocyanate, thiosulfate, or a putative sulfur analog of 
hydrogen peroxide (H2S2), respectively. Thiosulfate is a known intermediate in the 
oxidation of H2S within animals and the major product formed in glutathione-depleted 
cells or mitochondria. Importantly, oxidation of H2S by SQOR with sulfite as the sulfane 
sulfur acceptor is rapid and highly efficient at physiological pH (kcat/Km,H2S = 2.9 × 107 
M-1 s-1). We propose that this highly efficient oxidation of H2S by SQOR is the 
predominant source of the thiosulfate in mammalian tissues and that sulfite is the 
physiological acceptor of the sulfane sulfur. Our proposal opposes an alternative 
hypothesis that glutathione is an acceptor of the sulfane sulfur, which we have 
compelling evidence against.  
 The discovery that sulfite was the physiological acceptor of the sulfane sulfur and 
SQOR produced thiosulfate, led us to postulate a role in H2S metabolism for a TST that 
transfers the sulfane sulfur of thiosulfate to glutathione producing GSS- and sulfite. We 
postulate that the TST links together the SQOR and sulfur dioxygenase (SDO) steps in 
the pathway because it consumes the thiosulfate from the SQOR reaction and produces 
glutathione persulfide (GSS-), a substrate required for SDO. Although an active TST 
enzyme had been found in yeast, attempts by other laboratories to isolate and characterize 
the mammalian enzyme have been unsuccessful.  
 We also discovered genes that encode for human and yeast TST (TSTD1 and 
RDL1, respectively). We demonstrated that GSS- was released into solution and 
consumed by SDO. Additionally, GSS- is a potent inhibitor of TSTD1 and RDL1, as 
!xvi!
judged by initial rate accelerations and ≥25-fold lower Km values for glutathione observed 
in the presence of SDO. Our studies support the conclusion that TST is the missing link 
between the SQOR and SDO reactions.  
 The discovery of bacterial proteins that are fusions of SDO and TSTD1 provides 
phylogenetic evidence of the association of these enzymes. We successfully purified and 
characterized the fusion protein from Nitrosococcus oceani encoded by the gene 
Noc_2007. We showed that operationally, the fusion is a glutathione-dependent 
thiosulfate dioxygenase, which is the TST reaction followed by the SDO reaction. The 
thiosulfate dioxygenase reaction requires one mole of thiosulfate in the presence of 
oxygen to produce two moles of sulfite with a catalytic amount of glutathione. Lastly, the 
TST reaction is the apparent rate-limiting step in the thiosulfate dioxygenase reaction.  
 From this study, we propose a new pathway for H2S metabolism, which opens the 
door to future research.  
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Chapter 1: Introduction 
 
1.1 Biosynthesis of hydrogen sulfide  
 Hydrogen sulfide is the newest gasotransmitter, a family of gases that diffuse 
through membranes and act as biological signaling molecules. Nitric oxide (NO) and 
carbon monoxide (CO) are the only other known gasotransmitters. Their half-life can be 
on the order of seconds to minutes. Hydrogen sulfide exists in three forms: H2S, HS- (the 
predominant species at physiological pH) and S2-. For brevity, we will refer to the total 
pool as H2S or sulfide. H2S was initially regarded as the least important gasotransmitter, 
however the publication of more than 250 reviews on H2S within the last few years has 
proved otherwise. H2S is the only gasotransmitter that is enzymatically metabolized. 
Although the pathway for H2S metabolism is poorly understood, the three major 
biological sources of H2S are well characterized.  H2S biosynthesis enzymes, 
cystathionine β-synthase (CBS) and cystathionine γ-lyase (CSE) were originally 
discovered as part of the transsulfuration pathway. CBS produces H2S in a condensation 
reaction requiring cysteine and homocysteine and is the main producer of H2S in the 
brain. CSE is the major producer of H2S from cysteine in peripheral tissues. Another 
source of H2S production from cysteine is a pathway involving cysteine aminotransferase 
and 3-mercaptopyruvate sulfurtransferase (1). Although, H2S has physiological effects 
within mammals and plants, only the effects in mammals will be discussed. For more 
information on H2S’s role within plants please see a recent review by Hancock and 
Whiteman (2).  
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1.2 Mammalian metabolism of hydrogen sulfide  
 When radiolabeled H2S (H2S35) is injected subcutaneously in mammals, H2S is 
oxidized into radiolabeled organic sulfur compounds that are removed from the animal 
through the urine (3). One of those compounds, sulfate, produced by the oxidation of 
sulfite by sulfite oxidase, is the major product of H2S metabolism within the liver (4). 
Sulfite oxidase was originally studied because of its role in the oxidative degradation 
pathway of cysteine and methionine (5). Moreover, thiosulfate (SSO32−), is a known 
intermediate in the metabolic pathway of H2S to sulfate (SO42−) and is found within 
animals and perfused liver (4, 6-11). Thiosulfate is not only an intermediate in the 
pathway but can be a major product as shown within the colon of mammals, a tissue that 
must detoxify large amounts of H2S that are produced by sulfate-reducing bacteria (12, 
13). Furthermore, H2S oxidation to sulfate or thiosulfate has been shown to be dependent 
on glutathione (4, 7).   
1.3 Previously proposed pathways for hydrogen sulfide metabolism 
 Hildebrandt and Grieshaber proposed a pathway for the metabolism of H2S to 
thiosulfate in mammals and invertebrates based upon the knowledge at that time (14).  
The first step in the proposed mitochondrial metabolism of H2S is catalyzed by 
sulfide:quinone oxidoreductase (SQOR), an inner mitochondrial membrane-bound 
enzyme with a flavin adenine dinucleotide (FAD) cofactor, which catalyzes a two-
electron oxidation of H2S to sulfane sulfur (S0) using coenzyme Q as the electron 
acceptor (14-16). Reduced coenzyme Q can then be shunted to the electron transport 
chain, making H2S the only inorganic compound in mammals that can produce ATP via 
the electron transport chain (17). Within mammals SQOR requires an acceptor for the 
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sulfane sulfur, which was at the time unknown. Cyanide has been used as a substitute 
because it is known to be an acceptor of sulfane sulfur and produces thiocyanate, which 
can easily be quantified (14, 18-20). Hildebrandt and Grieshaber postulated that 
glutathione (GS-) is the physiological acceptor of the sulfane sulfur producing glutathione 
persulfide (GSS−) for the next step in the pathway (14). 
 Hildebrandt and Grieshaber postulated that the second enzyme in the metabolism 
of H2S is catalyzed by sulfur dioxygenase (SDO). SDO is a mitochondrial matrix 
enzyme, requiring oxygen to catalyze the four-electron oxidation of the sulfane sulfur in 
glutathione persulfide (GSS-) to produce sulfite (SO32−) and glutathione (14, 21, 22). 
Human SDO belongs to a superfamily of enzymes called dioxygen-activating 
mononuclear non-heme iron(II) enzymes that require a 2-His-1-carboxylate facial triad 
for iron binding (23, 24). Mutations of the enzyme have been linked to ethylmalonic 
encephalopathy, a disease associated with high levels of H2S and thiosulfate (for more 
information on ethylmalonic encephalopathy see, section 1.6 Diseases associated with 
abnormal H2S levels) (22, 25). SDO activity has also been detected within bacteria (26, 
27).  
  Hildebrandt and Grieshaber postulated that the third step requires a sulfur 
transferase, rhodanese (thiosulfate:cyanide sulfurtransferase) (14). In the “forward” 
direction rhodanese catalyzes the transfer of the sulfane sulfur on thiosulfate to cyanide 
producing thiocyanate and sulfite. In their pathway, Hildebrandt and Grieshaber postulate 
that rhodanese operates in the "reverse" direction by catalyzing the conversion of 
glutathione persulfide and sulfite to thiosulfate and glutathione (14). 
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 Thiosulfate is a final product of H2S metabolism in the pathway postulated by 
Hildebrandt and Grieshaber.  However, these authors also propose a two-step process for 
the conversion of thiosulfate to sulfate, involving a thiosulfate reductase and sulfite 
oxidase (14).  The thiosulfate reductase will catalyze the transfer of the sulfane sulfur 
from thiosulfate to glutathione producing sulfite and glutathione persulfide.  In a non-
enzymatic reaction, the glutathione persulfide generated by the thiosulfate reductase is 
thought to react with glutathione to produce H2S and oxidize glutathione (GSSG). The 
sulfite product will be oxidized to sulfate by sulfite oxidase.  
1.4 Sulfide:quinone Oxidoreductase  
1.4.1 Background, classification and general purification 
 This section contains a background on SQORs, followed by a summary of their 
classification, and then a detailed review of selected SQORs. SQOR as mentioned above, 
is a membrane-associated mitochondria protein. The fact that SQOR is a membrane-
associated protein has made it challenging to express and isolate the enzyme. The enzyme 
was first isolated from O. limnetica and identified as a flavoprotein because it contained a 
FAD cofactor (28-30). Since then, SQOR has been studied in many organisms ranging 
from lugworm to bacteria (19, 31-34). Some SQORs bind the FAD cofactor covalently, a 
feature shared by approximately 10% of known flavoproteins (35). The FAD in 
eukaryotic SQORs was postulated to be covalently attached to a conserved tyrosine 
residue (15). SQORs are part of the flavoprotein disulfide reductase superfamily (36). 
Within this superfamily SQORs are classified as group 1 enzymes which includes 
lipoamide dehydrogenase, glutathione reductase, trypanothione reductase, and 
mycothione reductase (36). The group 1 enzymes have a super secondary structural 
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element called a Rossmann fold, which is commonly found in FAD and NAD(P) 
containing proteins. These enzymes not only require the FAD, but also a cysteine-
cysteine disulfide bridge for a second redox-active center (15, 36). A notable difference 
between SQORs and the group 1 enzymes of flavoprotein disulfide reductase superfamily 
is that sulfide replaces NADPH as the electron donor.  
 Originally, SQORs were divided into three types based on the evolutionary origin 
of the gene found in bacteria and eukaryotes (37). Currently there are only three known 
crystal structures of SQOR, all from bacteria: (i) Aquifex aeolicus, (ii) Acidianus 
ambivalens, and (iii) Acidithiobacillus ferrooxidans (32-34).  Recently, Marco et al.  
divided SQORs into 5 types (Type I-V) based on sequence fingerprints, in addition to an 
unclassified group (Type VI); Pham et al. proposed a similar classification system (38). 
From Marco et al.’s classification Type I enzymes contain a loop region that blocks the 
active site from the bulk solvent allowing for sulfide specificity and a C-terminus 
amphipathic helix with an elongated loop (15). The A. aeolicus and A. ferrooxidans, 
SQORs, for which the structures are known for are both Type I enzymes. Type II SQORs 
are found in some bacteria, pathogens, and all eukaryotes, except for plants (15, 18). 
Type III enzymes are found in green sulfur bacteria and Archaea; their physiological role 
in these organisms is currently unknown (15).  Type IV enzymes are classified by five 
elongated loops throughout the protein. Type V SQORs have an elongated capping loop 
and a shorter C-terminus compared to Type I (15).  The A. ambivalens SQOR, the third 
known structure, is a Type V SQOR.  
 The majority of groups that have purified SQOR have used detergents to 
solubilize the enzyme from the membrane (19, 28, 31, 32, 39-43). Interestingly, the A. 
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ferrooxidans SQOR did not require detergent for purification (33, 44, 45). Some groups 
have been able to detect SQOR activity within isolated mitochondria and thylakoids (14, 
28, 46). Thylakoids are compartments that are bound to the membrane of cyanobacteria 
and the location of photosynthesis (light-dependent step). SQOR activity is typically 
measured under anaerobic conditions by monitoring the reduction of a quinone substrate, 
such as decylubiquinone. As mentioned above, mammalian SQORs require an acceptor 
for the sulfane sulfur, a feature apparently shared with other type II SQORs. In addition 
to mammalian SQORs, Type II enzymes include SQORs from lower eukaryotes and 
some bacteria. Unlike bacterial Type II enzymes, other types of bacterial SQORs do not 
appear to require an acceptor for the sulfane sulfur. Instead, these bacterial SQORs 
produce sulfane sulfur in the form of polysulfide chains or cyclooctasulfur rings 
(elemental sulfur, S8). Table 1.1 summarizes some properties reported for SQORs from 
various organisms. A detailed discussion of the results summarized in table 1.1 with 
selected SQORs is presented in sections 1.4.2-1.4.10.  
1.4.2 Acidithiobacillus ferrooxidans SQOR 
 SQOR from A. ferrooxidans, a chemolithotrophic, iron-oxidizing bacterium, is a 
Type I SQOR that has been recently characterized and crystallized (33, 42, 44, 45). It is 
believed that these bacteria couple sulfide oxidation with carbon dioxide fixation, the 
process of converting inorganic carbon to organic carbon (47). In a study prior to 
isolating A. ferrooxidans SQOR, Kamimura’s group showed that there was SQOR 
activity within isolated membranes (48). In a subsequent study, Kamimura’s group 
succeeded in isolating natural SQOR without detergent. The purified enzyme had a 
molecular weight (MW) of 47 kDa (42, 48). The optimal pH for the enzymatic activity 
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was 7.0 (42). Zhang and Weiner, determined a similar pH optimum of 6.5-7.0 with 
recombinant SQOR (45).   
 Recombinant A. ferrooxidans SQOR was overexpressed in E. coli and isolated 
without detergent, as with the natural enzyme (45).  With the recombinant enzyme, the 
FAD was determined to be non-covalently bound with greater than 95% of the FAD 
being released into solution (45). The spectrum of the purified enzyme exhibited two 
flavin absorption peaks, at 379 and 448 nm.  
 In the same study, mutagenesis was conducted to help elucidate the enzymatic 
mechanism. A common feature of Type I SQORs is three conserved cysteines. From 
sequence alignments the three conserved cysteine residues within A. ferrooxidans SQOR 
were hypothesized to be, Cys128, Cys160, and Cys356. The three residues were mutated 
along with two-conserved histidine residues (His 198 and His132) (33, 45). All five 
residues had significantly lower SQOR activity compared to the wild type enzyme, 
confirming their importance for activity (45). 
 To further elucidate the mechanism, stopped-flow experiments were performed to 
characterize the reductive half-reaction, by monitoring the reduction of the FAD visible 
absorption maximum at 448 nm for the wild type and mutant enzymes. The observed rate 
for the wild type enzyme with excess sulfide was almost 2-fold faster than when 
monitoring decylubiquinone reduction. The Cys128 and His132Ala mutations did not 
affect the FAD reductive half-reaction. The Cys160 and Cys356 mutations did not 
catalyze the FAD reductive half-reaction. These results show that Cys160 and Cys356 are 
required for the FAD reductive half-reaction and presumably comprise the redox-active 
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disulfide bridge. The His198 mutation catalyzed the FAD reductive half-reaction but its 
activity compared to the wild type enzyme was approximately 4-fold lower.  
 A crystal structure was also solved for A. ferrooxidans SQOR (33, 44). The 
recombinant enzyme was purified for crystallography under the same protocol used to 
isolate the enzyme for kinetic studies (33, 44, 45). The solved crystal structure had a 
resolution of 2.3 Å (33). For determining the structure of SQOR, two different crystal 
structures were used: (i) in the detergent dodecyl-maltoside and (ii) without detergent 
(33). In the solved crystal the enzyme forms a dimer. Each monomer contains two-
consecutive Rossmann folds and two amphipathic helices at the C-terminus, which are 
most likely required for anchoring the enzyme within the membrane (33). Dimerization 
of SQOR occurs via the hydrophobic interactions at the C-terminus, which is observed 
with the other known structures of A. aeolicus and A. ambivalens SQOR (33).   
 Because the monomers are joined at the same hydrophobic region that interacts 
with the membrane, Cherney et al. proposed a slightly different structure based on the 
enzyme’s binding energy, ΔG°, when it would be associated with the membrane (33). 
According to this model, the amphipathic helices are embedded  ~20 Å within the 
membrane; the FAD ring is located at the membrane-cytoplasm interface. This is to be 
expected, because the FAD transfers the electrons from soluble H2S to an insoluble 
quinone, located within the membrane. As shown biochemically by denaturing the 
enzyme, the FAD was non-covalently bound to the enzyme in the crystal structure. 
Located within the first Rossmann fold, the FAD prosthetic group is stabilized by van der 
Waals forces, electrostatic interactions, and hydrogen bonding with the enzyme (33).  
Even though there is a second Rossmann fold, a second molecule of FAD (or NAD) 
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cannot bind because there is a loop that prevents binding. The two cysteines (Cys160 and 
Cys356) that comprise the redox-active disulfide bridge are located on the re side of the 
FAD isoalloxazine ring, parallel to the ring, and ~5 Å away from the ring (33).  
 The structure was also solved with bound decylubiquinone. Within the structure 
there are pockets, two of which contain the FAD cofactor and the decylubiquinone. 
Additionally, there is a channel that is proposed to allow for sulfide to enter the active 
site from the bulk solution. The redox-active disulfide bridge as expected, has access to 
the sulfide channel, with Cys356 closer to the bulk solvent. The decylubiquinone has its 
hydrophilic ring positioned within the enzyme near the si face of the isoalloxazine ring 
and its hydrophobic aliphatic chain pointed out, near the part of SQOR that is predicted to 
be within the membrane.  
 Zhang and Weiner, proposed a catalytic mechanism for sulfide oxidation by 
SQOR (Scheme 1.1). In the proposed mechanism the disulfide bridge is presumably 
between Cys356 and Cys160. Additionally, the third conserved cysteine residue, Cys128, 
exists as a protein-bound persulfide, Cys128SS-, in the resting enzyme.  The first step, 
involves a nucleophilic attack of sulfide at Cys356, forming a protein-bound persulfide, 
Cys356SS- and the thiolate form of Cys160 (45).For the second step, the persulfide 
attacks the C(4a) position of the isoalloxazine ring forming a covalent FAD 4a-adduct. In 
the third step, there is a nucleophilic attack of Cys160S- at the sulfur atom in the 4a-
adduct, resulting in the formation of a trisulfide bridge (Cys160S-SSCys356) and reduced 
FAD (FADH2). For the fourth step, the FADH2 is oxidized to FAD by transferring the 
electrons to ubiquinone forming ubiquinol. These four steps are repeated seven more 
times to form an octasulfur ring. The octasulfur ring is released by the nucleophilic attack 
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of Cys128SS- (the third conserved cysteine residue), forming a trisulfide bond with 
Cys160 (Cys128SSSCys160) (step 5). In the last step, Cys356 attacks the gamma sulfur 
on Cys160 regenerating the disulfide bridge and Cys128SS- persulfide (step 6). 
1.4.3 Aquifex aeolicus SQOR 
 SQOR from A. aeolicus is another Type I SQOR that has been crystalized (49). A. 
aeolicus is a hyperthermophilic bacterium, which lives in environments of 60 °C and 
above. Additionally, it is a chemolithoautotrophic bacterium that does not require light as 
an energy source; instead, it obtains its energy from inorganic compounds including H2S.  
A. aeolicus SQOR activity was originally detected in isolated membranes (46). The 
observed activity was temperature dependent; the activity of the enzyme increased with 
increasing temperature (46). To determine how tightly SQOR associated with the 
membrane, Nubel et al. solubilized the membrane with sodium bromide or thesit, a non-
ionic detergent. They observed that thesit solubilized active SQOR, releasing it from the 
membrane (46). For isolation of A. aeolicus SQOR, membranes were solubilized in 
dodecyl-maltoside (49, 50). After solubilization the dodecyl-maltoside was exchanged for 
Zwittergent 3-10 (49).  
  The purified enzyme was determined to be monomer, ~47 kDa, with SDS-PAGE. 
In the presence of a covalent cross linker, the purified enzyme also ran as a dimer (~ 94 
kDa) and trimer (~141 kDa) (49). To determine the oligomeric state of SQOR in solution, 
Marcia et al.  performed native PAGE, analytical size-exclusion chromatography (SEC), 
and sedimentation velocity analytical ultracentrifugation (SV-AUC) (51). The MW of 
SQOR based on native gels without detergent was ~150 kDa. However, in the presence 
of dodecyl-maltoside the MW was 250 kDa and with dodecyl-maltoside and 
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deoxycholate the MW was ~75 kDa (51). This shows that detergents can affect the 
protein-protein interactions, making it hard to determine the predominant oligomer state 
of SQOR in solution.  The MW of SQOR in solution from the analytical SEC and SV-
AUC was ~120 and 160 (±10 %) kDa respectively. From these experiments they 
determine that A. aeolicus SQOR can be a monomer, dimer, or trimer, depending on the 
solution’s conditions of the purified sample (34, 51).   
 In a crystallographic study with A. aeolicus SQOR, the solved crystal structure 
had a resolution of ~2.15 Å and was a trimer (34). The enzyme for these studies was 
purified using the same method used to characterize the enzyme. Similar to A. 
ferrooxidans SQOR, A. aeolicus SQOR has two amphipathic helices located at the at C-
terminus, that are postulated to anchor the enzyme to the membrane. Additionally, there 
are two Rossmann folds, with only one containing a FAD cofactor. The FAD is 
covalently attached to Cys124 via the methyl group at the C(8) position of the FAD 
isoalloxazine ring [C(8m)]. Cys124 thought is too far away for a direct covalent linkage. 
Marcia et al. propose that because Cys124 is too far away that in solution there must be a 
conformational change that brings Cys124 closer to the C(8m) position (34). However, 
from structural analysis performed by Marcia et al. there does not seem to be evidence for 
that degree of flexibility (51). Importantly, there is a heavy atom between Cys124 and the 
C(8m) position of the FAD, that they propose to be a sulfur that forms a protein-bound 
persulfide (Cys124SS-) and allows for the formation of the covalent C(8m) adduct 
[Cys124S-S-C(8m) position of the FAD ring].  
 Surface analysis of the protein revealed, negativity and positively charged surface 
areas near the Rossmann folds and on the opposite side to the Rossmann folds, 
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respectively. Additionally, on the surface there was a hydrophobic area on each 
monomer. It is the hydrophobic area on the monomers that most likely interacts with the 
membrane and forms the trimer. They calculate that the trimer is embedded ~12 Å within 
the membrane.  
 When decylubiquinone was crystallized with the enzyme, the hydrophobic portion 
was facing the solvent and the ring was inside the enzyme, on the si face of the FAD ring. 
Membrane insertion is postulated to help trimerization of the monomers. Additionally, 
insertion into the membrane prevents the reduction of oxidants other than ubiquinone by 
protecting the si face from soluble oxidants, such as, NAD(P)H. They would not be able 
to enter the active site since the si face of the FAD is facing the membrane (34). Located 
on the re face of the FAD ring is a cavity that contains the three conserved cysteines 
(Cys124, Cys156, Cys347). The cavity is connected to the bulk solvent by a channel that 
allows for sulfide to enter the active site. Located at the opening of the channel is a valine 
residue (Val 294) that is conserved in Type I SQORs and has been shown to play an 
important role in activity (41).  
 Marcia et al. proposed an enzymatic reaction from the structural analysis (Scheme 
1.2) (34). Their proposed mechanism is similar to what has already been described for the 
A. ferrooxidans SQOR. The residues that are postulated to comprise the redox disulfide 
bridge are Cys156 and Cys347. However, within the solved structure they are too far 
away to form a disulfide bridge. Instead, Marcia et al. determined by using an electron 
density map, that a cyclooctasulfur ring is covalently bound to Cys156 persulfide 
(Cys156SS-). Marcia et al. proposed two different mechanisms assuming that the 
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interaction between the persulfide on Cys124 (the third conserved cysteine), Cys124SS- 
and the FAD is either (i) static or (ii) dynamic (34).  
 For the mechanism with a static interaction between Cys124SS- and the C(8m) 
position of the FAD, the first step involves a nucleophilic attack by sulfide at Cys156 
forming a protein-bound persulfide (Cys156SS-) and the thiolate form of Cys347 
(Scheme 1.2). The protein-bound persulfide forms a charge-transfer complex 
intermediate with the C(4a) position of the FAD ring (step 1) followed by the formation 
of a covalent FAD 4a-adduct, with the persulfide (step 2). For the third step, Cys347S- 
attacks the sulfur atom in the 4a-adduct, forming a trisulfide bridge (Cys347S-SSCys156) 
and reduced FAD (FADH2). During the fourth step, the FADH2 is oxidized back to FAD 
by reducing ubiquinone to ubiquinol. After the formation of a eight sulfur atom chain on 
Cys347, the chain is transferred to Cys156SS- and in the process closes on its self 
forming a cyclooctasulfur that is bound to Cys156, through a trisulfide bridge 
(Cys156SS-S8ring) intermediate before being released into solution. Lastly, the sulfur 
ring is released into solution when the thiolate on Cys347 attacks the sulfane sulfur on 
Cys156. This step results in the formation of a trisulfide bridge (Cys347S-SSCys156), 
which is the same intermediate produced after step 4 (Scheme1.2). The other postulated 
mechanism, is similar except that there is no 4a-adduct intermediate.   
 For the second mechanism the first step is a nucleophilic attack by the thiolate on 
Cys156 on the sulfur atom in the C(8m) adduct forming a trisulfide bridge (Cys156S-
SSCys124) intermediate and reduced FAD (FADH2) (similar to step 3 in scheme 1.2.). 
Next sulfide attacks the trisulfide bridge forming two protein bound persulfides, 
Cys156SS- and Cys124SS-. The persulfide, Cys124SS- attacks the C(8m) position on the 
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FAD reforming the C(8m) adduct. During this step the sulfane sulfur on Cys156SS- is 
transferred to Cys347, the residue that the polysulfide chain grows on. After the 
formation of a eight sulfur atom chain, the chain is transferred to Cys156SS- and in the 
process closes on its self forming a cyclooctasulfur that is bound to Cys156, through a 
trisulfide bridge (Cys156SS-S8ring) intermediate before being released into solution 
(similar to scheme 1.2 step 5). Lastly, the sulfur ring is released into solution resulting in 
a protein bound persulfide, Cys156SS-.  
1.4.4 Acidianus ambivalens SQOR 
 A. ambivalens SQOR is a Type V SQOR, with a solved crystal structure. A. 
ambivalens SQOR’s DNA is more than 70% different compared to the Type I A. 
ferrooxidans SQOR (32, 33). A. ambivalens is a thermoacidophilic archaeon that belongs 
to the order of Sulfolobales and its optimal growth conditions are at 85 °C and pH 2 (52, 
53). Originally, a proteolytically cleaved form of the enzyme was classified as a type II 
NADH dehydrogenase because it exhibited NADPH oxidase activity (MW of 43 kDa) 
(54-56). However, the enzyme name was changed from NADPH oxidase to SQOR 
because the natural full-length enzyme exhibited only SQOR activity (32). Isolation of 
the full-length natural enzyme followed a similar method to that which was used to 
isolate the truncated SQOR (32).  Isolation of SQOR required a solubilization step with 
dodecyl-maltoside to release it from the membrane. To confirm the purity of the full-
length protein, mass spectrometry and SDS-PAGE were conducted. Unlike SQOR from 
A. aeolicus, A. ambivalens SQOR was a monomer in solution, with a MW of ~48 kDa 
determined by SEC. The enzyme had a covalently bound FAD and a typical FAD 
spectrum with absorption peaks at 350 and 454 nm (32). Because A. ambivalens is a 
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thermoacidophilic bacterium, SQOR activity with respect to temperature was tested. 
SQOR activity increased with temperature from 25 to 70 °C and had an optimal pH of 
~6. SQOR activity was similar with decylubiquinone and caldariella quinone, the natural 
quinone within A. ambivalens.  
 The structure of A. ambivalens SQOR solved by Brito et al. is similar to A. 
ferrooxidans and A. aeolicus SQORs (32). The FAD is bound to one of the two 
Rossmann folds. A loop extending through the second fold prevents NAD(P) from 
binding. The FAD is covalently bound to the protein via a thioether bond between C(8m) 
and Cys129 (one of the three conserved cysteine residues). The residues Cys178 and 
Cys350 comprise the redox-active disulfide bridge and are located on the re face of the 
FAD. In proximity to the disulfide are two aspartic residues, Asp215 and Asp353, which 
are postulated to stabilize H2S by hydrogen bonding. The hydrogen bonding is between 
the carboxylate on each aspartate side chain and the hydrogen atoms on H2S causing the 
sulfur atom to be a stronger nucleophile. Crystal structures have not been obtained with a 
bound quinone. It is presumed that the large cavity on the si face of the FAD is the 
quinone binding site. Within the cavity there is a hydrophilic region adjacent to the 
isoalloxazine ring suitable for the hydrophilic quinone ring of caldariella quinone. As 
with the other two known SQOR structures, A. ambivalens SQOR is hypothesized to 
interact with the membrane with the amphipathic helix located at the C-terminus (32). It 
is worth noting, that no helix was observed in the crystal structure; the last 53 residues 
were disordered and could not be visualized (32).       
 From the structural analysis, Brito et al. postulated a mechanism for A. 
ambivalens SQOR (Scheme 1.3) (32). The first step, involves a nucleophilic attack by 
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sulfide at Cys350, forming Cys350SS- persulfide and the thiolate form of Cys178. This 
results in the formation of a charge-transfer complex between the sulfane sulfur on the 
persulfide and the C(4a) position on the FAD ring (step 2). This is followed by the 
formation of a 4a-adduct with the persulfide (step 3). Cys178S- attacks the sulfur atom in 
the 4a-adduct producing a trisulfide bridge (Cys350SS-SCys178) and FADH2 (step 4).  
FADH2 is oxidized back to FAD by reducing caldariella quinone to a quinol (step 5). A 
second molecule of sulfide enters the active site and the above process is repeated until 
the polysulfide chain becomes too large. It is proposed that the longest chain that can 
grow on Cys350 is five sulfur atoms.  For step six, the chain is released when the sulfur 
atom on Cys178 attacks the gamma sulfur on Cys350 regenerating the disulfide bridge.   
1.4.5 Rhodobacter capsulatus SQOR 
 R. capsulatus is a purple “non-sulfur” bacterium, containing a Type I SQOR, 
which has a MW of ~48 kDa, and is located in the periplasm. The enzymatic reaction for 
this SQOR produces a soluble polysulfide chain rather than elemental sulfur. Next 
soluble polysulfide chains that have been released by SQOR are transported outside the 
cell where through a series of steps requiring a metal ion are deposited as elemental 
sulfur (S8,,ring) (yellowish in color) (41, 57). What makes R. capsulatus unique is that 
this phenomenon is normally observed with green sulfur bacteria (58). Prior to the 
isolation of SQOR, it was known that R. capsulatus could enzymatically oxidize H2S, 
under dark conditions within the chromatophores (vesicles that reflect light) in a reaction 
requiring ubiquinone (59, 60). R. capsulatus strains expressing either wild type SQOR or 
mutations of the conserved cysteine residues were grown on sulfide plates; to determine 
if the mutations affected the growth of the bacterium. To create the mutant strains, 
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transposon (which is DNA that can move within the genome) mutagenesis was performed 
via a conjugative method called triparental mating (41, 61). Transposon mutagenesis is 
when a transposon is inserted into a gene, which renders the translated protein inactive. 
Triparental mating requires a bacterium, which assists in the transfer of the plasmid of 
interest from one bacterium to another.  None of the three mutants were able to grow on 
the sulfide plates (41).  
 Griesbeck et al. expressed recombinant R. capsulatus SQOR in E. coli and 
solubilized the enzyme using thesit to release it from the membrane (41).  The spectrum 
of the purified enzyme exhibited two flavin absorption peaks at ~375 and ~450 nm. As 
observed with mostly other SQORs, the recombinant R. capsulatus SQOR had a pH 
optimum of ~6.5. Cyanide was shown to inhibit SQOR activity (40).  
 To confirm the three-conserved cysteine residues (Cys127, Cys159, and Cys353) 
mutagenesis was conducted. A mutation was also made to a conserved valine (Val300), 
which is believed to be critical for SQOR activity (41, 62, 63). Additionally, two 
conserved histidines (His131 and His 196) were mutated, which are proposed to help in 
the transfer of electrons from FADH2 to a quinone (41, 62, 63). As expected the cysteine 
mutations lost more than 98% of their enzymatic activity. The Val300, His131, and 
His196 all had a significant decrease in activity. Additionally, the Val300 mutation 
caused a ~5-fold increase in the Km for decylubiquinone. The His131 and His196 
mutations had a significant loss in activity and caused a shift in the optimal pH from ~6.5 
to ~4.5 and 6.2 respectively. The low activity observed even at the optimal pH could be 
due to the unfavorable acidic conditions for the enzyme (41).  
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 Spectral studies showed that both the wild type and Val300 mutant enzyme 
catalyzed the reduction of FAD (to FADH2). Additionally, the FADH2 was oxidized to 
FAD and the quinone was reduced to quinol. The three-cysteine mutations could not 
catalyze the reduction of FAD. With the histidine mutations, FAD was still reduced to 
FADH2. However, FADH2 was not oxidized back to FAD with the addition of 
decylubiquinone. The observed spectral changes with the histidine mutants showed that 
they helped facilitated the oxidation of FADH2 to FAD and the reduction of the quinone 
to quinol.  
 From the experimental data, Griesbeck et al. postulated a mechanism for R. 
capsulatus SQOR (Scheme 1.4) (41). They postulate that the disulfide bridge between 
Cys159 and Cys127 is in equilibrium with a disulfide bridge between Cys127 and 
Cys353. The first step in the catalytic mechanism involves a nucleophilic attack by 
sulfide at Cys353 forming a protein-bound persulfide (Cys353SS-). Next, a second 
molecule of sulfide reacts with the sulfane sulfur on the persulfide forming a polysulfide 
(H2S2) that is released into solution and the thiolate on Cys159, forms a charge-transfer 
complex at C(4a) position within the FAD ring (step 2). For the third step, Cys159 forms 
a covalent 4a-adduct, intermediate. Next, the thiolate on Cys127 attacks the sulfur atom 
on the 4a-adduct producing a disulfide bridge between Cys159 and Cys127 and FAD is 
reduced to FADH2 (step 4). The last step is the oxidation of FADH2 to FAD, reducing the 
quinone to quinol (step 5).  
1.4.6 Oscillatoria limnetica SQOR 
 The O. limnetica SQOR, is a Type I SQOR that was one of the first ones 
characterized. Within O. limnetica thylakoids it was first discovered that H2S in the 
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presence of light can induce NADPH and ATP production through the cytochrome b6f 
complex (part of the electron transport chain) (30). When O. limnetica were grown in the 
dark, H2S oxidation via the addition of a quinone caused the reduction of NADP to 
NADPH. Under dark conditions it was hypothesized that there was a SQOR transferring 
the electrons from H2S to the electron transport chain (29). Ariel et al. successfully 
isolated and characterized O. limnetica SQOR from the thylakoids (28). In order to 
isolate a sufficient amount of the natural enzyme O. limnetica bacteria were “induced” 
with sulfide (28, 29). SQOR was isolated from thylakoid membranes by solubilization 
with dodecyl-maltoside. The SQOR had a MW of  ~57 kDa and exhibited a typical flavin 
spectrum with absorption peaks at 373 and 461 nm. The enzymatic assay monitored the 
reduction of plastoquinone-1, which is an analog of plastoquinone, a natural substrate for 
O. limnetica SQOR. It is worth noting that, Bronstein et al. were able to express this 
SQOR recombinantly in E. coli along with a SQOR from another cyanobacteria, 
Aphanothece halophytica (64).  While the enzymes were not isolated, they showed that 
the enzymes were localized to the membrane (64).    
1.4.7 Geobacillus stearothermophilus SQOR 
 Geobacillus stearothermophilus formally known as Bacillus stearothermophilus, 
is a thermophilic bacterium found in many environments (40, 65, 66). The b-hmt2 gene 
encodes for a SQOR, which most likely is a Type II SQOR. SQOR was expressed 
naturally in G. stearothermophilus and recombinantly in E. coli. For purification the 
membranes were solubilized with Triton X-100 to isolate active SQOR. The purified 
enzyme had a MW of ~40 kDa. Shibata et al. stated that the absorbance spectrum of the 
denatured enzyme exhibited a typical flavin spectrum (but not shown) (40). Activity 
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assays were performed by monitoring the reduction of decylubiquinone or 2 3-dimethyl-
1,4-naphthoquinone, which is a water soluble analog of menaquinone, a natural quinone 
in G. stearothermophilus (40). SQOR activity was similar with decylubiquinone or 2 3-
dimethyl-1,4-naphthoquinone as the electron acceptor. Importantly, in assays with the 
addition of cyanide (as an acceptor of the sulfane sulfur) and phosphatidylcholine there 
was an over 700-fold rate increase in SQOR activity. Additionally, there was a decrease 
in the Km value for sulfide. The Type II SQORs do not produce polysulfide chains or 
cyclooctasulfur rings and require an acceptor of the sulfane sulfur. This work supports the 
notation that G. stearothermophilus SQOR is a Type II SQOR.  
 The postulated mechanism for this SQOR is significantly different compared to 
the other bacterial SQORs because there is an acceptor of the sulfane sulfur. The 
similarities are that there is a redox-active disulfide bridge and after the reduction of FAD 
the electrons are transferred to a quinone. A possible mechanism for G. 
stearothermophilus is similar to the one that is proposed for Arenicola marina SQOR in 
scheme 1.5 (Cys 1 corresponds to A. marina Cys387 and Cys2 corresponds to Cys208). 
For the proposed mechanism Cys1 and Cys 2 comprise the redox-active disulfide bridge 
(Cys1 and Cys2, numbers do not correspond to their location in the protein sequence). 
The first step involves a nucleophilic attack by sulfide at Cys1, forming a persulfide 
(Cys1SS-) and a thiolate (Cys2). Next, cyanide reacts with the sulfane sulfur, on the 
persulfide Cys1SS- forming thiocyanate. This is followed by, nucleophilic attack of Cys2 
at the C(4a) position of the FAD ring producing a covalent 4a-adduct (similar to scheme 
1.5  step 3). The disulfide bridge is regenerated by nucleophilic attack by the thiolate on 
Cys1 at the sulfur atom on the 4a-adduct. During this step there is a two-electron 
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reduction of FAD to FADH2 (same as scheme 1.5 step 4). Lastly, FADH2 transfers its 
electrons to a quinone forming a quinol and regenerating FAD (same as scheme 1.5 step 
5).  
1.4.8 Pseudomonas putida SQOR   
 Pseudomonas putida gene PP0053, encodes for a putative Type II SQOR 
homolog. P. putida is a saprotrophic bacterium, which are known to break down dead 
organic matter within the soil. Prior studies showed that P. putida could remove H2S 
from water at a pH optimum between 6 and 8 (67). The optimal pH for most known 
SQORs is ~6.5-7.0.  Natural P. putida SQOR localized to the membrane (39). When the 
P. putida gene PP0053 was inactivated via insertional mutagenesis, no SQOR activity 
was detected in P. putida. The protein was also expressed recombinantly in E. coli. For 
purification, SQOR was solubilized with the detergent, Triton X-100, to release it from 
the membrane (39). The purified enzyme had a MW of ~43 kDa and a typical flavin 
absorption spectrum with peaks at 372 and 452 nm. In the presence of cyanide there is an 
increase in SQOR activity and a decrease in the Km value for sulfide, which is similar to 
G. stearothermophilus SQOR, another Type II bacterial SQOR. (39).  
1.4.9 Schizosaccharomyces pombe SQOR 
 Schizosaccharomyces pombe is a Type II SQOR. The postulated S. pombe gene 
that encodes for SQOR is called heavy metal tolerance 2 (Hmt2). Mutations to the gene 
resulted in the organism becoming hypersensitive to heavy metals (31, 68). The amino 
acid sequence has 35%, 20%, 38% identity to lugworm, R. capsulatus and a human 
SQOR (at the time this had not been studied) respectively (31). All eukaryotic SQORs 
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are Type II, which have the disulfide bridge as Type Is but lack the conserved third 
cysteine residue (51).  
 S. pombe SQOR localized to the mitochondria. Recombinant S. pombe SQOR was 
expressed in E. coli and solubilized with Triton X-100 to release it from the membrane 
(31). The solubility of S. pombe SQOR could be enhanced if the solution was increased 
to a pH of 11. This enhancement of solubility at pH 11 has also been observed with other 
peripheral membrane proteins (31). The recombinant SQOR had a MW of ~52 and ~50 
kDa. The 50 kDa MW protein could be due to it being truncated (ie. protein degradation). 
It was postulated by Marcia et al. that in eukaryotic SQORs the FAD would be covalently 
bound to a conserved tyrosine residue (15).  However, for recombinant S. pombe SQOR 
the FAD was noncovalently bound. The spectrum of the purified enzyme exhibited two 
flavin absorption peaks at 375 and 455 nm and the ratio of FAD to protein was  ~1:3. The 
low ratio may reflect the loss of FAD through purification (31). Enzymatic activity was 
determined by measuring the reduction of coenzyme Q2, an analog of coenzyme Q, a 
natural quinone (31). Weghe and Ow determined a mole ratio of 1:1 for sulfide consumed 
to reduced coenzyme Q2, meaning that the sulfide is oxidized to sulfane sulfur because 
two electrons are required to fully reduce coenzyme Q2 (31).  Activity was detected in 
yeast mitochondria in the presence of cyanide. Additionally, in assays containing 
cyanide, cyanide lowered the Km value for sulfide (unpublished data) (18). This is also 
observed with, Arenicola marina, P. putida, and G. stearothermophilus SQORs, which 
like S. pombe SQOR, are Type II SQORs. 
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1.4.10 Arenicola marina SQOR 
 Another eukaryotic Type II SQOR that has been studied is from A. marina, 
commonly known as lugworm (19). Lugworm SQOR has a 45%, 35% and 23% amino 
acid sequence identity to human, S. pombe and R. capsulatus SQORs respectively (19). 
Lugworms are found in marine sediments that can contain up to 2 mM H2S (19). H2S 
oxidization has been shown to be localized to the mitochondria and produce equimolar 
amounts of thiosulfate (11, 69). SQOR activity was the highest within the mitochondrial 
matrix (14). Cyanide was required to observe SQOR activity with decylubiquinone and 
sulfide. In the assay with mitochondria, the amount of sulfide consumed was equal to the 
amount of thiocyanate produced. The formation of thiocyanate in the enzymatic assay 
occurs from the transfer of the sulfane sulfur in sulfide to cyanide (19). 
 Theissen and Martin expressed lugworm SQOR recombinantly in Saccharomyces 
cerevisiae, which lacks its own SQOR (19). SQOR was isolated from the mitochondrial 
membrane by solubilization with Triton X-100. The purified SQOR had a MW of ~47 
kDa; and information regarding the FAD content of the preparation was not provided 
(19). The Asp342 is conserved within eukaryotic SQORs and postulated to be required 
for FAD binding (19). Mutation to Asp342 caused a significant decrease in SQOR 
activity.  
 For observing enzymatic activity of lugworm SQOR cyanide was required. 
Enzymatic assays replacing cyanide with thioredoxin exhibited thioredoxin-dependent 
activity, however, the activity was significantly lower than with cyanide. SQOR activity 
was optimal at a pH of 9, which is higher than the 6.5-7.0 for the bacterial enzymes. The 
cysteine residues, Cys208 and Cys387, were identified from sequence alignments as the 
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conserved cysteines that comprise the disulfide bridge. Mutations of the cysteines 
exhibited no detectable SQOR activity. Conserved histidines, His86 and His299 were 
identified as possible residue to promote quinone binding and reduction.  These two 
residues along with the proposed active-site base, Glu159, were mutated. Mutations to 
His86, His299, and Glu159 exhibited no detectable SQOR activity.  
 From the biochemical data a enzymatic mechanism was proposed (Scheme 1.5) 
(19). The first step involves a nucleophilic attack by sulfide at Cys387 forming a protein 
bound persulfide, Cys387SS-. Next, cyanide reacts with the sulfane sulfur on Cys387SS-, 
forming thiocyanate. This is followed by, nucleophilic attack of Cys208S- at the C(4a) 
position of the FAD ring producing a covalent 4a-adduct (step 3). The thiolate on Cys387 
will attack the sulfur atom in the 4-adduct producing the original disulfide bridge and 
FADH2 (step 4). Lastly, the electrons from FADH2 are transferred to a quinone reducing 
it to a quinol and regenerating FAD (step 5).  
1.5 Hydrogen sulfide signaling  
 The emerging signaling mechanism for H2S is protein sulfhydration. In this 
process, a sulfur atom is covalently attached to a cysteine residue to produce a persulfide 
derivative (CysSS-). Many proteins in mammals have been shown to undergo 
sulfhydration including: actin, tubulin, transcription factor NF-κB, and the ATP-sensitive 
potassium channel (KATP channel), which is a key regulator of heart activity, smooth 
muscle tone, insulin secretion, and neurotransmitter release (70-74). Sulfhydration is 
believed to occur not only in mammals but in invertebrates too (75, 76). Invertebrates can 
live in habitats in which H2S concentrations can be as high as 1-2 mM (19, 75). As a 
result most of these invertebrates have sulfide-hemeprotein interactions to aid in the 
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transport of the H2S to symbiotic bacteria, which will oxidize the H2S (75). For a review 
of H2S signaling see reference (77).  
1.6 Diseases associated with abnormal hydrogen sulfide levels 
 Ethylmalonic encephalopathy is an autosomal recessive disease that results in 
extremely elevated levels of H2S. The disease is caused by a defect in the gene (ETHE1) 
that encodes for SDO and results in death within the first decade of life (22, 25). Many of 
the known abnormalities in these patients can be attributed to the toxic effects of H2S. 
Ethylmalonic encephalopathy patients and the mouse model exhibit elevated urinary 
excretion of ethylmalonic acid, a biochemical indicator of short-chain acyl-CoA 
dehydrogenase deficiency. 
 Ulcerative colitis is a type of inflammatory bowel disease, in colonic epithelia 
cells. Associated with this disease is a block in the β-oxidation of short chain fatty acids 
(78). This impairment of fatty acid metabolism is also observed with ethylmalonic 
encephalopathy patients.  The excessive levels of H2S in patients with ulcerative colitis is 
proposed to be due to sulfate-reducing bacteria in the large intestine or impairment in the 
metabolism of H2S (79, 80). This disease can be recapitulated when cells are exposed to 
millimolar levels of sulfide (78). The removal of H2S by the colon has been shown to be a 
result of the metabolic pathway where thiosulfate is the main product, even though cells 
have the ability to remove H2S by methylation (12, 80). For more information on H2S’s 
role in ulcerative colitis see reference (79). 
 Down syndrome patients have an extra copy of the CBS gene that encodes for 
CBS, the enzyme that produces H2S in the brain. As a result CBS is enriched in the brains 
of Down’s patients (81). These patients exhibit a 300% increase in the brain’s expression 
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of CBS as well as numerous symptoms, such as elevated levels of sulfhemoglobin 
consistent with the overproduction of H2S. It has been suggested that the chronically 
elevated levels of H2S may contribute to the progressive decrease in the mental abilities 
of Down syndrome children who exhibit near normal intelligence at birth (82-85).  
 Alzheimer's disease is the most common form of dementia for which there is 
currently no cure or prevention method. Alzheimer’s disease is related to damage of the 
hippocampus where the loss of memory is a result of a deficiency in long-term 
potentiation (86). Long-term potentiation helps in neuronal plasticity, which facilities 
learning and memory and has been shown to be dependent on the activation of the N-
methyl-D-aspartate (NMDA) receptor (87). The NMDA receptor is activated by H2S (88, 
89). In patients with Alzheimer’s disease H2S levels are severely decreased due to low 
CBS activity caused by low levels of S-adenosyl-L-methionine, an activator of the 
enzyme (90, 91). In Alzheimer’s disease mice models, a H2S donor has been shown to 
increase learning and memory (92).  For comprehensive reviews on sulfide’s role in the 
nervous system see references (93, 94).  
1.6.1 Hydrogen sulfide’s role in cardiovascular health and pathology 
  H2S protects against ischemia/reperfusion injury, mediates vasodilation, 
promotes angiogenesis, and inhibits plaque formation (atherogenesis) (95-98). Sulfide’s 
role in pre- and post- ischemia/reperfusion injury has been extensively studied ranging 
from animal models to renal transplants (96, 99-102). For example, a H2S donor had 
protective effects during reperfusion.  
 Hypertension in mice has been shown to be associated with a deficiency in H2S. 
CSE-/- mice develop age-dependent hypertension (95). This was reversed with a H2S 
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donor (95).  Hypertension was also shown in rats when they were administered an 
inhibitor of CSE (103). H2S causes a decrease in blood pressure via sulfhydration of the 
Katp channels and not the voltage-dependent K+ channels (72, 104-106).  
 H2S is an endogenous stimulator of angiogenesis (97). Papapetropoulos et al. 
showed that H2S promotes angiogenesis via Katp channels and inhibition of the channels 
mitigated the effects of H2S (97). Additionally, H2S promotes new blood vessel formation 
via activation of the MAPK/Erk pathway (97, 107). Along with promoting angiogenesis 
H2S can also affect atherosclerosis. Compared to wild type mice, CSE-/- mice fed an 
atherogenic diet, develop atherosclerotic lesions and plaque formation (108). H2S has 
subsequently become a therapeutic target of interest (109). For a review on H2S’s effects 
on atherosclerosis see reference (110).  
H2S has been shown to mediate oxygen sensing within the carotid body (111). 
The carotid body is a cluster of receptors and cells that monitor oxygen levels along with 
carbon dioxide, pH, and temperature. CSE-/- mice compared to wild type mice had a 
decreased overall response to hypoxia (12 % O2) (111). Under hypoxia within the carotid 
body it is postulated that H2S activates the L-type high voltage-gated calcium channels 
(111). Another possible mechanism for oxygen sensing is via the calcium-activated 
potassium channel (112). This is critical because calcium influx into glomus cells are 
important for carotid body activation during hypoxia (113). For a review on H2S’s role as 
an oxygen senor see reference (114).  
1.6.2 Hydrogen sulfide’s other physiological roles    
  Within a small concentration window H2S will act as an anti-cancer therapeutic 
agent (115). Studying H2S’s effects on cancer, Lee et al. showed that continuous 
  
28!
exposure of a slow releasing H2S compound caused intercellular acidification, leading to 
apoptosis of breast cancer cells (116). In non-cancer breast cell lines there were no effects 
in cell survival (116). As stated above H2S can promote angiogenesis under hypoxia 
conditions (97).  Angiogenesis can be upregulated in cancers because of their rapid 
growth, and large nutrient requirements.  Szabo et al. demonstrated that CBS is 
upregulated in colon cancer (117). Chattopadyay et al. studied many different cancer cell 
lines and found that H2S-releasing non-steroidal anti-inflammatory drugs (HS-NSAIDs) 
inhibited cell growth (118). HS-NSAIDs are a new anti-inflammatory drug class 
containing both nitric oxide and H2S releasing moieties (119). For reviews on HS-
NSAIDs’ treating cancer and general drug design with H2S see references (120, 121).  
 Recently Hine et al. looked into the effects of H2S on dietary restriction. They 
showed that when mice are on a restricted diet there was an increase in H2S levels (122). 
By measuring the protein concentration of CSE and CBS, Predmore et al. further proved 
the idea that over time in rats, caloric restriction will alter H2S signaling, with tissue 
specific affects (123).  
 Caenorhabditis elegans exposed continuously to a low concentration of H2S in 
the atmosphere before early development lived longer compared to C. elegans grown 
under a normal atmosphere (124). If the animals were placed in a H2S atmosphere after 
early development then there was no increase in their life span (124). It appears that there 
are other factors besides exposure to H2S related to the life span of the animals. For more 
information about H2S’s therapeutic benefits related to aging see reference (125).    
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1.7 Summary  
 H2S is the third known gasotransmitter similar to nitric oxide and carbon 
monoxide. It is the only gasotransmitter that is enzymatically degraded. Although 
originally believed to be toxic to animals it is now understood that it plays an important 
role within mammals ranging from high blood pressure to a neuroprotectant and 
modulator.  H2S has also been associated with diseases including, Down syndrome and 
Alzheimer’s disease.  
 The goal of this thesis is to enhance the understanding of the metabolic pathway 
of H2S. To achieve this we first characterized recombinant human SQOR. SQOR is a 
mitochondria membrane-associated flavoprotein. The fact that SQOR is membrane-
associated made it difficult to express properly folded and functional enzyme. After an 
extensive screening process we determined that 1,2-diheptanoyl-sn-glycero-3-
phosphocholine was the optimal detergent for solubilization. Unlike most bacterial 
SQORs, eukaryotic and bacterial Type II SQORs require an acceptor of the sulfane 
sulfur. We discovered that sulfite was the physiological acceptor in a reaction that 
produced thiosulfate. This discovery lead us to postulate a role in H2S metabolism for a 
thiosulfate sulfurtransferase (TST), which can transfer the sulfane sulfur of thiosulfate to 
glutathione producing GSS- and sulfite. We postulate that the TST links together the 
SQOR and SDO steps in the pathway because it consumes thiosulfate from the SQOR 
reaction and produces glutathione persulfide, a substrate required for SDO. Moreover, we 
identified and characterized the genes for the yeast and human TST. We demonstrated 
that the TST produced glutathione persulfide, which was released into solution and 
consumed by SDO. Further supporting the coupling of the TST and SDO reactions was 
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the discovery of a bacterial fusion protein containing both a TST domain and a SDO 
domain.  Our findings provide new insight into the metabolic pathway of H2S.  
 
 
 
 
Table 1.1 Properties of SQORs from different organisms 
Organism Type Cyanide Effect Flavoprotein 
FAD covalent 
or 
noncovalently 
bound 
A. ferrooxidans(42, 45) I ND Yes Noncovalent 
A. aeolicus(49) I ND Yes Covalent 
O. limnetica(28) I ND Yes ND 
R. capsulatus(40, 41) I Inhibits Yes ND 
A. marina(19) II Required ND ND 
G. 
stearothermophilus(40)  II 
Increases activity and 
decrease Km for 
sulfide 
Yes ND 
P. putida (39) II Activates and reduces the Km for sulfide Yes ND 
Rat (14) II Required ND ND 
S. pombe (18, 31) II Activates and reduces the Km for sulfide Yes Noncovalent 
A. ambivalens(32) V Inhibits Yes Covalent 
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Scheme 1.1 Proposed catalytic mechanism of Acidithiobacillus ferrooxidans SQOR. The 
proposed mechanism is modified from reference (45). For an explanation go to section 
1.4.2.  
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Scheme 1.2 Proposed catalytic mechanism of Aquifex aeolicus SQOR. The proposed 
mechanism is modified from reference (49). For an explanation go to section 1.4.3. 
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Scheme 1.3 Proposed catalytic mechanism of Acidianus ambivalens SQOR. The 
proposed mechanism is modified from reference (32). For an explanation go to section 
1.4.4. 
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Scheme 1.4 Proposed catalytic mechanism of Rhodobacter capsulatus SQOR. The 
proposed mechanism is modified from reference (41). For an explanation go to section 
1.4.5. 
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Scheme 1.5 Proposed catalytic mechanism of Arenicola marina SQOR. The proposed 
mechanism is modified from reference (19). For explanation go to section 1.4.10. 
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Chapter 2: Human sulfide:quinone oxidoreductase catalyzes the first step in 
hydrogen sulfide metabolism and produces a sulfane sulfur metabolite 
 
 
Adapted from Michael R. Jackson, Scott L. Melideo, and Marilyn Schuman Jorns 
Biochemistry, 2012 
2.1 Abstract  
 Sulfide:quinone oxidoreductase (SQOR) is a membrane-bound enzyme that 
catalyzes the first step in the mitochondrial metabolism of H2S. Human SQOR is 
successfully expressed at low temperature in Escherichia coli by using an optimized 
synthetic gene and cold-adapted chaperonins. Recombinant SQOR contains 
noncovalently bound FAD and catalyzes the 2-electron oxidation of H2S to S0 (sulfane 
sulfur) using CoQ1 as electron acceptor. The prosthetic group is reduced upon anaerobic 
addition of H2S in a reaction that proceeds via a long-wavelength absorbing intermediate 
(λmax = 673 nm). Cyanide, sulfite, or sulfide can act as the sulfane sulfur acceptor in 
reactions that: (i) exhibit pH optima at 8.5, 7.5 and 7.0, respectively; and (ii) produce 
thiocyanate, thiosulfate, or a putative sulfur analog of hydrogen peroxide (H2S2), 
respectively. Importantly, thiosulfate is a known intermediate in the oxidation of H2S by 
intact animals and the major product formed in glutathione-depleted cells or 
mitochondria. H2S oxidation by SQOR with sulfite as the sulfane sulfur acceptor is rapid 
and highly efficient at physiological pH  (kcat/Km H2S = 2.9 × 107 M-1 s-1). A similar 
efficiency is observed with cyanide, a clearly artificial acceptor, at pH 8.5 whereas a 100-
fold lower value is seen with sulfide as acceptor at pH 7.0. The latter reaction is unlikely 
to occur in healthy individuals but may become significant under certain pathological 
conditions. We propose that sulfite is the physiological acceptor of the sulfane sulfur and 
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that the SQOR reaction is the predominant source of the thiosulfate produced during H2S 
oxidation by mammalian tissues.  
2.2 Introduction 
 Hydrogen sulfide is the most recently identified member of a small family of 
labile biological signaling molecules, termed gasotransmitters, which includes nitric 
oxide and carbon monoxide. Mitochondrial metabolism of H2S is coupled to the synthesis 
of ATP (126). The first step of this pathway is catalyzed by sulfide:quinone 
oxidoreductase (SQOR), a poorly characterized inner mitochondrial membrane-bound 
flavoenzyme that is ubiquitously expressed in animals and also found in some lower 
eukaryotes (14, 15, 18, 19, 31, 127). SQOR catalyzes a 2-electron oxidation of H2S to 
sulfane sulfur (S0) using coenzyme Q as electron acceptor. The enzyme also appears to 
require an acceptor for the sulfane sulfur. Cyanide has been used in vitro as a substitute 
for the currently unknown acceptor (14, 18, 19). The sulfane sulfur produced in the 
SQOR reaction is a metabolic precursor of substrates for better-characterized downstream 
enzymes, such as sulfite oxidase. The identity of the sulfane sulfur-containing product of 
the SQOR reaction is necessary to address a major gap in our understanding of the 
mitochondrial pathway(s) for H2S metabolism. It is worth noting that a sulfane sulfur 
donor is required for conversion of cysteine to thiocysteine, suggesting that a possible 
link may exist between H2S metabolism and signaling. 
 SQOR has been purified from several bacteria (32-34). Unlike eukaryotic SQOR, 
the bacterial homologs produce sulfane sulfur in the form of polysulfide chains or 
cyclooctasulfur rings and do not require an acceptor molecule. Characterization of 
eukaryotic SQOR has proved far more challenging, as judged by difficulties encountered 
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in attempts to isolate recombinant forms of the lugworm or yeast enzyme (19, 31). In this 
paper, we describe the expression and characterization of human SQOR and the 
identification of the previously unknown physiological acceptor of the sulfane sulfur. Our 
studies suggest the enzyme may produce the sulfur analog of hydrogen peroxide (H2S2) 
under conditions where the physiological acceptor is limiting. To our knowledge, this is 
the first successful purification of a eukaryotic SQOR.  
2.3 Experimental procedures  
2.3.1 Materials 
 Sodium sulfite was obtained from Fluka. Potassium cyanide was purchased from 
Fisher. Sodium sulfide was obtained from Alfa Aesar. CoQ1 was purchased from Sigma-
Aldrich. Glutathione was obtained from Acros. DHPC was purchased from Avanti Polar 
Lipids. Isopropyl β-D-thiogalactopyranoside was purchased from Gold Biotechnology. 
Restriction enzymes and T4 DNA ligase were obtained from New England Biolabs. PFU 
turbo was obtained from Agilent Technologies. PCR mix was purchased from Amresco. 
2.3.2 Expression of human SQOR in Escherichia coli   
A synthetic version of the gene encoding human SQOR (sqrdl) was obtained from Blue 
Heron Biotechnology, Inc. (Bothell, WA). The synthetic gene (i) contained a single Met 
in place of an N-terminal mitochondrial-targeting presequence (41 amino acids)1; (ii) was 
optimized for expression in E. coli; and (iii) was flanked by unique Nde1 and Xho1 sites, 
a feature achieved by introducing a silent mutation to remove of an internal Nde1 site. 
(See Appendix 1 Figure 1 of the Supporting Information for the sequence of the synthetic 
gene). The synthetic gene was subcloned between the Nde1 and Xho1 sites of plasmid 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1Hauska, G., personal communication 
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pET23a (Novagen) to yield plasmid pET23a_MATopzSQOR. A pACYC-based plasmid 
(pCPN10/60)  was isolated from ArcticExpress (DE3) Competent Cells (Agilent 
Technologies). Plasmid pCPN10/60 contains genes (cpn10, cpn60) for cold-adapted 
chaperonins from Oleispira antarctica (Cpn10, Cpn60) and a gentamycin-resistance 
gene. Plasmid pET23a_MATopzSQOR was used to transform E. coli BL21 (DE3) cells 
to ampicillin resistance. Plasmid pCPN10/60 was then used to transform BL21 (DE3)/ 
pET23a_MATopzSQOR cells to gentamycin resistance. A starter culture was prepared 
by overnight growth of E. coli BL21 (DE3)/ pET23a_MATopzSQOR/pCPN10/60 cells at 
37 ̊C in LB media containing gentamycin (20 μg/mL) and ampicillin (100 μg/mL). The 
starter culture was used to inoculate TB media containing the same two antibiotics. Cells 
were grown with shaking in 2 L flasks containing 500 mL of media at 15 ̊C until the A595 
reached 1.1. SQOR expression was induced with isopropyl β-D-thiogalactopyranoside 
(0.5 mM). Cells were harvested 20 h after induction. The cell pellets (~100 g from 9 L of 
culture) were stored at -80 ̊C.  
2.3.3 Purification of recombinant human SQOR   
 All steps of the purification were conducted at 4 ̊C. Cell pellets (~50 g) were 
thawed and suspended in 75 mL of Tris-acetate buffer, pH 7.6 containing 0.5 M sucrose 
and 0.1 mM EDTA. The cell suspension was mixed with lysozyme (0.5 mg/mL) plus a 
cocktail of nucleases and protease inhibitors (DNAase, 20 μg/mL;  RNAase, 20 μg/mL; 5 
mM magnesium sulfate; soybean trypsin inhibitor, 12.6 μg/mL;  aprotinin, 2 μg/mL; 
phenylmethanesulfonyl fluoride, 25 μM/mL; and tosyllysine chloromethylketone, 3 
μg/mL). The suspension was incubated with stirring for 20 min and then sonicated 
(Branson Model 350, power setting = 6, duty cycle = 40%) for a total of 450 s in 30-s 
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intervals, separated by 30-s cooling periods. Cell debris was removed by centrifugation at 
low speed (10 min at 10,000 g). Membrane-bound SQOR is found in the supernatant 
which contains membrane fragments generated during sonication. The low speed 
supernatant was diluted 1:1 with 50 mM potassium phosphate buffer, pH 7.4, containing 
1% DHPC, 10% glycerol, and a cocktail of protease inhibitors and DNAase, as described 
above. The sample was incubated for 2 h on a rocking platform shaker to solubilize 
SQOR and then centrifuged at 120,000 g for 1 h. The high speed supernatant was 
collected and its buffer was modified to contain 200 mM Tris-HCl, pH 8.0, 200 mM 
sodium chloride and 40 mM imidazole. The high speed supernatant was loaded onto a 5-
mL HiTrap IMAC column (GE Healthcare), previously equilibrated with 40 mM Tris-
HCl buffer, pH 8.0, containing 150 mM sodium chloride and 40 mM imidazole-HCl. The 
column was washed with 50 mM Tris-HCl buffer, pH 8.0, containing 150 mM sodium 
chloride, 10% glycerol, 80 mM imidazole-HCl and 0.05% DHPC. SQOR was eluted with 
50 mM Tris-HCl buffer, pH 8.0, containing 150 mM sodium chloride, 10% glycerol, 160 
mM imidazole-HCl and 0.1% DHPC and stored at -80 ̊C. For the final step of the 
purification, eight batches of IMAC-purified SQOR obtained from ~400 g of cells were 
thawed, pooled, and dialyzed for 2 h versus a ~200-fold excess of Tris-HCl buffer, pH 
8.0, containing 50 mM sodium chloride and 5% glycerol. The sample was centrifuged for 
10 min at 30,000 g. The supernatant was loaded onto a 50-mL HiLoad 26/10 Q 
Sepharose High Performance anion exchange column (GE Healthcare), previously 
equilibrated with 50 mM Tris-HCl buffer, pH 8.0, containing 2% glycerol and 0.03% 
DHPC. The column was washed with 50 mM Tris-HCl buffer, pH 8.0, containing 2% 
glycerol, 100 mM sodium chloride, and 0.06% DHPC (buffer A). SQOR was eluted with 
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a 100 mL linear gradient formed with each of buffer A and buffer B (50 mM Tris-HCl 
buffer, pH 8.0, containing 2% glycerol, 1.0 M sodium chloride, and 0.06% DHPC ). 
SQOR-containing fractions were pooled, concentrated using a 10 K Macrosep Advance 
Centrifugal Device (Pall Life Sciences), and stored in aliquots at -80 ̊C.  
2.3.4 Flavin analysis  
 SQOR was denatured by heating for 5 min at 100 ̊C. The flavin was separated 
from the denatured protein by microfiltration (VWR Centrifugal Filter) and identified as 
FAD, as previously described (128). The stoichiometry of flavin incorporation and the 
extinction coefficient of SQOR at 451 nm were determined after denaturation of the 
enzyme with 3 M guanidine hydrochloride, as described by Wagner et al. (129).  
2.3.5 Activity and protein assays  
 Except as indicated, assays were conducted under anaerobic conditions at 25 ̊C 
using a cuvette (Spectrocell) with a screw-cap equipped with a Teflon-silicon membrane. 
Buffers used to prepare stock solutions of sodium sulfide, sodium sulfite or potassium 
cyanide were bubbled with argon for at least 20 min. Sodium sulfite and sodium cyanide 
(≤ 2 mM) stock solutions were prepared directly in the assay buffer. To prepare more 
concentrated sodium cyanide solutions, a 1 M solution of the substrate was neutralized to 
the desired pH with monobasic potassium phosphate and then diluted with assay buffer. 
Stock solutions of sodium sulfide were prepared in 50 mM potassium 
carbonate/bicarbonate buffer, pH 9.6, containing 250 mM EDTA. The sulfide 
concentration was determined based on its absorbance at 230 nm (e = 7200 M-1cm-1) 
(130). Stock solutions of CoQ1 were prepared in DMSO. Reagents were added to the 
cuvette using argon-purged gas-tight Hamilton syringes. Cuvettes containing buffer, 
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CoQ1, and, where indicated, sulfite or cyanide, were incubated at 25 ̊C for 2 min. An 
aliquot of SQOR was added, and the reaction was initiated immediately thereafter by 
addition of sodium sulfide. Reaction rates were determined by monitoring the reduction 
of CoQ1 at 278 nm (Δεox - red = 12,000 M-1 cm-1) and are corrected for the corresponding 
blank rate observed in the absence of SQOR. The value for Δεox - red was determined using 
the reported extinction coefficient for oxidized CoQ1 (ε278 = 14,500 M-1 cm-1) and the 
absorption spectrum of reduced CoQ1 (λmax = 287 nm; ε287 = 3340 M-1 cm-1) observed 2 s 
after addition of sodium sulfide to assays containing sodium sulfite and a large excess of 
SQOR (131). Unless otherwise indicated, the concentration of SQOR used in steady-state 
kinetic studies was estimated based on the absorbance of the enzyme at 451 nm (ε = 
11,500 M-1 cm-1).    
 Enzyme activity during purification was monitored using a routine assay that 
contained 100 mM potassium phosphate buffer, pH 7.5, 0.5 mM EDTA, 80 μM CoQ1, 
600 μM sodium sulfite and 200 μM sodium sulfide. Similar rates were observed in 
control studies when assays at these substrate concentrations were performed under 
aerobic or anaerobic conditions. Accordingly, the routine assay is conducted using 
aerobic buffer and uncapped 1-mL cuvettes. Stock solutions of sodium sulfide and 
sodium sulfite are, however, prepared and stored on ice under anaerobic conditions. 
During enzyme purification, protein was determined using the Pierce BCA 
(Bicinchoninic Acid Assay) Protein Assay Kit.  
2.3.6 Product analysis  
 To determine the sulfide oxidation product formed in the presence of sulfite, 
assays were conducted at 25 ̊C in 25 mM Tris-HCl, pH 8.0, containing 400 μM sodium 
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sulfide, 1.0 mM sodium sulfite, and 77.6 or 194 μM CoQ1. Reactions were monitored at 
278 nm until reduction of CoQ1 was complete. Aliquots were then withdrawn and 
analyzed for thiosulfate by cold cyanolysis in the presence of copper chloride, as 
previously described (132). To determine the product of sulfide oxidation generated in 
the presence of cyanide, assays were conducted at 25 ̊C in 100 mM potassium carbonate 
buffer, pH 9.0, containing 0.5 mM EDTA, 400 μM sodium sulfide, 1.0 mM potassium 
cyanide, and 277 μM CoQ1. Aliquots were withdrawn when reduction of CoQ1 was 
complete and analyzed for thiocyanate according to the procedure described by Wood 
(133). The product of sulfide oxidation produced in the absence of sulfite or cyanide was 
characterized as described in Results. 
2.3.7 Spectroscopy   
 All spectral data were recorded using an Agilent Technologies 8453 diode array 
spectrophotometer. The reaction of substrate amounts of SQOR with sulfide was 
monitored under anaerobic conditions at 4 ̊C using screw-cap cuvettes. Reaction buffer 
containing 50 mM sarcosine was bubbled with argon for 20 min prior to addition of 
SQOR and an “oxygen sponge” (0.74 μM monomeric sarcosine oxidase, ~10 U/mL of 
catalase). The samples were incubated for at least 20 min at 4 ̊C to scavenge trace 
amounts of oxygen prior to reaction with sulfide. Anaerobic stock solutions of sarcosine 
and sulfide were prepared similar to that described above.  
2.4 Results  
2.4.1 Expression and purification of recombinant human SQOR   
 Major barriers are frequently encountered when attempting to produce even 
modest amounts of a functional, recombinant, membrane-bound mammalian protein like 
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SQOR. In an attempt to overcome these obstacles, we surveyed a wide range of 
expression vectors, prokaryotic, and eukaryotic host cells, and growth conditions. We 
succeeded in expressing mature SQOR (47 kDa) in Escherichia coli by using a synthetic 
version of the human gene that lacked the N-terminal mitochondrial-targeting 
presequence and had been optimized for expression in E. coli. The synthetic gene was 
subcloned into plasmid pET23a to introduce a C-terminal (His)6-tag. E. coli BL21 (DE3) 
cells were sequentially transformed with the resulting SQOR expression plasmid and a 
second compatible (pACYC-based) plasmid containing two genes for cold-adapted 
chaperonins (134). SQOR is expressed as a catalytically active, membrane-bound protein 
when the clone harboring both plasmids is grown at 15 ̊C, conditions that minimize 
inclusion body formation. Optimal solubilization of SQOR was achieved using 0.5% 1,2-
diheptanoyl-sn-glycero-3-phosphocholine (DHPC), a mild, short-chain, phospholipid 
detergent (135). The solubilized enzyme was purified to >95% homogeneity (Figure 2.1) 
in two steps by using metal (Ni2+) affinity and anion exchange chromatography (Table 
2.1).  
 Recombinant human SQOR is stable and contains an approximately 
stoichiometric amount of FAD (Table 2.2). The enzyme exhibits a typical flavoprotein 
visible absorption spectrum with peaks at 451 and 385 nm and a pronounced shoulder at 
473 nm that is eliminated upon denaturation with guanidine hydrochloride (Figure 2.2). 
The yellow flavin color of the denatured enzyme is recovered in the filtrate obtained after 
microfiltration. The data indicate that FAD is noncovalently bound to human SQOR. The 
results fail to support a proposal that the coenzyme would be covalently attached to a 
highly conserved tyrosine residue in eukaryotic SQOR’s (15).  
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2.4.2 Sulfide oxidation with cyanide as the acceptor of the sulfane sulfur   
 An initial assessment of the catalytic activity of human SQOR was performed at 
pH 8.0 in assays containing cyanide as the acceptor of the sulfane sulfur and CoQ1, a 
water soluble ubiquinone derivative, as the electron acceptor. Sulfide oxidation is readily 
detected under these conditions by monitoring the reduction of CoQ1 at 278 nm (kcat app = 
82 ± 6 s-1) (Table 2.2). The reaction is accompanied by the formation of a stoichiometric 
amount of thiocyanate (Table 2.3), as observed with rat and lugworm SQOR (14, 19). 
The rate of sulfide oxidation observed with human SQOR is about 20-fold faster than 
reported for lugworm SQOR under similar conditions (kcat app = 4.5 s-1) (19). 
2.4.3 Identification of a putative physiological acceptor of the sulfane sulfur   
 The reaction with cyanide is clearly not biologically relevant. A clue regarding 
the possible physiological acceptor of the sulfane sulfur in the SQOR reaction was 
provided by an intriguing metabolic abnormality exhibited by patients suffering from 
ethylmalonic encephalopathy and the corresponding mouse model. The patients and the 
knockout mice harbor a defective gene, ETHE1, that codes for sulfur dioxygenase (SDO) 
(22). This enzyme produces sulfite by catalyzing the oxidation of the sulfane sulfur in 
glutathione persulfide (GSS-) (14, 22). Wild-type levels of SQOR activity are observed 
with liver homogenates from Ethe1-/- knockout mice in assays using cyanide as the 
acceptor of the sulfane sulfur. Nevertheless, both the mice and the ethylmalonic 
encephalopathy patients exhibit extremely high, toxic, levels of H2S (22). The observed 
impairment of H2S metabolism suggested that sulfite might be the physiological acceptor 
of the sulfane sulfur in the SQOR reaction.  
 Indeed, we discovered that human SQOR would readily oxidize sulfide in assays 
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containing sulfite in place of cyanide. The rate of sulfide oxidation in the presence of 600 
μM sulfite (kcat app = 251 ± 9 s-1) is 3-fold faster than observed for the reaction with 1.0 
mM cyanide in an otherwise identical assay at pH 8.0 (Table 2.2). Significantly, the 
reaction with sulfite is accompanied by the formation of a stoichiometric amount of 
thiosulfate (Table 2.3). The results show that sulfite can act as the acceptor of the sulfane 
sulfur produced during sulfide oxidation by SQOR. It is noteworthy that numerous 
studies have shown that the observed product, thiosulfate, plays a central role in 
mammalian metabolism of H2S, as will be discussed.   
2.4.4 Sulfide oxidation in the absence of cyanide or sulfite   
 Studies with rat and lugworm SQOR lead us to expect that sulfide oxidation by 
human SQOR would be difficult to detect in the absence an acceptor for the sulfane 
sulfur, such as cyanide (14, 19). However, we found that sulfide oxidation by human 
SQOR is readily detectable in assays containing only sulfide and CoQ1. The observed 
rate of sulfide oxidation in this apparently “acceptor-free” reaction at pH 8.0 (kcat app = 
18.5 ± 0.9 s-1) is, however, considerably slower than seen for the reaction in the presence 
of sulfite or cyanide (13.6- or 4.5-fold, respectively) (Table 2.2). It is worth noting that a 
similar “acceptor-free” reaction has been detected with yeast SQOR (31). 
 Various groups have postulated that SQOR might use glutathione as the acceptor 
of the sulfane sulfur in a reaction that would produce GSS-, the persulfide substrate for 
SDO (14, 22). In a preliminary test of this hypothesis, we sought to determine whether 
glutathione could accelerate the rate of sulfide oxidation by human SQOR, as observed 
with sulfite or cyanide. However, we found that the rate of sulfide oxidation in the 
presence of 1 mM glutathione was, within experimental error, identical to that observed 
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for the “acceptor-free” reaction with only sulfide and CoQ1 (Table 2.2). 
2.4.5 Identification of the sulfide oxidation product formed in the “acceptor-free” 
reaction 
 A working mechanism for SQOR catalysis predicts that turnover of the enzyme 
will occur only in the presence of an acceptor for the sulfane sulfur, as will be discussed. 
The putative “acceptor-free” reaction would appear to be incompatible with this 
mechanism, unless sulfide itself can act as the sulfane sulfur acceptor. In this case, the 
“acceptor-free” reaction should produce hydrogen disulfide, H2S2, the sulfur analog of 
hydrogen peroxide. The pKa values estimated for hydrogen disulfide (pKa1 = 5.0; pKa2 = 
9.7) suggest that the compound will exist predominantly as the monoanion, HS2-, at pH 
8.0 (136). The absorption spectrum of hydrogen disulfide is highly sensitive to its 
protonation state. The unionized H2S2 molecule exhibits a maximum at 258 nm whereas a 
maximum at 358 nm is estimated for the dianion, S2-2. The dramatic 100-nm 
bathochromic shift caused by the removal of two protons is attributed to resonance 
delocalization of electrons in the dianion that are localized to S-H σ bonds in the neutral 
molecule (137, 138). Intermediate spectral properties are expected for the monoanion, 
HS2-, but, to our knowledge, have not previously been described.  
 Based on the above considerations, we hypothesized that the “acceptor-free” 
SQOR reaction would generate the monoanion of hydrogen disulfide at pH 8.0, a species 
likely to absorb in the near-UV region. Evidence to evaluate this hypothesis was sought 
by monitoring the spectral course of assays conducted in the presence or absence of 
sulfite or cyanide. The reaction in the presence of 400 μM sulfite results in a progressive 
loss of the intense absorption band of oxidized CoQ1 at 278 nm and its tail of absorbance 
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at longer wavelengths (λ > 300 nm). The end of the reaction is signaled by the 
appearance of a stable, relatively weak absorption band at 287 nm due to reduced CoQ1 
(Figure 2.3a). A single minimum at 272 nm is seen in difference spectra calculated by 
subtracting the final spectrum of reduced CoQ1 from spectra observed during the reaction 
(data not shown). It is worth noting that similar kinetics are observed for the decrease in 
absorbance at 272 or 317 nm (Figure 2.3a, inset).  
 The same spectral course is observed for assays containing 1.0 mM cyanide 
instead of sulfite (see Appendix 1 Figure 2 of the Supporting Information). A striking 
difference is, however, observed when assays are conducted in the absence of sulfite or 
cyanide. In this case, the loss of the 278 nm absorption band of oxidized CoQ1 is 
accompanied by the formation of a species absorbing in the 300 to 400 nm region (Figure 
2.3b). The corresponding difference spectra exhibit a minimum at 272 nm and a 
maximum at 317 nm (data not shown). Except for a small initial lag, the increase in 
absorbance at 317 nm exhibits kinetics similar to that observed for the decrease in 
absorbance at 272 nm (Figure 2.3b, inset).  
 Hydrogen disulfide should readily react with nucleophiles, such as sulfide or 
cyanide, as judged by results obtained with other persulfides (133). To investigate its 
chemical reactivity, the near-UV absorbing product was generated by allowing the 
“acceptor-free” SQOR assay with limiting CoQ1 to proceed until complete reduction of 
CoQ1. Subsequent addition of 400 μM sulfite results in a rapid loss of the absorbance 
attributed to the putative hydrogen disulfide product in a reaction that is complete in less 
than 5 min. The spectrum observed at the end of the sulfite reaction coincides with that 
expected for reduced CoQ1 (Figure 2.4). The final spectrum was subtracted from the 
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spectrum observed prior to sulfite addition. The resulting difference spectrum exhibits 
maxima at 269 and 315 nm (Figure 2.4, inset). The maximum at 315 nm falls within the 
range expected for the hydrogen disulfide monoanion. A similar reaction is observed 
when sulfite is replaced with cyanide. However, a considerably higher cyanide 
concentration (56 mM) is required to achieve a comparable reaction rate (data not 
shown). The observed difference in the reactivity of the two nucleophiles is attributed to 
the fact that only a small amount of the added cyanide (<5%) will exist as the reactive 
cyanide anion in solution at pH 8.0 (pKa = 9.31) whereas most of the sulfite (>90%) will 
be present as the reactive SO3-2 dianion (pKa = 6.9) at this pH.  
 In addition to nucleophiles, hydrogen disulfide is expected to be consumed by 
thiols in a reduction reaction that produces H2S (λmax = 230 nm) (130, 133). Accordingly, 
studies were conducted to determine whether dithiothreitol (DTT) or glutathione, could 
reduce the product formed in the “acceptor-free” SQOR reaction. In fact, the near-UV 
absorbance of the product was eliminated within 15 min after addition of 1 mM DTT (see 
Appendix 1 Figure 3 of the Supporting Information) or 1 mM glutathione (data not 
shown). The reaction of hydrogen disulfide with DTT is expected to generate an organic 
persulfide intermediate, HS-CH2-(CHOH)2-CH2-SS-, that will undergo a rapid 
intramolecular reaction to produce oxidized DTT and H2S. We reasoned that a slower 
intermolecular reaction might permit detection of the persulfide intermediate formed with 
glutathione, GSS- (λmax = ~340 nm) (139). However, GSS- was not detected in the 
glutathione reaction which exhibited a spectral course very similar to that observed with 
DTT.  
 Addition of 1 mM glutathione to SQOR assays containing only sulfide and CoQ1 
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did not affect the rate of sulfide oxidation (see Table 2.2). The spectral course of these 
assays is, however, very similar to that seen in the presence of sulfite or cyanide (see 
Appendix 1 Figure 4 of the Supporting Information). The observed reduction of the near 
UV-absorbing product with thiols can account for the failure to detect formation of this 
species when SQOR assays are conducted in the presence of glutathione.  
2.4.6 Effect of pH on catalysis by human SQOR 
 We sought to evaluate the catalytic efficiency of SQOR with different sulfane 
sulfur acceptors by comparing sulfide oxidation rates under optimal conditions for each 
acceptor, including reaction pH. A bell-shaped pH-activity profile is observed for sulfide 
oxidation with cyanide as the sulfane sulfur acceptor. The reaction exhibits an optimum 
at pH 8.5 (Figure 2.5a). The data could be fitted to a double ionization titration curve (eq. 
1).  
 
The results indicate that maximal activity is observed when one group is unprotonated 
(AH2 ⇆ AH + H+) (pK1 app) and a second group is protonated (AH ⇆ A + H+) (pK2 app) 
(Table 2.4). A similar optimum at moderately alkaline pH (9.0) is observed for the 
lugworm SQOR reaction with cyanide (19). Sulfide oxidation by human SQOR with 
sulfite as the sulfane sulfur acceptor also exhibits a bell-shaped pH-activity profile. 
However, the optimum is at pH 7.5, close to physiological pH and one pH unit lower than 
observed for the cyanide reaction (Figure 2.5a). The values estimated for pK1 app and pK2 
app in the reaction with sulfite exhibit a similar shift to more acidic pH (Table 2.4). The 
“acceptor-free” SQOR reaction exhibits a pH optimum at 7.0 (Figure 2.5b) and apparent 
[H+]2VAH2 + [H+]K1VAH + K1K2VA
             K1K2 + [H+]K1 + [H+]2  
Vobs= (eq. 1) 
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pKa values that are most similar to those observed for the reaction with sulfite (Table 
2.4).   
2.4.7 Steady-state kinetic parameters for sulfide oxidation by SQOR with different 
acceptors of the sulfane sulfur   
 Turnover of SQOR with each acceptor was monitored at the pH optimum 
determined for the reaction. The reactions with sulfite or cyanide involve three different 
substrates. Steady-state kinetics parameters for such reactions can be estimated by 
varying the concentration of one substrate at a fixed, saturating concentration of the other 
two substrates (140). We found that reaction rates with sulfite or cyanide as acceptor 
exhibit an expected hyperbolic dependence on the concentration of each of the three 
varied substrates (kcat app = kcat[S]/(Km +[S]). Values obtained for kcat with either acceptor 
are independent of the nature of the varied substrate (Table 2.5). Interestingly, the 
turnover rate observed with sulfite at pH 7.5 is, within experimental error, identical to 
that observed with cyanide at pH 8.5, as judged by comparing the average values 
obtained for kcat with the two acceptors (kcat avg = 370 ± 14 and 345 ± 11 s-1, respectively). 
The apparent Km observed for sulfite is 4-fold smaller than observed for cyanide. 
However, very similar apparent Km values for sulfide and CoQ1 are obtained with either 
acceptor.  
 The reaction with sulfide as the sulfane sulfur acceptor is essentially an oxidative 
dimerization of two identical substrates. According to a steady-state equation derived for 
this type of reaction (eq. 2), the velocity observed at a fixed saturating concentration of 
CoQ1 should not exhibit a simple hyperbolic dependence on the concentration of sulfide 
except under the limiting condition where [sulfide] >> Km1 (141, 142).  
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 In fact, the latter is observed when the sulfide concentration is varied in the range from 
40 to 2100 μM (see Appendix 1 Figure 5 of the Supporting Information). Measurements 
at higher sulfide concentrations were not possible owing to prohibitively high blank rates. 
The apparent Km obtained for sulfide in this reaction (315 ± 28 μM) is about 25-fold 
larger than observed with sulfite or cyanide as the sulfane sulfur acceptor (Table 2.5). 
The high Km value precluded studies at a fixed saturating sulfide concentration and a 
variable concentration of CoQ1. The turnover rate estimated for the reaction with sulfide 
as sulfane sulfur acceptor (kcat = 65 ± 2 s-1) exhibits a relatively modest decrease (6-fold) 
compared with values obtained for the reactions with sulfite or cyanide. The catalytic 
efficiency of the reaction with sulfide as acceptor is, however, more than 100-fold lower 
than observed with sulfite or cyanide, as judged by values calculated for the ratio, kcat/Km 
H2S (Table 2.5).  
2.4.8 Anaerobic reduction of SQOR with sulfide   
 Anaerobic reaction of SQOR with 1 or 2 equivalents of sulfide results in the rapid 
formation of an intermediate that exhibits a moderately intense long-wavelength 
absorption band that is centered at 673 nm and extends out to nearly 900 nm, 
accompanied by a loss of ~35% of the absorbance of the oxidized enzyme at 451 nm 
(Figure 2.6, curve 1). The SQOR intermediate undergoes a slow isosbestic conversion to 
a reduced species that exhibits a maximum at 365 nm, a plateau around 450 nm, and a tail 
of absorbance extending into the long-wavelength region (Figure 2.6, curve 6). The 
conversion of the intermediate to the final reduced product exhibits apparent first-order 
Vmax%%
             1+%(Km2/[S])%(%1+%(Km1%/[S]))%
Vobs= (eq. 2) 
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kinetics (Figure 2.6, inset). However, the observed rate of this reaction (k = 4.1 ± 0.2 × 
10-3 s-1) is more than four orders of magnitude slower than rates observed for turnover of 
SQOR with sulfite, cyanide, or sulfide as the sulfane sulfur acceptor. The possible 
identity and catalytic significance of the two species observed during reaction of SQOR 
with sulfide will be discussed. Immediate oxidation of the reduced enzyme is observed 
upon addition of CoQ1 (Figure 2.6, curve 7). The re-oxidized enzyme exhibits a similar 
absorption band at 450 nm but enhanced absorbance in the 380 nm region as compared 
with untreated enzyme. The basis for the latter difference is unclear.  
2.5 Discussion 
 Human SQOR is expressed in E. coli at low temperature as a catalytically active 
membrane-bound protein, an outcome dependent on the use of a synthetic gene optimized 
for expression in a prokaryotic host and the assistance of cold-adapted bacterial 
chaperonins. Solubilized SQOR is readily purified to produce a stable homogenous 
holoenzyme that contains a nearly stoichiometric amount of noncovalently bound FAD. 
SQOR is one of a small group of mammalian membrane-bound proteins that have been 
successfully expressed in E. coli. A similar approach may facilitate the expression of 
other intrinsic mammalian proteins.  
 Recombinant SQOR catalyzes the 2-electron oxidation of H2S using CoQ1 as 
electron acceptor and one of three different nucleophiles (cyanide, sulfite, or sulfide) as 
the acceptor of the sulfane sulfur in reactions that exhibit pH optima at 8.5, 7.5 and 7.0, 
respectively. The reaction with cyanide is accompanied by the formation of a 
stoichiometric amount of thiocyanate. Our studies confirm the nucleophile’s ability to act 
as an artificial acceptor for eukaryotic SQOR, in agreement with results obtained with rat 
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and lugworm SQOR (14, 19). The reaction with sulfite produces thiosulfate, a known 
intermediate in H2S metabolism. The product of the reaction with sulfide as acceptor has 
been tentatively identified as hydrogen disulfide, H2S2, on the basis of its near-UV 
absorption and reactivity with nucleophiles and thiol reductants. The effect of the 
acceptor on the catalytic efficiency of H2S oxidation can be assessed by comparison of 
values obtained for kcat/Km H2S at the pH optimum of each reaction. The catalytic 
efficiency observed with sulfite at physiological pH (2.9 × 107 M-1 s-1) is similar to that 
observed with cyanide at moderately alkaline pH (3.1 × 107 M-1 s-1) whereas a 100-fold 
lower value is seen with sulfide (2.1 × 105 M-1 s-1). The reaction with sulfide as the 
acceptor is unlikely to occur in healthy individuals but may become significant under 
certain pathological conditions. We propose that sulfite is the biological acceptor, as 
discussed below.  
2.5.1 Role of SQOR in the biosynthesis of thiosulfate  
 Thiosulfate is the major product of H2S oxidation by:  (i) isolated mitochondria; 
(ii) hepatocytes depleted of glutathione; and (iii) the colon in intact animals where large 
quantities of H2S are produced by sulfate-reducing bacteria (9, 12, 14, 143). Oxidation of 
thiosulfate to sulfate:  (i) requires a glutathione-dependent thiosulfate reductase and 
sulfite oxidase (5, 144) and (ii) is observed when isolated mitochondria are supplemented 
with glutathione and with untreated hepatocytes (9, 143). Additionally, the elegant 
experiments of Koj et al. (144) and Szczepkowski et al. (8) support a central role for 
thiosulfate as a key intermediate in the oxidation of H2S by perfused liver and intact 
animals. 
 We propose that thiosulfate biosynthesis occurs in the first step of H2S oxidation 
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in a reaction catalyzed by SQOR with sulfite as the acceptor of the sulfane sulfur. Our 
studies with the recombinant human enzyme show that the reaction is rapid and highly 
efficient at physiological pH. In fact, the observed efficiency of SQOR is just 4-fold 
lower than reported for carbonic anhydrase, one of the most potent known catalysts 
(kcat/Km = 1.2 × 108 M-1 s-1) (145). Rhodanese is a mitochondrial enzyme best known for 
its ability to utilize thiosulfate as a source of sulfane sulfur in the production of 
thiocyanate (20). Hildebrandt and Grieshaber postulated that thiosulfate is produced from 
GSS- and sulfite in an alternate rhodanese reaction (14) . However, thiosulfate formation 
with human SQOR is more than 2 orders of magnitude faster than the rate of thiosulfate 
formation observed with bovine or rat rhodanese (kcat app = 2.3 or 0.22 s-1, respectively). 
Furthermore, the sluggish rhodanese reaction is unlikely to effectively compete with the 
much faster rate of GSS- oxidation observed with SDO (kcat app = 51 s-1)2. Finally, it is 
worth noting that inhibitors of SQOR reduce the production of thiosulfate from H2S by 
mouse colon (146). Overall, the results strongly implicate the SQOR reaction as the 
predominant source of thiosulfate produced during H2S oxidation by mammalian tissues.   
 Thiosulfate is the major product of H2S oxidation in glutathione-depleted cells or 
mitochondria. Formation of 1 mol of thiosulfate requires an 8-electron oxidation of 2 mol 
of H2S. A 4-step pathway can account for the observed conversion of H2S to thiosulfate 
under these conditions (Scheme 2.1, path A). Steps 1 and 4 are catalyzed by SQOR. The 
thiosulfate produced in step 1 is likely to act as the substrate for a sulfur transferase (ST) 
that regenerates the sulfite consumed in step 1 and produces GSS-. The latter undergoes a 
4-electron oxidation reaction catalyzed by SDO (step 3) that produces the sulfite required 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 Jackson, M. R. and Jorns, M. S., unpublished observations. 
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for step 4 and regenerates the glutathione consumed in step 2. The ST and SDO reactions 
are likely to be tightly coupled to prevent decomposition of GSS-, a labile metabolite 
(22)3. The pathway is largely short-circuited by the absence of SDO in ethylmalonic 
encephalopathy patients owing to their impaired ability to produce sulfite. The resulting 
greatly elevated H2S levels will promote H2S oxidation by SQOR in an alternate reaction 
that uses sulfide as acceptor and produces hydrogen disulfide instead of thiosulfate. 
Hydrogen disulfide is, however, likely to be reduced by glutathione in a futile cycle that 
regenerates H2S and causes oxidative stress by depleting the mitochondrial pool of 
reduced glutathione. In this regard it is noteworthy that N-acetylcysteine, an antioxidant 
and glutathione precursor, has been shown to reduce the severity of the pathology 
exhibited by ethylmalonic encephalopathy patents (147).  
 It is known that thiosulfate can be converted to sulfate in a glutathione-dependent 
pathway involving the sequential action of thiosulfate reductase (TSR) and sulfite 
oxidase (SO) (5, 7) (Scheme 2.1, path B). The operation of both paths A and B in the 
presence of glutathione means that two pairs of enzymes, SQOR/SO and ST/TSR, will 
compete for substrates (sulfite and thiosulfate, respectively) that are common to both 
pathways. Interestingly, SQOR and SO exhibit nearly identical catalytic efficiencies for 
sulfite utilization, as judged by values obtained for kcat/Km sulfite (2.1 × 106 and 2.4 × 106 M-
1 s-1, respectively) (148). Its inner mitochondrial membrane location may favor sulfite 
utilization by SQOR because reaction with SO requires transport of the metabolite from 
the matrix to the intermembrane space. However, the availability of H2S is likely to play 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3SDO has been reported to form a complex with rhodanese. The ST that produces GSS- 
is, however, currently unknown. 
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a decisive role in the partitioning of sulfite between the two pathways. Consistent with 
this hypothesis, elevated urinary excretion of thiosulfate is observed under conditions 
associated with elevated H2S levels, such as Down’s syndrome (82), environmental 
exposure to H2S gas (149), and ethylmalonic encephalopathy (22). A minor cysteine 
catabolic pathway is thought to provide the sulfite required to generate the elevated 
urinary thiosulfate observed in ethylmalonic encephalopathy patients (22, 150)4. The 
partitioning of thiosulfate is clearly regulated by the availability of glutathione, probably 
because 2 mol of glutathione are consumed by the TSR reaction in path B whereas only 
catalytic amounts are required for the ST-SDO reaction in path A.  
2.5.2 Mechanism of SQOR catalysis   
 SQOR exhibits homology with flavoprotein disulfide oxidoreductases, such as 
glutathione reductase and flavocytochrome c sulfide dehydrogenase (15). These enzymes 
utilize a Cys-S-S-Cys disulfide bridge as a redox center in addition to flavin. Human 
SQOR contains two cysteine residues (Cys201, Cys379) that are:  (i) conserved in all 
eukaryotic homologs (15); and (ii) essential for catalytic activity5. Cys201 aligns with the 
“proximal” cysteine of the redox-active disulfide in flavocytochrome c sulfide 
dehydrogenase, i.e., the cysteine closer to the C(4a) position of FAD (151). By analogy 
with mechanisms observed for other members of the flavoprotein disulfide 
oxidoreductase family (152), we propose that the SQOR reaction is initiated by 
nucleophilic attack of HS- (the predominant H2S form at physiological pH) at the distal 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
4 Cysteine sulfinic acid, produced from cysteine by cysteine dioxygenase, is mainly (70-
90%) converted to hypotaurine. However, a small amount of this metabolite may undergo 
transamination to produce β-sulfinylpyruvate, a compound that spontaneously 
decomposes to pyruvate and sulfite.  
5Melideo, S. L. and Jorns, M. S. unpublished observations. 
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cysteine, Cys379, to produce an intermediate containing:  (i) a protein-bound persulfide, 
Cys379SS- and (ii) a charge-transfer (CT) complex of FAD with Cys201S- or Cys379SS- 
(Scheme 2.2, step 1). Nucleophilic attack of Cys201S- at the C(4a) position of the flavin 
ring produces a covalent flavin adduct, 4a-adduct I (step 2). Reaction of this intermediate 
with a nucleophilic acceptor of the sulfane sulfur (N:) generates an intermediate, 4a-
adduct II, containing the thiolate form of Cys379 (step 3). Nucleophilic attack of Cys379S- 
at the sulfur atom in the 4a-adduct produces an intermediate containing 1,5-dihydroFAD 
plus the original disulfide (EFADred/disulfide) (step 4). The catalytic cycle is completed 
upon transfer of electrons from EFADred/disulfide to coenzyme Q (step 5). 
 Consistent with the proposed mechanism, turnover of SQOR requires an acceptor 
(N:) that may be sulfite, cyanide or HS-, and produces an expected sulfane sulfur-
containing product, thiosulfate, thiocyanate or hydrogen disulfide, respectively. An 
intermediate that exhibits a long-wavelength absorption band, centered at 673 nm and 
extending out to nearly 900 nm, is detected immediately after mixing SQOR with sulfide 
under anaerobic conditions. Blue neutral flavin radicals absorb in the long-wavelength 
region but exhibit maxima at shorter wavelengths and negligible absorbance at 700 nm 
(153). On the other hand, CT complexes with oxidized or 1,5-dihydroflavins exhibit 
maxima in the long-wavelength region that can vary over a wide range (>500 to ~800 
nm), depending on the difference in the 1-electron reduction potential of the donor and 
acceptor (154-157). The absorption spectrum of the SQOR intermediate is consistent with 
a CT complex of the oxidized flavin with Cys201S- or Cys379SS- that may be in equilibrium 
with 4a-adduct I. Studies to further characterize this intermediate are in progress.  
 The SQOR intermediate is slowly converted to a reduced species that exhibits a 
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maximum at 365 nm, a broad shoulder around 450 nm, and a tail of absorbance at λ > 
500 nm. The spectral properties of this species are highly suggestive of a 1,5-
dihydroflavin complex with a CT acceptor. The complex is, however, formed at a rate 
that is much slower than turnover, indicating that it is not a kinetically competent 
intermediate. We propose that a slow rearrangement of 4a-adduct I produces a CT 
complex of 1,5-dihydroFAD with thiocystine, Cys379SSSCys201 (Scheme 2.2, step 6). The 
reaction does not require a sulfane sulfur acceptor but does produce a species, 
EFADred/thiocystine, that could react with coenzyme Q to generate EFADox\thiocystine 
(Scheme 2.2, step 7). Step 7 can account for the reaction observed when the reduced 
species is mixed with CoQ1. It is worth noting that thiocystine is postulated as a catalytic 
intermediate in the oxidative polymerization of sulfide that is observed with prokaryotic 
SQOR’s (32-34).  
2.5.3 Concluding remarks   
 H2S is a signaling molecule with multiple physiological functions but also a 
highly toxic substance that must be tightly regulated to avoid potential adverse effects, 
such as inhibition of cytochrome oxidase and mitochondrial respiration. The highly 
efficient SQOR reaction will rapidly convert H2S to thiosulfate, a non-toxic metabolite 
and known intermediate in the mitochondrial oxidation of the gasotransmitter. 
Nevertheless, the observed metabolism of H2S to sulfate via a thiosulfate intermediate 
appears somewhat convoluted compared with a hypothetical 3-step pathway in which 
H2S is directly converted to GSS- and then sequentially oxidized to sulfite and sulfate 
(H2S ⇒ GSS- ⇒ SO3-2 ⇒ SO4-2). The alternative route is, of course, ruled out by the fact 
that glutathione does not act as an acceptor of the sulfane sulfur in the SQOR reaction. 
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However, the comparison suggests that the more convoluted metabolism of H2S via a 
thiosulfate intermediate may have evolved because the metabolite plays an important role 
in H2S signaling. Thus, the zero-valent sulfur in thiosulfate may provide a source of the 
sulfane sulfur that is required for sulfhydration of cysteine residues in proteins and/or act 
as an intracellular storage site from which H2S can be readily mobilized by a thiosulfate 
reductase. Unraveling the myriad aspects of H2S signaling will clearly require additional  
studies. 
  
 
 
 
Table 2.1 Purification of Recombinant SQOR from E. colia 
Purification step Total activity 
(U)b 
Total protein 
(mg) 
Specific activity 
(U/mg) 
Yield 
(%) 
High speed 
supernatant 
32,200 27,600 1.17 100 
IMAC 11,100 89.8 124 34.5 
Q Sepharose  8,330 14.3 581 25.9 
aSQOR was purified from ~400 g of cells, as detailed in Experimental Procedures. bA unit 
of activity is defined as the formation of 1 μmol of reduced CoQ1 at 25 ̊C using a routine 
aerobic assay, as described in Experimental Procedures. 
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Table 2.2 Spectral and Catalytic Properties of 
Recombinant Human SQOR 
λmax 451, 385, and 277 nm 
ε451 11,500 M-1 cm-1 
A280/A451 9.24 
mol FAD/mol protein 0.82 
catalytic activity  kcat app (s-1)a 
HS- + CN- + CoQ1 
HS- + SO3-2 + CoQ1 
HS- + CoQ1 
HS- + GSH + CoQ1 
    82 ± 6 
   251 ± 9 
18.5 ± 0.9 
   19 ± 3 
aReaction rates were measured at 25 ̊C by monitoring 
CoQ1 reduction at 278 nm in anaerobic 100 mM 
potassium phosphate buffer, pH 8.0, containing 0.5 mM 
EDTA, 200 μM sulfide, 80 μM CoQ1, and, where 
indicated, 600 μM sulfite, 1.0 mM cyanide or 1 mM 
glutathione (GSH).  
 
 
 
 
Table 2.3 Stoichiometry of Products formed in the SQOR 
Reaction with Different Acceptors of the Sulfane Sulfura 
Acceptor [CoQ1] (μM) [Product] (μM) 
thiosulfate  thiocyanate 
cyanide 277  243 ± 6 
sulfite 77.6 
194 
77.4 
182 
 
aAssays were conducted in the presence of a limiting 
amount of CoQ1, 400 μM sulfide, and 1.0 mM cyanide or 
1.0 mM sulfite, as described in Experimental Procedures. 
Aliquots were withdrawn when reduction of CoQ1 was 
complete and analyzed for thiocyanate or thiosulfate using 
previously described methods (132, 133) 
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Table 2.4 Effect of pH on Sulfide Oxidation by SQOR with 
Different Acceptors of the Sulfane Sulfura  
acceptor pH optimum pK1 app pK2 app 
cyanide 8.5 7.6 ± 0.3 9.6 ± 0.4 
sulfite 7.5 6.3 ± 0.2 8.4 ± 0.1 
sulfide 7.0 5.9 ± 0.1 8.22 ± 0.09 
aParameters were determined as described in the legend to 
Figure 2.5. 
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Table 2.5 Steady-state Kinetic Parameters for Three Reactions Catalyzed by Human 
SQORa 
sulfide  +  sulfite  +  CoQ1   ⇒  thiosulfate  +  CoQ1H2 
Variable substrate Fixed substratesb Km (μM) kcat (s-1) kcat/Km (M-1 s-1) 
sulfide sulfite, CoQ1 13 ± 3 379 ± 20 2.9 ± 0.6 × 107 
sulfite sulfide, CoQ1 174 ± 20 368 ± 14 2.1 ± 0.3 × 106 
CoQ1 sulfide, sulfite 19 ± 2 364 ± 8 1.9 ± 0.2 × 107 
sulfide  + cyanide  +  CoQ1   ⇒  thiocyanate  +  CoQ1H2 
Variable substrate Fixed substratesc Km (μM) kcat (s-1) kcat/Km (M-1 s-1) 
sulfide cyanide, CoQ1 10.9 ± 0.7 343 ± 9 3.1 ± 0.2 × 107 
cyanide sulfide, CoQ1 650 ± 80 330 ± 12 5.1 ± 0.7 × 105 
CoQ1 sulfide, cyanide 14 ± 2 360 ± 13 2.7 ± 0.3 × 107 
2 sulfide  +  CoQ1  ⇒  hydrogen disulfide  +  CoQ1H2 
Variable substrate Fixed substrated Km (μM) kcat (s-1) kcat/Km (M-1 s-1) 
sulfide CoQ1 315 ± 28 65 ± 2 2.1 ± 0.2 × 105 
aApparent Km values for the variable substrate were determined at saturating 
concentrations of the fixed substrates or at concentrations that yielded the maximum 
possible reaction rate in cases where excess substrate inhibition was observed. All 
measurements were made in buffers containing 0.5 mM EDTA at 25 ̊C. Reactions with 
sulfite, cyanide or sulfide as the sulfane sulfur acceptor were conducted in 100 mM 
potassium phosphate pH 7.5, 100 mM potassium pyrophosphate pH 8.5 or 100 mM 
potassium phosphate pH 7.0, respectively. bMeasurements were made at the following 
fixed substrate concentrations: 83 μM sulfide, 99 μM CoQ1, and 2000 μM sulfite. 
cMeasurements were made at the following fixed substrate concentrations: 47 μM 
sulfide, 72.5 μM CoQ1 and 6000 μM cyanide. dMeasurements were made at 66.2 μM 
CoQ1.  
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Scheme 2.1 Proposed pathways for H2S metabolism in: (i) glutathione-depleted cells or 
mitochondria (path A) and (ii) untreated cells or intact animals (paths A + B). ST, sulfur 
transferase; SDO, sulfur dioxygenase; TSR, thiosulfate reductase; SO, sulfite oxidase.  
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Scheme 2.2 The catalytic mechanism proposed for SQOR is indicated by the steps (1-5) 
enclosed within the dotted rectangle. The complex formed in step 1 may involve CT 
interaction with Cys201S-, as indicated, or with Cys379SS- (not shown). Step 6 is postulated 
to account for a slow step observed during the anaerobic reaction of the enzyme with 
sulfide, as discussed in the text. 
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Figure 2.1 Expression of recombinant human SQOR. The SDS-12% polyacrylamide gel 
was stained for protein with ProSieve Blue Protein Staining Solution (Lonza). Molecular 
markers are shown in lane M. Lane 1, crude cell lysate; lane 2, high speed supernatant; 
lane 3, IMAC wash; lane 4, IMAC eluate; lane 5, dialyzed IMAC eluate; lane 6, Q 
Sepharose eluate; lane 7, concentrated Q Sepharose eluate. 
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Figure 2.2 Absorption spectra of native and denatured SQOR. The black curve is the 
absorption spectrum of SQOR in 100 mM potassium phosphate buffer, pH 7.4, 
containing 0.04% DHPC. The red curve was recorded after denaturation with 3 M 
guanidine hydrochloride. 
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Figure 2.3 Effect of sulfite on the spectral course of SQOR catalytic assays. Reactions 
were conducted in 100 mM potassium phosphate, pH 8.0, containing 0.5 mM EDTA at 
25 ̊C in the presence (panel A) or absence (panel B) of sulfite. Red arrows indicate the 
direction of the spectral changes observed at λ > 300 nm. Panel A: The dotted black line 
was recorded before addition of 300 μM sulfide to an assay mixture containing 160 μM 
CoQ1, 400 μM sulfite and 7.2 nM SQOR. Curves 2 to 7 were recorded 1.4, 12, 27, 42, 62, 
82, and 132 s, respectively, after sulfide addition. Panel B: The dotted black line was 
recorded before addition of 300 μM sulfide to an assay mixture containing 160 μM CoQ1 
and 35.6 nM SQOR. Curves 1 to 9 were recorded 2.6, 33.2, 58.2, 88.2, 108, 133, 158, 
183, and 233 s, respectively, after sulfide addition. The inset in each panel shows the time 
course of absorbance changes at 272 and 317 nm plotted according to the left and right y-
axes, respectively.  
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Figure 2.4 Reaction of sulfite with the sulfur oxidation product formed during the 
apparent “acceptor-free” oxidation of sulfide by SQOR. Reactions were conducted in 100 
mM potassium phosphate, pH 8.0, containing 0.5 mM EDTA at 25 ̊C. The dotted black 
line was recorded after maximal formation of the sulfur oxidation product in an assay 
mixture containing 300 μM sulfide, 160 μM CoQ1 and 35.6 nM SQOR. Curves 1 to 6 
were recorded 22, 42, 62, 92, and 292 s, respectively, after addition of 400 μM sulfite. 
The inset shows a difference spectrum calculated by subtracting the spectrum observed at 
the end of the sulfite reaction from the spectrum observed before sulfite addition.  
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Figure 2.5  Effect of pH on the rate of sulfide oxidation observed with SQOR in the 
presence or absence of sulfite or cyanide. The red and blue curves in panel A were 
obtained for the reactions in the presence of sulfite or cyanide respectively. Panel B 
shows the results obtained for the reaction in the absence of sulfite and cyanide. 
Reactions were monitored at 25 ̊C by measuring the reduction of CoQ1 at 278 nm, as 
described in Experimental Procedures. Assays contained 200 μM sulfide, 80 μM CoQ1 
and, where indicated, 600 μM sulfite or 1.0 mM cyanide. All reactions contained 0.5 mM 
EDTA plus one of the following buffers: 100 mM potassium citrate, pH 5 to 6; 100 mM 
potassium phosphate, pH 6 to 8; 100 mM potassium pyrophosphate, pH 8 to pH 9; 100 
mM potassium carbonate/bicarbonate, pH 9 to 10.5. The solid lines were obtained by 
fitting equation 1 to the data (filled circles).  
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Figure 2.6 Anaerobic reaction of SQOR with sulfide and CoQ1. Curve 1 is the absorption 
spectrum of 6.82 μM SQOR in anaerobic 25 mM Tris-HCl buffer, pH 8.0 at 4 ̊C. Curves 
2 to 6  were recorded 0, 1, 3, 5, and 14 min, respectively, after addition of 16.4 μM 
sulfide. Curve 7 (dotted line) was recorded 1 min after addition of 17.5 μM CoQ1. The 
inset shows a plot of the absorbance decrease at 450 nm observed after sulfide addition. 
The black line was obtained by fitting a single exponential equation (y = Ae-k1t + B) to the 
data (red circles). Similar results were obtained in a separate experiment upon addition of 
1.1 equivalents of sulfide (data not shown).  
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Chapter 3: Biosynthesis of a central intermediate in hydrogen sulfide metabolism by 
a novel human sulfurtransferase and its yeast ortholog  
 
 
Adapted from Scott L. Melideo, Michael R. Jackson, and Marilyn Schuman Jorns 
Biochemistry 2014 
3.1 Abstract 
 Human sulfide:quinone oxidoreductase (SQOR) catalyzes the conversion of H2S 
to thiosulfate, the first step in mammalian H2S metabolism. SQOR’s inability to produce 
the glutathione persulfide (GSS-) substrate for sulfur dioxygenase (SDO) suggested that a 
thiosulfate:glutathione sulfurtransferase (TST) was required to provide the missing link 
between the SQOR and SDO reactions. Although TST could be purified from yeast, 
attempts to isolate the mammalian enzyme were not successful. We used bioinformatic 
approaches to identify genes likely to encode human TST (TSTD1) and its yeast ortholog 
(RDL1). Recombinant TSTD1 and RDL1 catalyze a predicted thiosulfate-dependent 
conversion of glutathione to GSS-. Both enzymes contain a rhodanese homology domain 
and a single catalytically essential cysteine, which is converted to cysteine persulfide 
upon reaction with thiosulfate. GSS- is a potent inhibitor of TSTD1 and RDL1, as judged 
by initial rate accelerations and ≥25-fold lower Km values for glutathione observed in the 
presence of SDO. The combined action of GSS- and SDO is likely to regulate the 
biosynthesis of the reactive metabolite. SDO drives to completion p-
toluenethiosulfonate:glutathione sulfurtransferase reactions catalyzed by TSTD1 and 
RDL1. The thermodynamic coupling of the irreversible SDO and reversible TST 
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reactions provides a model for the physiologically relevant reaction with thiosulfate as 
the sulfane donor. The discovery of bacterial Rosetta stone proteins that comprise fusions 
of SDO and TSTD1 provides phylogenetic evidence for the association of these enzymes. 
The presence of adjacent bacterial genes encoding SDO-TSTD1 fusion proteins and 
human-like SQORs suggests these prokaryotes and mammals exhibit strikingly similar 
pathways for H2S metabolism. 
3.2 Introduction  
 H2S is the only gasotransmitter that is enzymatically metabolized and the only 
inorganic compound that can be used by mammalian mitochondria to generate ATP 
(126). H2S metabolism is particularly important because the gasotransmitter is a Janus-
faced molecule that can exhibit toxic effects at supraphysiological concentrations. The 
first step in the mitochondrial metabolism of H2S is catalyzed by sulfide:quinone 
oxidoreductase (SQOR), an inner mitochondrial membrane-bound flavoenzyme that 
catalyzes a two-electron oxidation of H2S to sulfane sulfur (S0) using coenzyme Q as an 
electron acceptor (14-16, 158). The enzyme also requires an acceptor for the sulfane 
sulfur. Recently, the Jorns lab successfully expressed human SQOR as a membrane-
bound protein in Escherichia coli and identified sulfite (SO3-2) as the physiological 
acceptor of the sulfane sulfur (158). This reaction produces thiosulfate (SSO3-2) (Scheme 
3.1, step 1), a known intermediate in the oxidation of H2S to sulfate by animals or 
perfused liver (7-9). Thiosulfate is also a major product of H2S metabolism by colon, a 
tissue that must detoxify large amounts of H2S produced by sulfate-reducing bacteria (12, 
13). 
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 The identification of thiosulfate as the product of the SQOR reaction requires a 
major revision of previously suggested pathways for the downstream metabolism of the 
gasotransmitter (1, 14). We propose that thiosulfate acts as a substrate for a glutathione-
dependent thiosulfate sulfurtransferase (TST) (Scheme 3.1, step 2). The TST reaction 
produces glutathione persulfide (GSS-) and also regenerates the sulfite consumed in step 
1. GSS- is a known substrate for sulfur dioxygenase (SDO), an enzyme that catalyzes a 4-
electron oxidation of the sulfane sulfur in GSS- to produce sulfite (Scheme 3.1, step 3) 
(14, 21, 22). The last step of H2S metabolism may proceed via one of two competing 
alternative reactions, a scenario that can account for observed tissues differences in the 
final product. In one path, the sulfite produced in step 3 undergoes a 2-electron oxidation 
catalyzed by sulfite oxidase (SO) using cytochrome c as electron acceptor to produce 
sulfate (Scheme 3.1, step 4). This path results in an overall 8-electron oxidation of 1 mol 
of H2S to sulfate, the major product of H2S metabolism in liver. Alternatively, the sulfite 
produced in step 3 may be further metabolized by SQOR (Scheme 3.1, step 5). This path 
achieves an overall 8-electron oxidation of 2 mol of H2S to 1 mol of thiosulfate, the major 
metabolic product observed in colon. SQOR and SO exhibit nearly identical catalytic 
efficiencies for sulfite utilization (kcat/Km sulfite = 2.11 × 106 and 2.4 × 106 M-1 s-1, 
respectively), suggesting that the availability of H2S is likely to play a key role in the 
partitioning of sulfite between the two competing reactions (148, 158). Consistent with 
this hypothesis, elevated urinary excretion of thiosulfate is observed under conditions that 
result in pathologically high levels of H2S (e.g, Down’s syndrome, sub-lethal 
environmental exposure to H2S gas, ethylmalonic encephalopathy and in patients affected 
by sulfite oxidase deficiency (22, 82, 149, 159). The ability to rapidly convert H2S to 
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thiosulfate is forcefully illustrated by the large increase in blood thiosulfate levels (up to 
200-fold) that is observed in fatal cases of H2S poisoning where death occurs virtually 
instantaneously, before thiosulfate can be detected in the urine (160). 
 The proposed  (scheme 3.1) is consistent with key features observed for 
mammalian metabolism of H2S, including the known catalytic properties of SQOR, SDO 
and SO. Little information is, however, currently available regarding the postulated TST. 
Operationally, TST can be defined as an enzyme that uses thiosulfate to produce sulfite in 
a glutathione-dependent reaction. The same operational definition has been used in 
studies with enzymes referred to as thiosulfate reductases (TRs), a nomenclature that 
implies that the reactions also generate H2S and oxidized glutathione (GSSG) (eq. 3) 
(144, 161-163).  
SSO32- + 2GS- + H+ ! SO32- + HS- + GSSG  (eq. 3) 
For simplicity, an enzyme that satisfies the operational definition described above will be 
referred to as a TST with the understanding that additional studies are required to justify 
the rigorous use of this terminology. 
 Although TST activity is readily detected in liver extracts, attempts to isolate the 
mammalian enzyme have not been successful (144, 164). On the other hand, a TST was 
purified from Saccharomyces cerevisiae more than 30 years ago; the corresponding gene 
was not, however, identified (161-163). In this paper, we have used bioinformatics 
approaches to successfully identify the genes that encode the yeast TST (RDL1) and the 
corresponding human ortholog (TSTD1). We provide definitive evidence to show that the 
yeast and human enzymes act as genuine TSTs that synthesize and release GSS- into 
solution. We present biochemical evidence for the functional interaction of human SDO 
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with the novel human TST and its yeast ortholog. Our discovery of bacterial Rosetta 
stone proteins that comprise fusions of human SDO and human TST provides 
phylogenetic evidence for the association of the two enzymes. 
3.3 Experimental procedures  
3.3.1 Materials  
 All enzymes required for ligation-independent cloning were purchased from New 
England Biolabs. Isopropyl β-D-1-thiogalactopyranoside (IPTG) was purchased from 
Gold Biotechnology. Thiosulfate, glutathione, D,L-homocysteine, coenzyme A and D,L-
dihydrolipoic acid were purchased from Sigma-Aldrich. Potassium cyanide and 
dithiothreitol (DTT) were obtained from Fisher. L-Cysteine was obtained from Amresco. 
Potassium p-toluenethiosulfonate was purchased from TCI scientific. 
3.3.2 Expression of yeast RDL1 in Escherichia coli   
 PCR was used to amplify the RDL1 gene from Saccharomyces cerevisiae 
genomic DNA (EMD chemicals). The reactions were conducted using Taq polymerase 
(Qiagen) and primers (see Appendix 2 Table 1) designed to introduce unique NdeI and 
Xhol restriction sites, as previously described (165). The Topo TA Cloning® kit 
(Invitrogen) was used to insert the PCR product into the pCR®2.1-TOPO vector for 
blue/white screening. The screening was conducted using One Shot® TOP10 E. coli 
cells, supplied with the kit, as the host cell. Plasmid DNA from a white colony was 
digested with NdeI and XhoI to yield a desired 420 bp fragment that was subcloned 
between the NdeI and XhoI sites of plasmid pET21b (Novagen). The resulting plasmid, 
pET21b_rdl1, was used to transform E. coli BL21(DE3) cells to ampicillin resistance and 
sequenced across the insert (Genewiz, Inc.). A starter culture of E. coli 
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BL21(DE3)/pET21b_rd1l cells was prepared by overnight growth at 37 ̊C in LB medium 
containing ampicillin (100 μg/mL) and used to inoculate 2.5 L flasks containing 1 L of 
TB medium supplemented with ampicillin (100 μg/mL). Cells were grown with shaking 
at 30 ̊C. Expression of yeast RDL1 was induced with IPTG (0.1 mM) when the cell 
density reached A595 ~ 0.6. Cells were harvested 4 h after induction (~ 20 g from 3 L) and 
stored at –80 °C.  
3.3.3 Purification of recombinant yeast RDL1  
 The enzyme was purified at 4 ̊C by a modification of a previously described 
protocol (165). Cells (10 g) were suspended in 15 mL of 20 mM Tris-HCl, pH 8.0, 
containing 150 mM NaCl and 20 mM imidazole-HCl. The cell suspension was mixed 
with a nuclease/protease inhibitor cocktail (20 μg/mL DNAase, 20 μg/mL RNAase, 5 
mM magnesium sulfate, 12.6 μg/mL soybean trypsin inhibitor, 2 μg/mL aprotinin, 25 μg/ 
mL phenylmethanesulfonyl fluoride, and 3 μg/mL tosyllysine chloromethylketone). The 
cells were disrupted by sonication. Cell debris was removed by centrifugation (10,000 g, 
10 min). The supernatant was mixed with 10 mL of Ni affinity matrix (Talon affinity 
resin, Qiagen), previously equilibrated with buffer A (20 mM Tris-HCl, pH 8.0, 
containing 500 mM NaCl, 20 mM imidazole-HCl), and rocked gently for 1 h. The 
mixture was poured into a column, which was washed with 4 column volumes of buffer 
A. Yeast RDL1 was eluted using a 120 mL linear gradient from 20 to 250 mM imidazole, 
which was formed with buffer A and buffer B (20 mM Tris-HCl, pH 8.0, containing 500 
mM NaCl, and 250 mM imidazole-HCl). The eluate was dialyzed against 50 mM Tris-
HCl, pH 8.0, containing 50 mM NaCl and 5% (w/v) glycerol. The supernatant, obtained 
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after centrifugation (30,000 g, 10 min), was concentrated using a 5K Macrosep Advance 
Centrifugal Device (Pall Life Sciences) and then stored in aliquots at -80 °C. 
3.3.4 Expression of Human TSTD1 Isoforms 1, 2 and 3 in E. coli  
 A synthetic version of the human gene for each isoform, which had been 
optimized for expression in E. coli, was obtained from Blue Heron Biotechnology, Inc. 
(Bothell, WA) (see Appendix 2 figures 1, 2, 3 for the sequences of synthetic genes). 
Ligation-independent cloning was used to add a cleavable (His)6-SUMO tag to the N-
terminus of each synthetic gene. The cloning was conducted by using the PCR primers 
listed in Appendix 2 Table 1, plasmid pETHSUL (gift from Dr. Patrick Loll), and a 
protocol similar to that described by Weeks et al. (166). The resulting constructs for 
isoforms 1, 2 and 3 (pETHSUL_tstd1IF1, pETHSUL_tstd1IF2, and pETHSUL_tstd1IF3, 
respectively) were used to transform E. coli BL21(DE3) cells to ampicillin resistance and 
sequenced across each insert (Genewiz, Inc.).  
 For expression of isoform 1, a starter culture of  E. coli 
BL21(DE3)/pETHSUL_tstd1IF1 cells was prepared by an overnight growth at 37 °C in 
LB medium containing ampicillin (100 μg/mL) and used to inoculate 2 L flasks 
containing 1 L of the same medium. Cells were grown with shaking at 37 ̊C. Expression 
of (His)6-SUMO-tagged isoform 1 was induced with 0.5 mM IPTG when the cell density 
reached A595 ~ 0.6. Cells were harvested 2 h after induction (~ 35 g of cells from 15 L) 
and stored at –80 °C.  
 A similar procedure was used for expression of isoform 2 or 3 except that E. coli 
cells (BL21(DE3)/pETHSUL_tstd1IF2 or BL21(DE3)/pETHSUL_tstd1IF3, respectively) 
were induced with 0.5 mM IPTG at A595 ~ 0.6 and harvested 3 h post induction. The yield 
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of cells was similar to that obtained with isoform 1 (isoform 2, 33 g from 18 L; isoform 3, 
31 g from 15 L).  
3.3.5 Purification of recombinant human TSTD1 Isoforms 1, 2, and 3 
 The same procedure was used to purify each isoform, except as noted. All steps 
were conducted at 4 °C, following a modification of a previously described generic 
protocol (166). Cells (20 g) were suspended in 35 mL of 25 mM Tris-HCl, pH 8.0, 
containing 500 mM NaCl, 10% (w/v) glycerol, and 8 mM imidazole-HCl. The cell 
suspension was mixed with a nuclease/protease inhibitor cocktail, as described above. 
The cells were disrupted by sonication. Cell debris was removed by centrifugation 
(39,000 g, 10 min). The supernatant was mixed with 10 mL of Ni affinity matrix (Talon 
affinity resin, Qiagen), previously equilibrated with buffer C (25 mM Tris-HCl, pH 8.0, 
containing 500 mM NaCl, 10% (w/v) glycerol, 2 mM thiosulfate, and 8 mM imidazole-
HCl) and rocked gently for 1 h. The mixture was poured into a column, which was 
washed with 4 column volumes of buffer C. The (His)6-SUMO-tagged TSTD1 isoforms 
were eluted with a 20 mL linear gradient from 8 to 250 mM imidazole, which was 
formed with buffer C and buffer D [25 mM Tris-HCl, pH 8.0, containing 500 mM NaCl, 
10% (w/v) glycerol, 2 mM thiosulfate, and 250 mM imidazole-HCl]. (In the case of 
isoform 3, the column eluate was centrifuged (30,000 g, 10 min) to remove a small 
precipitate.)  The peptide bond between the (His)6-SUMO tag and the N-terminus of each 
TSTD1 isoform was cleaved using the UD1 domain of the S. cerevisiae  Ulp1 peptidase 
(0.5 % , v/v),  an engineered SUMO-specific protease containing a C-terminal (His)6 tag 
(166) (gift from Dr. Simon Cocklin). After a 6 h incubation with gentle rocking at 4 ̊C, 
the reaction mixture was dialyzed against 2 changes of a ~ 60-fold excess of buffer C. 
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The supernatant obtained after centrifugation (30,000 g, 10 min) was applied to the Ni 
affinity matrix column described above, which had been re-equilibrated with buffer C. 
Tag-free TSTD1 isoforms do not bind to the matrix and are recovered in the column 
flow-through. The purified isoforms were dialyzed against 50 mM Tris-HCl, pH 8.0, 
containing 50 mM NaCl, 2 mM thiosulfate, and 5% (w/v) glycerol and then centrifuged 
(30,000 g, 10 min). The supernatants were stored in aliquots at -80 °C.  
3.3.6 Protein assays 
 Protein concentration during enzyme purification was assessed by using a Nano 
Drop 2000 spectrometer (Thermo Scientific). All other absorbance measurements were 
made using an Agilent Technologies 8453 diode array spectrophotometer. The 
concentration of purified RDL1  (ε280 = 25, 440 M-1 cm-1) and purified TSTD1 isoforms 1, 
2 and 3 (ε280 = 11,460, 11,460 and 9970  M-1 cm-1, respectively) was determined using 
extinction coefficients calculated using the ProParam tool 
(http://web.expasy.org/protparam/).  
3.3.7 Catalytic assays with thiosulfate as sulfane sulfur donor and glutathione as 
acceptor   
 TST activity during enzyme purification was monitored using a sulfite endpoint 
assay, similar to that previously described (163). Briefly, reactions were initiated by 
addition of enzyme to assays containing 50 mM Tris-acetate, pH 9.0, 20 mM thiosulfate, 
and 20 mM glutathione at 37 ̊C in a final volume of 500 μL. Assays were quenched after 
2 min by addition of mercuric chloride to a final concentration of 115 mM and 
centrifuged. The supernatant was assayed for sulfite by using a p-rosaniline colorimetric 
assay (ε570 = 35,300 M-1 L-1).  
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3.3.8 Effect of sulfur dioxygenase on catalytic assays with glutathione and 
thiosulfate 
 Assays were conducted at 37 ̊C in 50 mM Tris-acetate, pH 9.0 or at 25 ̊C in 50 
mM potassium/sodium phosphate, pH 8.0 in the presence of 20 mM thiosulfate and 2.4 or 
20 mM glutathione. Reactions in the presence or absence of SDO were initiated by 
addition of glutathione, quenched after 2 min, and assayed for sulfite formation, as 
described above. Recombinant human SDO was expressed in E. coli 
BL21(DE3)/pMW172ETHE and purified similar to that previously described (22). 
Plasmid pMW172ETHE was obtained as a gift from Valeria Tiranti.  
3.3.9 Steady-state kinetic analysis of the thiosulfate:glutathione sulfurtransferase 
reaction 
 Steady-state kinetic studies were performed by using the sulfite endpoint assay. 
Studies were conducted at 37 ̊C in 50 mM Tris-acetate, pH 9.0 in the absence or presence 
of SDO, as indicated. Steady-state kinetic parameters were estimated by fitting an 
equation for a sequential mechanism (eq. 4, A = thiosulfate, B = glutathione) to the data. 
V=   kcat[A] [B]       (eq. 4 ) 
KiaKb+Ka[B]+Kb[A]+ [A][B] 
 
3.3.10 Sulfurtransferase reactions with p-toluenethiosulfonate as sulfane sulfur 
donor and glutathione as acceptor  
 Reactions using p-toluenethiosulfonate (p-Tol-SO2S-) as sulfane sulfur donor were 
conducted using 2 mm cuvettes at 25 ̊C in 50 mM potassium/sodium phosphate buffer, 
pH 8.0. Reaction progress was monitored by following the disappearance of p-Tol-SO2S- 
at 242 nm (Δε242 = 5080 M-1 cm-1), as described in the text. The data are not corrected for 
absorbance changes due to the conversion of reduced glutathione to glutathione 
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persulfide, which are likely to be small, as judged by the similar extinction coefficients 
determined for reduced and oxidized glutathione (ε242 = 540 M-1 and 410 M-1 cm-1, 
respectively). Reactions were conducted in the absence or presence of human SDO, as 
indicated.  
3.3.11 Substitution of glutathione by alternate small molecule acceptors in 
sulfurtransferase reactions with thiosulfate as sulfane sulfur donor  
 Apparent steady-state kinetic parameters for reactions in which glutathione was 
replaced with other thiols (cysteine, coenzyme A, DTT) or cyanide were determined by 
varying the acceptor concentration at a fixed, saturating concentration of thiosulfate and 
by varying the thiosulfate concentration at a fixed, saturating concentration of the 
acceptor. Reactions were conducted at 37 ̊C in 50 mM Tris-acetate, pH 9.0, and were 
initiated by addition of yeast RDL1 or human TSTD1. Reaction rates with thiol acceptors 
were determined by monitoring sulfite formation in an endpoint assay, as described 
above. Reaction rates with cyanide were determined by using a thiocyanate endpoint 
assay, similar to that previously described (20). Briefly, reactions were quenched by the 
addition of 5% formaldehyde; thiocyanate was measured based on the formation of a red 
complex upon addition of an acidic solution of ferric nitrate (ε460 = 4300 M-1 cm-1). 
3.3.12 Mutation of the single cysteine in yeast RDL1 or human TSTD1 Isoform 1  
 PCR site-directed mutagenesis was used to replace Cys98 in yeast RDL1 or 
Cys79 in human TSTD1 isoform 1 with Ala or Ser. PCR reactions were conducted using 
pET21b_rd1l or pETHSUL_tstd1IF1 as template, PCR Mix (Amresco®), Pfu turbo DNA 
polymerase  (Agilent Technologies), and the primers listed in Appendix 2 Table 1. After 
treatment with Dpn1 (New England Bio Labs) to remove template DNA, the PCR 
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products were used to transform E. coli BL21(DE3) cells to ampicillin resistance and 
sequenced across the insert (Genewiz, Inc.). Transformants harboring the mutant 
plasmids (pEt21b_rdl1_C98A, pET21b_rdl1_C98S, pETHSUL_tstd1 C79A # 6, 
pETHSUL_tstd1 C79S # 1) were used to express and purify the enzyme variants, 
following the same procedures described for the corresponding wild-type enzymes. 
3.3.13 Detection of cysteine persulfide in yeast RDL1 or human TSTD1   
 Enzyme samples were incubated for 10 min on ice with 2 mM thiosulfate and 
then subjected to gel filtration at 4 ̊C on a Sephadex G-15 column equilibrated with 50 
mM potassium phosphate buffer, pH 7.5. The protein concentration in the gel eluate was 
estimated based on the absorbance at 280 nm. The persulfide concentration in the 
untreated eluate and in samples incubated for 10 min at room temperature with 7 mM 
glutathione and 1.2 μM SDO was determined using the cold cyanolysis method, as 
previously described (133).  
3.4 Results 
 
3.4.1 Use of bioinformatics to identify potential candidate gene(s) for yeast 
thiosulfate sulfurtransferase   
 Yeast TST is a ~17,000 Da protein that exhibits an isoelectric point of 5.1 and 
contains a single cysteine residue, as judged by properties observed for the natural 
enzyme isolated from S. cerevisiae more than 30 years ago (163). We sought to identify 
potential candidate gene(s) for yeast TST by searching the S. cerevisiae genomic 
database (http://www.yeastgenome.org) for entries annotated as sulfurtransferases, a term 
used to describe enzymes that transfer a sulfane sulfur atom from a donor substrate to a 
thiophilic acceptor molecule. This search retrieved two genes of unknown function 
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(RDL1 and RDL2) plus seven other genes of known function (TUM1, UBA4, YCH1, 
NFS1, LIP5, BIO2, SLM3)  (Table 3.1). An additional gene of known function (OAC1) 
was retrieved using thiosulfate as the search term. Searches performed using other terms 
(e.g., rhodanese, rhodanese-like protein, sulfur transfer, thiosulfate cyanide 
transsulfurase, thiosulfate reductase) did not identify any additional candidate genes. 
Except for RDL1, all of the retrieved genes could be eliminated as potential candidates 
for yeast TST on the basis of the isoelectric point, molecular weight and/or the cysteine 
content of the corresponding gene product (Table 3.1). On the other hand, the protein 
encoded by the RDL1 gene (RDL1) contains a single cysteine and exhibits other 
properties (MW 15.4 kDa, pI = 5.9) remarkably similar to those reported for the natural 
TST purified from yeast.  
3.4.2 Expression and purification of recombinant yeast RDL1   
 We used PCR to amplify the RDL1 gene from yeast genomic DNA. The PCR 
product was subcloned into plasmid pET21b to introduce a C-terminal His-tag. 
Recombinant RDL1 is highly expressed in E. coli and readily isolated by metal affinity 
chromatography (Figure 3.1). A typical preparation yields 50 mg of purified RDL1 from 
10 g of cells. 
3.4.3 Does recombinant yeast RDL1 exhibit thiosulfate:glutathione sulfurtransferase 
activity   
 The standard TST assay is performed at pH 9, the optimum observed with the 
natural yeast enzyme (163). This assay is initiated by addition of enzyme to reaction 
mixtures containing 20 mM thiosulfate and 20 mM glutathione. The reaction is quenched 
after a specified time when sulfite formation is measured using a colorimetric assay. 
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Using this assay, we found that RDL1 catalyzed the formation of sulfite in a reaction that 
exhibits a linear dependence on time and enzyme concentration (data not shown).  
 A complete steady-state kinetic analysis of the reaction catalyzed by RDL1 was 
conducted by measuring turnover rates at various concentrations of thiosulfate and 
glutathione. Double reciprocal plots of reaction rate versus thiosulfate at different 
concentrations of glutathione or versus glutathione at different concentrations of 
thiosulfate are linear and intersect to the left of the y-axis, just above the x-axis (Figure 
3.2A, 2B). The observed intersecting line kinetics are in agreement with results obtained 
in previous studies with TST isolated from yeast (163). Recombinant RDL1 exhibits a 
10-fold faster limiting turnover rate (kcat) but other steady-state kinetic parameters are 
nearly identical to values reported for the natural enzyme isolated from yeast (Table 3.2). 
The lower turnover rate observed for the natural enzyme is probably attributable to 
stability problems encountered during the multiple steps required to purify TST from 
yeast (163). The results provide compelling evidence that the RDL1 gene encodes yeast 
TST.  
3.4.4 Use of bioinformatics to identify a potential candidate gene for human 
thiosulfate sulfurtransferase   
 A BLASTp search of the human genome database using RDL1 as the query 
sequence retrieved a single promising candidate gene (TSTD1, thiosulfate 
sulfurtransferase rhodanese-like domain containing 1) for the human ortholog of yeast 
TST (Table 3.3). The TSTD1 gene contains four exons and is annotated as having three 
splice variants (RefSeq mRNAs). The predicted protein isoforms (TSTD1 isoforms 1, 2, 
and 3) differ in size (115, 74, and 109 amino acids, respectively) but share a common 
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core of 55 amino acids that contains the single cysteine residue found in each isoform 
(Appendix 2 figure 4). The TSTD1 isoforms exhibit about 34% identity (~52% 
similarity) with yeast RDL16. The rank ordering of the TSTD1 isoforms by the BLAST 
algorithm (1 > > 3 > 2) is based on the calculated Expect value (E) (see Table 3.3) which 
takes into account both the number of conserved residues and the length of the RDL1 
query sequence that overlaps with each human isoform.  
3.4.5 Expression and purification of recombinant human TSTD1 Isoforms 1, 2, and 
3  
 The mRNA for the top-ranking isoform 1 contains all four of the exons in the 
TSTD1 gene. We obtained a synthetic version of the corresponding cDNA that had been 
optimized for expression of isoform 1 in E. coli. The synthetic gene was subcloned into 
plasmid pET21b to introduce a C-terminal (His)6 tag. The resulting construct was then 
used to transform E. coli BL21(DE3) cells, following a strategy similar to that used to 
successfully express recombinant RDL1. However, no expression of TSTD1 isoform 1 
was observed in cell lysates produced under a range of growth conditions, as judged by 
SDS-PAGE analysis. In an attempt to overcome this difficulty, we introduced a (His)6-
SUMO tag at the N-terminus of the synthetic gene. The (His)6-SUMO-TSTD1 isoform 1 
fusion protein is highly expressed in E. coli (Figure 3.3, lane 2) and readily purified by 
metal affinity chromatography (Figure 3.3, lane 5). Quantitative cleavage of the fusion 
protein is achieved by digestion with a SUMO-specific protease (Figure 3.3, lanes 6, 7). 
Rechromatograpy of the digest on a metal affinity column yields pure, tag-free TSTD1 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
6 Calculated values were obtained in pairwise local sequence alignments using EMBOSS 
Water (http://www.ebi.ac.uk/Tools/psa/emboss_water/). 
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isoform 1 (Figure 3.3, lanes 8, 10). We obtained 90 mg of TSTD1 isoform 1 from 20 g of 
cells.  
 The mRNA for the smallest isoform 2 lacks exon 2 but contains the other three 
exons of the TSTD1 gene. A different exon is missing in the mRNA that encodes isoform 
3 (exon 4). Additionally, intron 3 is retained in the mRNA for isoform 3 and encodes a 
predicted decapeptide at the C-terminus of the protein (see Appendix 2 figure 4). 
Isoforms 2 and 3 were successfully expressed as SUMO fusion proteins and readily 
isolated, as described in Experimental Procedures and shown in Appendix 2 figures 5 and 
6. We obtained 68 mg of TSTD1 isoform 2 and 54 mg of TSTD1 isoform 3 from 20 g of 
cells.  
3.4.6 Do human TSTD1 Isoforms 1, 2, and/or 3 exhibit thiosulfate:glutathione 
sulfurtransferase activity   
 A survey was conducted using the standard TST assay to determine whether 
activity could be detected with any of the human TSTD1 isoforms. Isoform 1 was found 
to catalyze the conversion of thiosulfate to sulfite in a glutathione-dependent reaction that 
exhibits a linear dependence on time and enzyme concentration (data not shown). In 
contrast, neither of the other two TSTD1 isoforms exhibits detectable TST activity. The 
results with isoform 2 suggest that the peptide encoded by exon 2 is essential for the 
activity observed with isoform 1. The absence of activity with isoform 3 may reflect the 
loss of the peptide encoded by exon 4 and/or the translation of retained intron 3. It is 
worth noting that catalytically inactive isoforms are known to exhibit a regulatory 
function in metabolism (167). This intriguing possibility is, however, beyond the scope of 
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the current investigation. Instead, our studies have focused on isoform 1, as described 
below. 
 A complete steady-state kinetic analysis of the thiosulfate:glutathione 
sulfurtransferase reaction catalyzed by TSTD1 isoform 1 was conducted at pH 9.0 (37 ̊C). 
Double reciprocal plots of reaction rate versus thiosulfate or versus glutathione intersect 
to the left of the y-axis, just above the x-axis (Figure 3.4), as observed with yeast RDL1. 
The human enzyme exhibits catalytic parameters fairly similar to RDL1, except that 
turnover is ~25-fold slower (Table 3.2). The results show that the TSTD1 gene encodes 
the human ortholog of yeast TST. The catalytically active isoform 1 will henceforth be 
referred to as human TSTD1. 
3.4.7 Use of sulfur dioxygenase to distinguish between thiosulfate:glutathione 
sulfurtransferase versus thiosulfate reductase activity   
 TSTs and TRs both catalyze the glutathione-dependent conversion of thiosulfate 
to sulfite. The TST reaction is, however, accompanied by the formation of a 
stoichiometric amount of glutathione persulfide (GSS-). Formation of GSS- as a product 
is a feature that uniquely distinguishes between TSTs (eq. 5) versus TRs (eq. 3). SDO 
catalyzes the oxidation of the sulfane sulfur in GSS- to produce sulfite (eq. 6). 
Consequently, addition of SDO to assays containing thiosulfate and glutathione should 
cause a 2-fold increase in the rate of sulfite formation observed with an authentic TST 
(eq. 5 + 6) whereas the rate observed with a TR should be unaffected.  
SSO32- + GS- ! SO32- + HS- + GSS-  (eq. 5) 
GSS- + O2 + H2O ! SO32- + GSS- + 2H+  (eq. 6) 
SSO32- + O2 + H2O ! 2SO32- + 2HS-   (eq. 5 + 6) 
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 Indeed, a 2-fold increase in the rate of sulfite formation is observed with TSTD1 
or RDL1 upon addition of excess SDO to the standard TST assay (pH 9, 37 ̊C) which 
contains 20 mM thiosulfate and 20 mM glutathione (Figure 3.5A). A very similar effect 
is observed in assays containing the same substrate concentrations but conducted at a 
lower pH and temperature (pH 8.0, 25 ̊C) (Figure 3.5B). However, much larger rate 
increases (4- to 9-fold) are observed upon addition of SDO to assays containing 2.4 mM 
glutathione. The greater than anticipated rate enhancements at the lower glutathione 
concentration are observed in assays with TSTD1 or RDL1 at pH 9 or pH 8 (Figure 3.5). 
The observed increase in the rate of sulfite formation in SDO-coupled assays at 2.4 mM 
glutathione corresponds to a 2- to 4.5-fold increase in the rate of the sulfurtransferase 
reaction (eq. 5). 
 The results provide definitive evidence that TSTD1 and RDL1 are authentic TSTs 
that catalyze the formation of GSS- as a product that is released into solution (eq. 5). The 
data also indicate the GSS- is a potent inhibitor of both the human and yeast enzymes. 
The fact that inhibition by GSS- is observed at lower but not higher glutathione 
concentrations suggests that the product acts as a competitive inhibitor with respect to 
glutathione.  
3.4.8 Steady-state kinetics of the yeast RDL1 or human TSTD1 reaction with 
thiosulfate and glutathione in the presence of sulfur dioxygenase 
 Intersecting line double-reciprocal plots are obtained for the yeast RDL1 reaction 
in the presence of SDO (Figure 3.2C and 2D), as observed in the absence of SDO. The 
presence of SDO results in a 25-fold decrease in the Km value obtained for glutathione 
whereas only modest changes are observed for other steady-state kinetic parameters 
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(Table 3.2). A complete steady-steady kinetic analysis of the TSTD1 reaction in the 
presence of SDO is not possible owing to a large decrease in the Km value for glutathione 
(< 0.04 mM). It is worth noting that SDO causes only minor changes in the TSTD1 
turnover rate or the Km for thiosulfate, as judged by apparent steady-state kinetic 
parameters obtained by varying the concentration of thiosulfate at a saturating 
concentration of glutathione (Table 3.2). The decreased Km value for glutathione 
observed with RDL1 or TSTD1 in the presence of SDO is consistent with the hypothesis 
that GSS- is a potent competitive inhibitor with respect to glutathione. 
3.4.9 Reaction of yeast RDL1 or human TSTD1 with a chromogenic substrate as an 
alternate sulfane sulfur donor  
 p-Toluenethiosulfonate (p-Tol-SO2S-) is more a reactive sulfane sulfur donor than 
thiosulfate (168). The compound exhibits a moderately intense absorption band in the UV 
region (ε242 = 6760 M-1 cm-1) that is lost upon transfer of the sulfane sulfur to an acceptor 
and formation of  p-toluenesulfinate (p-Tol-SO2-) (Appendix 2 figure 7) (169). 
Consequently, the reaction with p-Tol-SO2S- as sulfane donor can be monitored by 
measuring the disappearance of the substrate at 242 nm (Δε242 = 5080 M-1 cm-1). This 
continuous spectrophotometric assay is less cumbersome than the fixed time point assay 
used to monitor sulfite formation with thiosulfate as donor.  
 To minimize the blank rate with the more reactive donor, assays with p-Tol-SO2S- 
and glutathione are conducted at a lower pH and temperature (pH 8.0, 25 ̊C) than the 
standard TST assay with thiosulfate as donor (pH 9.0, 37 ̊C). Human TSTD1 and yeast 
RDL1 exhibit p-Tol-SO2S-:glutathione sulfurtransferase activity; the observed initial rates 
of these reactions are directly proportional to the enzyme concentration (Figure 3.6A and 
  
91!
6B). Apparent turnover rates for the TSTD1 and RDL1 reactions were estimated from the 
slopes of these plots (kcat app = 96 ± 5 s-1 and 104 ± 3  s-1, respectively). It is worth noting 
that replacing thiosulfate with p-Tol-SO2S- appears to eliminate the difference in the 
turnover rate of the human and yeast enzymes that is observed with the less reactive 
donor (see Table 3.2). 
 A 2.3- or 2.0-fold increase in the initial rate of p-Tol-SO2S- disappearance is 
observed when assays with RDL1 or TSTD1, respectively, are conducted in the presence 
of SDO (Figure 3.6C and 6D). The observed rate enhancements are similar to those seen 
in assays at the same glutathione concentration (2.4 mM) with thiosulfate as the sulfane 
sulfur donor. In addition to the effect on initial rates, SDO causes a dramatic change in 
the extent of the reactions observed with p-Tol-SO2S-. In the absence of SDO, the 
reactions with RDL1 and TSTD1 appear to be complete in about 200 s, as judged by the 
observed plateau in the progress curves (Figure 3.6C and 6D, curve 2). However, the 
maximal ΔA242 observed with either enzyme is only 50% of that expected for complete 
consumption of p-Tol-SO2S-, as indicated by the dotted lines (curve 4) in Figure 3.6C and 
6D. The observed progress curves suggested that the reactions may have reached 
equilibrium after 200 s  (eq. 7).  
p‐Tol‐SO2S− + GS− ⇌ p‐Tol‐SO2− + GSS− (eq. 7) 
Consistent with this hypothesis, a quantitative conversion of p-Tol-SO2S- to p-Tol-SO2- is 
observed when GSS- is oxidatively decomposed, as judged by the reaction traces obtained 
for the RDL1 and TSTD1 reactions in the presence of SDO (Figure 3.6C and 6D, curve 
3).  
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3.4.10 Reaction of yeast RDL1 or human TSTD1 with alternate sulfane sulfur 
acceptors  
 We investigated the specificity of yeast RDL1 and human TSTD1 with respect to 
the sulfane sulfur acceptor by determining whether alternate acceptors could substitute 
for glutathione. We surveyed four physiologically relevant thiols and two 
nonphysiological compounds in reactions conducted at pH 9.0 with thiosulfate as the 
sulfane sulfur donor. Activity was observed with RDL1 or TSTD1 using L-cysteine, 
coenzyme A, DTT, or cyanide as the acceptor. No activity was, however, detected with 
D,L-homocysteine or D,L-dihydrolipoic acid.  
 Apparent steady-state kinetic parameters for reactions observed with different 
acceptors were determined by varying the acceptor concentration in the presence of a 
saturating concentration of thiosulfate and vice versa. The observed velocities exhibit a 
hyperbolic dependence on the concentration of the varied substrate except for the reaction 
with RDL1 when thiosulfate is varied at a saturating concentration of coenzyme A. In 
this case, a sigmoidal dependence on the thiosulfate concentration is observed. Varying 
the nature of the acceptor causes only modest changes (≤ 3.5-fold) in the apparent 
turnover rate or the Km for thiosulfate, as judged by results obtained for the RDL1 or 
TSTD1 reactions with glutathione and four alternate acceptors (Table 3.4). Similar Km 
values are observed for L-cysteine and glutathione with RDL1 or TSTD1. The Km value 
obtained for coenzyme A with RDL1 or TSTD1 is, however, 40- or 20-fold lower, 
respectively, than the Km value observed for glutathione. The potential significance of the 
observed Km values will be discussed. 
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3.4.11 Role of the single cysteine residue in yeast RDL1 or human TSTD1  
 Yeast RDL1 and human TSTD1 exhibit a signature motif characteristic of a 
rhodanese homology domain (RHOD). This alpha beta fold domain is found in other 
sulfurtransferases and is also observed in the crystal structure of RDL1, which was 
determined as part of a structural genomics initiative and published in an online database 
(3D1P.pdb). An invariant cysteine occupies the first position of a six-amino acid active 
site loop observed in other RHOD-containing sulfurtransferases (170). The single 
cysteine in yeast RDL1 (Cys98) occupies the same location within an active site loop 
found in the crystal structure of the protein (Figure 3.7, top panel). A sequence alignment 
indicates that the putative catalytic cysteine and three other residues in the active site loop 
of yeast RDL1 are conserved in human TSTD1 (Figure 3.7, bottom panel).  
 To evaluate the possible catalytic role of Cys98 in yeast RDL1 and Cys79 in 
human TSTD1, we mutated each residue to Ala or Ser. The mutations did not affect 
protein expression. However, each of the purified mutant enzymes was found to be 
catalytically inactive. The results provide compelling evidence that the single cysteine in 
the yeast and human enzymes is catalytically essential. In contrast, Chancey and Westley 
concluded that the cysteine was not required for catalysis by the yeast enzyme based on 
the failure of iodoacetate to inactivate the enzyme (162). Unfortunately, the postulated 
site of iodoacetate incorporation was not identified in this study. 
 The mutagenesis results suggested that catalysis by yeast RDL1 and human 
TSTD1 might occur via a double-displacement mechanism involving transfer of the 
sulfane sulfur from thiosulfate to the active site cysteine (eq. 8) and subsequent reaction 
of the persulfide-containing intermediate with glutathione (eq. 9).  
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Evidence to evaluate this hypothesis was sought by determining whether cyanolyzable 
sulfur could be detected in enzyme isolated by gel filtration after a short incubation with 
thiosulfate. We found that about 10 or 20% of the cysteine in the column eluate of RDL1 
or TSTD1, respectively, is present as cysteine persulfide. The persulfide is largely 
eliminated upon incubation of the isolated intermediates with glutathione in the presence 
of SDO, which was included to oxidize the cyanolyzable sulfur in the GSS- product  
(Table 3.5). 
3.4.12 Identification of bacterial SDO-TSTD1 fusion proteins  
 Rosetta Stone proteins are fusion proteins consisting of two non-homologous 
proteins that are found as separate proteins in another genome. The fusion is thought to 
be maintained by selection because it facilitates a functional interaction between proteins, 
such as the kinetic coupling of consecutive enzymes in a pathway (170). Six bacterial 
proteins were previously classified as fusions of SDO with rhodanese, a 
thiosulfate:cyanide sulfurtransferase encoded by the TST gene (22, 171). The functional 
interaction between human TSTD1 and human SDO observed in the present study led us 
to question the validity of this assignment. Accordingly, we performed BLASTp searches 
of the human genome database using each of the putative SDO-rhodanese fusion proteins 
as the query sequence. Contrary to the previous classification, TSTD1 was the top 
scoring BLAST hit for the C-terminal domain in all six proteins (Table 3.6, entries 2, 4, 
10, 11, 14, 15). Furthermore, rhodanese was not found among the lower scoring BLAST 
(eq.%8)%
%
(eq.%9)%
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hits for the C-terminal domain. On the other hand, SDO was the highest scoring BLAST 
hit for the N-terminal domain in each query sequence. The results indicate that all six 
bacterial proteins are more appropriately classified as fusions of SDO and TSTD1.  
 We reasoned that the six SDO-TSTD1 fusion proteins might be part of a larger 
group of homologous Rosetta Stone proteins. To evaluate this hypothesis, the fusion 
protein from Methylobacter tundripaludum (Table 3.6, entry 4) was used as the query 
sequence in a BLASTp search against all non-redundant GenBank CDS translations, with 
the maximum number of target sequences set to 500. The search retrieved 116 bacterial 
proteins that exhibit 96-99% coverage with the query sequence and low E values (3e-65 
and 9e-165), properties expected for homologs of the M. tundripaludum SDO-TSTD1 
fusion protein. The group of 116 retrieved proteins included each of the six previously 
identified SDO-TSTD1 fusion proteins. The remainder of the 500 retrieved sequences are 
SDO homologs that align only with the N-terminal domain of the query fusion protein 
(60-66% query coverage) with E values between 1e-65 to 6e-109. We performed BLASTp 
searches against the human genome using query sequences from a selected subset of the 
116 hits that included no more than one representative species from within each genus. 
Satisfyingly, SDO and TSTD1 were the highest scoring BLAST hits obtained for the N- 
and C-terminal domains, respectively, in each tested query. The newly identified fusion 
proteins were rank-ordered with respect to the E values obtained for the TSTD1 hits; 
those exhibiting E values ≤ 6e-04 are listed in Table 3.6.  
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3.4.13 Are human-like SQORs found in bacteria that express SDO-TSTD1 fusion 
proteins   
 H2S and thiosulfate are the most abundant reduced inorganic sulfur species in the 
environment (172). Bacteria that express SDO-TSTD1 fusion proteins might utilize 
exogenously derived thiosulfate as the substrate for the TSTD1 reaction. Alternatively, 
these bacteria might contain human-like SQORs that initiate the oxidation of H2S and 
produce an endogenous source of thiosulfate for the TSTD1 reaction, analogous to that 
proposed for mammalian H2S metabolism (see Scheme 3.1).  
 The proteomes of twelve of the thirteen bacteria that harbor top scoring SDO-
TSTD1 fusion proteins are available in the NCBI database (Table 3.6, entries 1-10, 12-
13). We conducted BLASTp searches of these proteomes using human SQOR as the 
query sequence. The searches identified SQOR homologs in eleven of the twelve 
searchable proteomes (Appendix 2 Table 2). Complete genomic data are available for 
two of the eleven bacteria that contain both SQOR and SDO-TSTD1 fusion proteins (N. 
oceani, N. watsonii); whole-genome shotgun contigs are available for the other nine 
bacteria. The genes for SQOR and the SDO-TSTD1 fusion protein in N. oceani and N. 
watsonii are transcribed in the same direction and separated by just 73 nucleotides. 
Although not predicted to lie in the same operon, the genes for the two proteins in N. 
oceani are considered to be functionally related as part of a regulon cluster, according to 
MicrobesOnline (http://www.microbesonline.org/operons/). Genomic distances could 
also be determined in four other bacteria where the genes for SQOR and the SDO-TSTD1 
fusion protein were found within the same contig. In these cases, the genes were 
separated by 21 to 246 nucleotides (Appendix 2 Table 2).  
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 Seven of the eleven identified bacterial SQORs, including the N. oceani and N. 
watsonii enzymes, exhibit high similarity to human SQOR (E ≤ 5e-90) (see Appendix 2 
Table 2). SQORs have been classified into six types (15). A phylogenetic tree shows that 
the seven top-scoring bacterial enzymes cluster with type II SQORs, a category that 
includes all known eukaryotic SQORs and a subset of prokaryotic enzymes (Figure 8). 
The lower-scoring hits include one that clusters with type I bacterial SQORs and three 
that did not cluster with representatives of other known types of bacterial SQORs (not 
shown).  
3.5 Discussion  
  The first step in mammalian H2S metabolism was previously postulated to 
produce the GSS- substrate for SDO, an enzyme thought to catalyze the second step in the 
pathway (1, 14). This hypothesis was contradicted by the discovery that glutathione does 
not act as an acceptor of the sulfane sulfur generated during H2S oxidation by human 
SQOR. Instead, SQOR catalyzes the oxidative conversion of H2S to thiosulfate, a 
reaction in which sulfite acts as the sulfane sulfur acceptor from an enzyme persulfide 
intermediate (E-CysSS- + SO3-2 ⇒ E-CysS- + SSO3-2) (158). The inability of SQOR to 
produce GSS- led others to suggest that SDO might directly oxidize the sulfane sulfur in 
the persulfide intermediate (E-CysSS- + O2 + H2O ⇒ E-CysS- + SO3-2 + 2H+) (21). 
However, human SDO cannot replace sulfite in the SQOR reaction, as judged by its 
inability to accelerate the slow rate of H2S oxidation observed in the absence of sulfite7. 
Similar negative results were obtained with coenzyme A, which was tested because the 
corresponding persulfide is an alternate, albeit poor, substrate for SDO (21). The results 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
7 K. Acharya and M. S. Jorns, unpublished observations. 
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strongly suggested that a thiosulfate:glutathione sulfurtransferase was required to provide 
the missing link between the SQOR and SDO reactions.  
 Although TST could be purified from S. cerevisiae, attempts to isolate the 
mammalian enzyme were not successful (144, 161-164). We used bioinformatic 
approaches to identify the genes that encode human TST (TSTD1) and its yeast ortholog 
(RDL1). Both genes produce small RHOD-containing proteins. Recombinant yeast RDL1 
catalyzes the glutathione-dependent conversion of thiosulfate to sulfite in a reaction that 
proceeds via a ternary complex mechanism and exhibits steady-state kinetic parameters 
similar to those reported for the natural yeast enzyme (163). The human TSTD1 gene 
contains four exons and has three splice variants. TSTD1 isoform 1 is produced from a 
transcript that contains all four exons and exhibits TST activity; the smaller TSTD1 
isoforms are catalytically inactive. TSTD1 (isoform 1) exhibits steady-state kinetic 
parameters similar to RDL1, except that turnover of the human enzyme is ~25-fold 
slower. Proteomics studies indicate that human TSTD1 is highly expressed in various 
tissues, including liver and heart (173, 174). Data for the individual isoforms is 
unavailable except in tumor cell lines where only isoform 1 is detected by Western 
blotting (175).  
 Yeast RDL1 and human TSTD1 contain a single cysteine (Cys98 and Cys79, 
respectively) that is catalytically essential, as judged by the loss of activity observed 
when the cysteines are replaced by serine or alanine. The detection of albeit modest 
amounts of cysteine persulfide in the human or yeast enzyme isolated after reaction with 
thiosulfate suggests that catalysis occurs via a double-displacement mechanism involving 
the formation of a cysteine persulfide-containing intermediate (see eqs. 6-7), as observed 
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with other RHOD-containing sulfurtransferases (176-179). Formation of the persulfide 
intermediate may be rate-limiting during catalysis by human TSTD1, as judged by the 
substantial increase in turnover rate observed when thiosulfate is replaced by a more 
reactive sulfane donor, p-Tol-SO2S-. Coenzyme A and L-cysteine can act as alternate 
sulfane sulfur acceptors for the yeast and mammalian enzymes. Human TSTD1 exhibits 
Km values for glutathione and coenzyme A that are below or within the normal range 
reported for the concentrations of these thiols in animal cells (180, 181). The Km value 
obtained for L-cysteine is, however, an order of magnitude higher than the L-cysteine 
level in liver cells (182). The results suggest that coenzyme A, but not L-cysteine, may be 
a possibly significant alternate acceptor for TSTD1 in mammalian cells. It is worth noting 
that coenzyme A persulfide is the only currently known alternate (albeit poor) substrate 
for human SDO (21).  
3.5.1 Functional interaction between human SDO and human TSTD1 or yeast 
RDL1  
 The operational definition of a TST as an enzyme that catalyzes a glutathione-
dependent conversion of thiosulfate to sulfite does not distinguish between an authentic 
TST that produces GSS- as a product versus a TR that catalyzes a glutathione-dependent 
reduction of thiosulfate to sulfite plus H2S. Definitive evidence that TSTD1 and RDL1 
are authentic TSTs is provided by studies, which show that the reaction product is 
oxidized by human SDO, as evidenced by an expected doubling of the rate of sulfite 
formation upon addition of SDO to assays at saturating glutathione8. The greater than 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
8 Oxidation of GSS- by SDO is also detectable by measuring oxygen consumption using 
an oxygen electrode-based TSTD1-SDO coupled assay (S. L. Melideo and M. S. Jorns, 
unpublished observations). 
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expected rate accelerations observed when SDO is added to assays at lower glutathione 
concentrations indicates that GSS- is an inhibitor of both the yeast and human enzymes. 
The presence of SDO results in a ≥25-fold decrease in the Km value obtained for 
glutathione with RDL1 or TSTD1, suggesting that GSS- is a potent competitive inhibitor 
with respect to glutathione. SDO also enhances the initial rate of glutathione-dependent 
sulfurtransferase reactions observed with p-Tol-SO2S- as the sulfane sulfur donor. The 
observed inhibition of the TST reactions by GSS-, which is circumvented in the presence 
of human SDO, provide an apparent mechanism to regulate mammalian GSS- 
biosynthesis and prevent the accumulation of a highly reactive metabolite.  
 The reactions observed with p-Tol-SO2S- and TSTD1 or RDL1 in the absence of 
SDO reach equilibrium when about 50% of the substrate has been consumed. A 
quantitative conversion of p-Tol-SO2S- to p-Tol-SO2- is, however, observed when GSS- is 
oxidatively decomposed in the presence of SDO. The ability of human SDO to drive the 
reaction with a reactive sulfane sulfur donor to completion provides a paradigm for the 
thermodynamic coupling of the irreversible SDO reaction with the less favorable, but 
physiologically relevant, sulfurtransferase reaction with thiosulfate as sulfane donor. 
 The effect of SDO on the extent of the reaction with p-Tol-SO2S- is similar to that 
reported in a previous study with the natural yeast TST for the effect of cyanide on the 
extent of a reaction observed with glutathione and benzenethiosulfonate (Ph-SO2S-) 
(161). However, the authors attributed the observed formation of a stoichiometric amount 
of thiocyanate to the reaction of cyanide with GSS- that had been released into solution. 
This interpretation is rendered problematic by the fact that cyanide is an alternate 
substrate for yeast TST, as shown by results obtained in the present study and in a 
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previous survey of the thiosulfate:cyanide sulfurtransferase activity exhibited by RHOD-
containing yeast proteins (165). 
3.5.2 Phylogenetic association of human TSTD1 and human SDO  
 Using bioinformatic approaches, we identified a group of bacterial SDO-TSTD1 
fusion proteins that includes six members previously misclassified as SDO-rhodanese 
fusions. The C-terminal TSTD1-like domain in the fusion proteins is connected to the N-
terminal SDO-like domain by a variable length linker region (Appendix 2 figure 8). 
Catalytically important residues and signature motifs are conserved between the 
respective bacterial domains and human TSTD1 or SDO, as judged by multiple sequence 
alignments of the bacterial domains with the human proteins (Appendix 2 figure 9). The 
phylogenetic data reinforce the biochemical evidence obtained for the functional 
interaction of human TSTD1 and SDO. 
 It is worth noting that at least some of the bacteria that express SDO-TSTD1 
fusion proteins also contain an adjacent gene that encodes a human-like SQOR. The 
results suggest that these organisms metabolize H2S via a pathway that is strikingly 
similar to the first three steps proposed for mammalian H2S metabolism (see Scheme 
3.1)9. The metabolic similarity is not surprising from an evolutionary perspective given 
that the genes for H2S metabolism were acquired by eukaryotic cells from an 
endosymbiotic bacterial ancestor. Nevertheless, bacteria and mammals exhibit 
considerable divergence with respect to the role of H2S metabolism. Bacterial metabolism 
of environmental H2S provides an important source of energy and reducing equivalents. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
9 The SDO-TSTD1 fusion proteins may also function in the bacterial oxidation of 
environmental thiosulfate, providing an alternative to the widely distributed Sox (sulfur 
oxidizing) system (172) 
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In contrast, the primary physiological significance of H2S metabolism in mammals is 
closely tied to the acquired role of endogenously produced H2S as an important signaling 
molecule.  
3.5.3 Concluding remarks  
 In summary, we describe a novel human sulfurtransferase that catalyzes the 
formation of a central intermediate in mammalian H2S metabolism. We propose that 
human TSTD1 constitutes the hitherto missing link between the reactions catalyzed by 
SQOR and SDO. The biosynthesis of glutathione persulfide by human TSTD1 provides a 
rare example of a mammalian enzyme that catalyzes the biosynthesis of a reactive sulfane 
sulfur donor that is released into solution. A recent study show that a reactive sulfane 
sulfur donor is produced by two other mammalian enzymes (cystathionine β-synthase, 
cystathionine γ-lyase), which catalyze the conversion of cystine to cysteine persulfide 
(183). In this regard, it is worth noting that glutathione persulfide and polysulfides have 
been found to mediate protein sulfhydration (184, 185). It has recently been suggested 
that persulfides and other reactive sulfane sulfur donors may be the actual signaling 
molecules that implement many of the biological effects previously attributed to H2S 
(184, 185). Additional studies are clearly required to evaluate the intriguing possibility 
that H2S metabolism may have an unanticipated direct role in H2S signaling.  
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Table 3.1 Potential Candidate Genes for Yeast Thiosulfate Sulfurtransferasea 
       
       Function 
Gene Molecular 
Weight 
(Da) 
Isoelectric 
Point (pI) 
Cysteine 
Residues Name Location 
thiosulfate 
sulfurtransferaseb 
unknown  unknown ~17,000 5.1 1 
unknown RDL1 YOR285W 15,413 5.91 1 
unknown RDL2 YOR286W 16,697 9.65 1 
thiolation tRNA TUM1 YOR251C 34,219 5.71 4 
thiolation tRNA UBA4 YHR111W 49,361 6.12 13 
phosphatase YCH1 YGR203W 17,248 7.01 2 
thiolation tRNA, iron-
sulfur cluster biogenesis 
NFS1 YCL017C 54,467 8.35 6 
lipoic acid biosynthesis LIP5 YOR196C 46,247 9.55 10 
biotin biosynthesis BIO2 YGR286C 41,884 8.76 10 
thiolation tRNA 
    
SLM3 YDL033C 47,049 8.72 6 
mitochondrial inner 
membrane transporterc 
OAC1 YKL120W 35,153 10.37 3 
aUnless otherwise noted, genes were retrieved by searching the S. cerevisiae genome 
database (http://www.yeastgenome.org) for entries that contained the term 
“sulfurtransferase” in the gene annotation/description. bData reported by Uhteg and 
Westley for the enzyme isolated from S. cerevisiae (163). cGene retrieved using 
“thiosulfate” as the search term. 
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Table 3.2  Steady-State Kinetic Parameters for Thiosulfate:Glutathione Sulfurtransferase 
Reactions Catalyzed by Yeast RDL1 or Human TSTD1a 
Enzyme SDO (μM) 
Km 
glutathione 
(mM) 
Km thiosulfate 
(mM) 
Ki 
thiosulfate 
(mM) 
kcat 
(s-1) 
Natural yeast TSTb 0 2.9 3.7 10 6.4 
Yeast RDL1 0 4.6 ± 0.9 2.0 ± 0.5 7 ± 2 68 ± 6 
Human TSTD1 0 1.0 ± 0.2 14 ± 2 37 ± 13 2.7 ± 0.1 
Yeast RDL1 1.8 0.2 ± 0.05 7.6 ± 0.6 54 ± 18 94 ± 3 
Human TSTD1c 0.8 < 0.04 10.7 ± 0.5 nd 1.83 ± 0.04 
aReactions were conducted at 37 ̊C in 50 mM Tris-acetate buffer, pH 9.0 in the absence 
or presence of SDO, as indicated. Unless otherwise noted, steady-state kinetic 
parameters were obtained upon fitting eq. 4 to the data. Values for kcat are determined 
based on the rate of sulfite formation; data obtained in the presence of SDO are corrected 
for fact that the coupled reaction converts 1 mol of thiosulfate into 2 mol of sulfite (eq. 5 
+ 6). bData for the natural TST isolated from S. cerevisiae, as reported by Uhteg and 
Westley (163). cApparent steady-state kinetic parameters for the TSTD1 reaction in the 
presence of SDO were estimated by varying the concentration of thiosulfate at a 
saturating concentration of glutathione (2 mM). 
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Table 3.3 BLASTp Search of the NCBI Database of Human Proteins Using Yeast 
RDL1 as the Query Sequence 
Gene Description Isoform
a 
 
Max 
Score 
Total 
Score 
Query 
Cover 
(%) 
E 
Value 
Identity 
(%) 
TSTD1 thiosulfate 
sulfurtransferase/ 
rhodanese 
domain-
containing 
protein 1 
1 (115 aa) 
3 (109 aa) 
2 (74 aa) 
58.5 
50.1 
43.9 
58.5 
50.1 
43.9 
63 
53 
43 
9e-11 
7e-08 
7e-06 
34 
36 
34 
TSTD3 thiosulfate 
sulfurtransferase/ 
rhodanese 
domain-
containing 
protein 3 
 35.8 35.8 47 0.011 30 
TSTD2 3-
mercaptopyruvate 
sulfurtransferase  
 33.5 33.5 53 0.22 28 
TST rhodanese  33.1 33.1 53 0.30 26 
aThe listed TSTD1 isoforms are encoded by mRNA transcripts with a CCDS (consensus 
coding sequence) identifier indicative of a well-understood and validated coding 
sequence. The number of amino acids (aa) in each isoform is shown in parentheses. 
Isoforms predicted by automated computational analysis or conceptual translation are 
not shown. 
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Table 3.4 Apparent Steady-State Kinetic Parameters Observed for Yeast RDL1 or Human TSTD1 
Reactions with Various Sulfane Sulfur Acceptors and Thiosulfate as Donora   
acceptor 
yeast RDL1 human TSTD1 
Km (mM)  
kcat (s-1) 
Km (mM)  
kcat (s-1) thiosulfate acceptor thiosulfate acceptor 
glutathione 3.1 ± 0.3 5.6 ± 0.8 60 ± 2 (60 ± 3) 11 ± 1 1.7 ± 0.3 
1.91 ± 0.06  
(1.9 ± 0.1) 
cysteine 5.5 ± 0.7 2.9 ± 0.3 49 ± 4 (45 ± 1) 10.4 ± 0.7 2.5  ± 0.2 
1.67 ± 0.04 
(2.25 ± 0.05) 
coenzyme A 4.3 ± 0.8 0.15 ± 0.05 29 ± 3 (21 ± 2) 36  ± 3 0.09 ± 0.01 
1.53 ± 0.06  
(1.32 ± 0.05) 
DTT 3.9 ± 0.6 0.16 ± 0.03 27 ± 1 (40 ± 2) 14 ± 2 0.12 ± 0.02 
2.8 ± 0.1 
(2.82 ± 0.07) 
cyanide 4.0 ± 0.4 2.6 ± 0.3 38 ± 1 (36 ± 1) 12 ± 1 0.22 ± 0.02 
2.41 ± 0.08  
(2.05 ± 0.06) 
aApparent steady-state kinetic parameters were determined at 37 ̊C in 50 mM Tris-acetate buffer, pH 9.0, 
by varying the thiosulfate concentration at a saturating concentration of the acceptor and by varying the 
acceptor concentration at a saturating concentration of thiosulfate. The values obtained for kcat by varying 
the acceptor concentration are shown in parentheses.  
 
 
 
 
 
 
Table 3.5 Detection of Cysteine Persulfide in RDL1 or TSTD1 
Isolated by Gel Filtration after Reaction with Thiosulfatea 
Enzyme 
Persulfide Content (%) 
As Isolated GSH-treated 
RDL1  8.9 ± 0.8 1.3 ± 0.8 
TSTD1 19 ± 2 3.4 ± 0.8 
aSamples were isolated and analyzed as described in 
Experimental Procedures.  
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Table 3.6  BLASTp Search of the NCBI Database of Human Proteins Using Bacterial Fusion Proteins as 
the Query Sequencea 
 
Bacterial Query 
Sequence (GenBank 
accession number) 
C-terminal TSTD1-like Domain N-terminal ETHE1 (SDO)-like domain 
Human 
Gene 
Query 
Cover 
(%) 
E 
Value 
Identity 
(%) 
Human 
Gene 
Query 
Cover 
(%) 
E 
Value 
Identity 
(%) 
1 Nitrosococcus 
oceani 
(WP_01133083
1.1) 
TSTD1 26 3e-11 33 ETHE1 63 9e-75 52 
2 Nitrosococcus 
watsonii 
(WP_01322076
0.1)b 
TSTD1 26 2e-08 34 ETHE1 63 3e-73 51 
3 Methylocella 
silvestris 
(WP_01259163
8.1) 
TSTD1 26 3e-08 28 ETHE1 65 2e-70 49 
4 Methylobacter 
tundripaludum 
(WP_00689275
6.1) b 
TSTD1 26 2e-07 31 ETHE1 62 2e-68 50 
5 Methylomicrobi
um album 
(WP_00537124
8.1) 
TSTD1 26 9e-07 33 ETHE1 63 9e-69 49 
6 Methyloglobulu
s morosus 
(WP_02349523
0.1) 
TSTD1 25 2e-06 31 ETHE1 60 2e-65 48 
7 Methylocystis 
rosea 
(WP_01840785
6.1) 
TSTD1 25 5e-06 31 ETHE1 66 3e-63 46 
8 Methylosarcina 
fibrata 
(WP_02056527
2.1) 
TSTD1 24 8e-06 30 ETHE1 63 1e-67 49 
9 Bradyrhizobiac
eae bacterium 
(WP_00973722
8.1) 
TSTD1 25 1e-05 29 ETHE1 65 2e-64 47 
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10 Afipia 
broomeae 
(WP_00602173
9.1)b 
TSTD1 24 4e-05 33 ETHE1 65 1e-63 47 
11 γ-
proteobacteriu
m HTCC2148 
(WP_00722949
1.1)b 
TSTD1 23 1e-04 36 ETHE1 64 5e-80 54 
12 Rhizobium 
giardinii 
(WP_01833015
2.1) 
TSTD1 26 2e-04 32 ETHE1 66 7e-64 46 
13 Mesorhizobium 
amorphae 
(WP_00620352
3.1) 
TSTD1 26 6e-04 28 ETHE1 66 9e-67 48 
14 Polaromonas 
sp. JS666 
(WP_01148570
3.1)b 
TSTD1 29 0.005 30 ETHE1 60 5e-33 37 
15 Burkholderia 
cepacia 
(WP_01490086
9.1)b 
TSTD1 21 0.31 29 ETHE1 64 3e-87 59 
aResults are shown for the highest scoring BLAST hit in the human genome that aligns with the C- or N-
terminal domain in the bacterial query sequence. bProteins previously classified as fusions of SDO with 
rhodanese (22, 171).  
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Scheme 3.1 Proposed scheme for mammalian hydrogen sulfide metabolism. SQOR, 
sulfide:quinone oxidoreductase; TST, thiosulfate:glutathione sulfurtransferase; SDO, 
sulfur dioxygenase; SO, sulfite oxidase 
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Figure 3.1 Purification of recombinant yeast RDL1. The SDS 12% polyacrylamide gel 
was stained for protein with ProSieve Blue Protein Staining Solution (Lonza); lane M, 
molecular markers; lane 1, whole cell lysate; lane 2, low speed supernatant; lane 3, Ni 
affinity column flow-through; lane 4,  Ni affinity column wash; lane 5, Ni affinity 
column eluate; lane 6, dialyzed and concentrated Ni affinity column eluate.  
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Figure 3.2 Steady-state kinetic analysis of the thiosulfate:glutathione sulfurtransferase 
reaction catalyzed by recombinant yeast RDL1. Reactions were conducted at 37 ̊C in 50 
mM Tris-acetate buffer, pH 9.0, containing 0 (panels A, B) or 1.8 μM SDO (panels C, 
D). Panel A: Data obtained with 3.0, 4.5, 6.0, 12.0, 15.0, and 20.0 mM glutathione are 
shown by the black, red, green, blue, magenta, and cyan circles, respectively. Panel B: 
Data obtained with 1.0, 2.0, 4.0, 6.0, 8.0, and 16.0 mM thiosulfate are shown by the 
black, red, green, blue, magenta, and cyan circles, respectively. Panel C: Data obtained 
with 0.16, 0.32, 0.6, 2, and 15 mM glutathione are shown by the black, red, green, blue, 
and magenta circles, respectively. Panel D: Data obtained with 2, 5, 8, 10, 20, and 40 mM 
thiosulfate are shown by the black, red, green, blue circles, magenta, and cyan circles, 
respectively. The solid lines in panels A to D were obtained by fitting eq. 4 to the data. 
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Figure 3.3 Purification of recombinant human TSTD1 isoform 1 with a cleavable N-
terminal His-SUMO tag. The SDS 12% polyacrylamide gel was stained for protein with 
ProSieve Blue Protein Staining Solution (Lonza); lane M, molecular markers. lane 1, 
crude cell lysate; lane 2, low speed supernatant; lane 3, Ni affinity column flow-through; 
lane 4, Ni affinity column wash; lane 5, Ni affinity column eluate; lane 6, Ni affinity 
column eluate after cleavage with SUMO hydrolase; lane 7, SUMO hydrolase-treated 
sample after dialysis; lane 8, second Ni affinity column flow-through; lane 9, second Ni 
affinity column eluate; lane 10, dialyzed sample from lane 8.  
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Figure 3.4 Steady-state kinetic analysis of the thiosulfate:glutathione sulfurtransferase 
reaction catalyzed by recombinant human TSTD1. Reactions were conducted in 50 mM 
Tris-acetate buffer, pH 9.0 at 37 ̊C. Panel A: Data obtained with 0.63, 1.25, 2.5, 5, and 15 
mM glutathione are shown by the black, red, green, blue, and magenta circles, 
respectively. Panel B: Data obtained with 5, 10, 20, and 55 mM thiosulfate are shown by 
the black, red, green, and blue circles, respectively. The solid lines in panels A and B 
were obtained by fitting eq. 4 to the data. 
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Figure 3.5  Effect of human SDO on thiosulfate:glutathione sulfurtransferase reactions 
catalyzed by human TSTD1 or yeast RDL1. Reactions were conducted in 50 mM Tris-
acetate buffer, pH 9.0, at 37 ̊C (panel A) or 50 mM sodium/potassium phosphate, pH 8.0 
at 25 ̊C (panel B). Assays containing 20 mM thiosulfate, and 20 mM (solid filled bars) or 
2.4 mM (diagonal stripped bars) glutathione were conducted in the absence or the 
presence of 4 μM (panel A) or 800 nM (panel B) SDO. The bar graph shows the rate 
increase (fold) calculated by dividing values observed in the presence of SDO by those 
obtained for the same reaction in the absence of SDO.  
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Figure 3.6 Reaction of recombinant yeast RDL1 or human TSTD1 with p-
toluenethiosulfonate (p-Tol-SO2S-) and glutathione as sulfane sulfur donor and acceptor, 
respectively. Reactions were conducted at 25 ̊C using 2 mm cuvettes in 50 mM 
potassium/sodium phosphate buffer, pH 8.0, containing 0.75 mM p-Tol-SO2S- and 2.4 
mM glutathione, plus enzyme(s), as indicated. Panels A and B: The plots show the effect 
of the concentration of yeast RDL1 or human TSTD1 on the velocity observed during the 
initial 20 s of reactions conducted in the absence of SDO. The data are corrected for the 
blank rate observed in the absence of enzyme. Panels C and D show the effect of SDO 
(368 nM) on the extent of the reaction observed with 40.8 nM RDL1 and 80.3 nM 
TSTD1, respectively. In each panel: curve 1 is the blank reaction; curves 2 and 3 were 
obtained for the reactions with RDL1 or TSTD1 in the absence or presence of SDO, 
respectively; the dotted line (curve 4) shows the absorbance change calculated for 100% 
conversion of p-Tol-SO2S- to p-Tol-SO2-. The first data point in curves 2 and 3 in panels 
C and D corresponds to the absorbance of p-Tol-SO2S-, observed immediately prior to 
enzyme addition. The apparent gap between the first and subsequent data points is due to 
the enzyme reaction that occurs during mixing (< 5 s), before readings can be made.  
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Figure 3.7 The active site loop and putative catalytic cysteine in RDL1 and TSTD1. The 
top panel is a stereo ribbon drawing of yeast RDL1 (3D1P.pdb), which is shown as a 
magenta ribbon, except for the white active site loop. Cys98 is shown in ball and stick. 
The bottom panel shows a region of a sequence alignment of RDL1 and TSTD1 around 
the putative catalytic cysteine (Cys98 and Cys79, respectively), which is located at the 
first position of the six-amino acid active site loop. 
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Figure 3.8 Phylogenetic tree of SQOR homologs. A multiple sequence alignment of 31 
homologs was performed using COBALT (http://www.ncbi.nlm.nih.gov/tools/cobalt/). 
The alignment included eleven SQORs produced in bacteria that express SDO-TSTD1 
fusion proteins (see Appendix 2 Table 2) and twenty previously identified type I and type 
II SQORs25. The phylogenetic tree was rendered using the Newick file generated by 
COBALT and  the online PHY·FI application63 (. The red boxes mark the eleven SQOR 
homologs found in bacteria that express SDO-TSTD1 fusion proteins. Starting from the 
upper left hand corner of the tree, the bacterial sequences include enzymes from: 
Bradyrhizobiaceae bacterium, Afipia broomeae, Mesorhizobium amorphae, 
Methylocystis rosea, Rhodobacter capsulatus, Acidithiobacillus ferrooxidans, Aquifex 
aeolicus, Pseudomonas putida,  Rhizobium giardinii, Ralstonia solanacearum, 
Nitrosococcus oceani, Nitrosococcus watsonii, Methylobacter tundripaludum, 
Methyloglobulus morosus, Methylomicrobium album, Methylosarcina fibrata, Bacillus 
anthracis, Bacillus cereus, and Staphylococcus aureus. The eukaryotic sequences include 
SQORs from Schizosaccharomyces pombe, Arenicola marina (lugworm) and various 
higher eukaryotic animals, as indicated.  
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Chapter 4: Characterization of the SDO-TSTD1 fusion enzyme from Nitrosococcus 
oceani  
 
 
4.1 Introduction 
 Hydrogen sulfide (H2S) is a gasotransmitter similar to nitric oxide and carbon 
monoxide. However, it is the only gasotransmitter that is enzymatically metabolized 
within the mitochondria. The first step is the two-electron oxidation of H2S catalyzed by 
SQOR to sulfane sulfur (S0) using coenzyme Q as an electron acceptor. In Chapter 2, we 
identified sulfite (SO32-) as the physiological acceptor of the sulfane sulfur. This reaction 
produces thiosulfate (SSO32-) (scheme 3.1, step 1), a known intermediate in the oxidation 
of H2S to sulfate (SO42-) (4, 6-11). By contrast, most bacterial SQORs do not require an 
acceptor of the sulfane sulfur. Instead, they produce polysulfide chains and 
cyclooctasulfur rings (S8, elemental sulfur). Our proposed scheme states that the 
thiosulfate produced by the SQOR reaction is a substrate for a glutathione-dependent 
thiosulfate sulfurtransferase (TST) (for more information on our proposed metabolic 
pathway of H2S see section 3.1) (Scheme 3.1, step 1) (2). In Chapter 3, we discovered a 
novel TST in humans, TSTD1, which transfers the sulfane sulfur in thiosulfate to 
glutathione (GS-), producing glutathione persulfide (GSS-) (eq. 10). In the presence of 
oxygen, human sulfur dioxygenase (SDO) will consume the GSS-, producing sulfite and 
regenerating the glutathione (scheme 3.1 step 3) (eq. 11).  
GS- + SSO3-2 ! GSS- + SO3-2 (eq. 10) 
GSS- + O2 + H2O ! GS- + SO3-2  + 2H+ (eq. 11) 
 As described in Chapter 3, we found phylogenetic evidence to further support the 
biochemical interaction of human TSTD1 and human SDO. A summary of this discovery 
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is below. Bioinformatic approaches were used to identify a possible fusion protein in 
bacteria containing two domains: a N-terminal SDO-like domain and a C-terminal 
TSTD1-like domain (186). The fusions are referred to as Rosetta stone proteins, which 
consist of two nonhomologous proteins that are found separately in another genome. It is 
postulated that the fusion is preserved by selection because it promotes a functional 
interaction, such as the kinetic coupling of consecutive enzymes in a pathway (170). 
Previously, six bacterial proteins were classified as fusions of SDO and rhodanese, which 
is a known thiosulfate:cyanide sulfurtransferase (22, 171). The functional interaction 
between TSTD1 and SDO that was observed in Chapter 3 brought into question the 
validity of this assignment. BLASTp searches of the human genome database were 
performed using each of the putative SDO-rhodanese fusion proteins as the query 
sequence. Our search results showed this to be an inaccurate label and more appropriately 
classified them as SDO-TSTD1 fusions.  
 We hypothesized that the six SDO-TSTD1 fusion proteins are part of a larger 
group of homologous Rosetta stone proteins. To evaluate this hypothesis, we used the 
fusion protein from Methylobacter tundripaludum as the query sequence in a BLASTp 
search against all non-redundant GenBank CDS translations. A selected subset of the hits 
obtained from the BLASTp search were used to further confirm that there was both a 
SDO and TSTD1 domain within the fusions. The selected hits were used as query 
sequences for BLASTp searches against the human genome. SDO and TSTD1 were 
indeed the highest scoring BLASTp hits obtained for the N- and C-terminal domains 
respectively in each tested query. Nitrosococcus oceani ATCC 19707 gene Noc_2007 
had the lowest Expect (E) value (3 x 10-11) with respect to the human TSTD1 gene and 
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was chosen for biochemical studies (see Table 3.6). The E value is a parameter that is 
used in sequence alignments to determine if a hit is truly related to the query sequence 
(187-189). The lower the E value or closer to zero, the increased likelihood that the two 
are related (187-189). Operationally, the fusion is a glutathione-dependent thiosulfate 
dioxygenase (TSDO), which is the TST reaction (eq. 10) followed by the SDO reaction 
(eq. 11). The net reaction requires a catalytic amount of glutathione to facilitate the 
oxidation of one mole of thiosulfate in the presence of oxygen to two moles of sulfite (eq. 
12). 
 
 N. oceani is an ammonia-oxidizing bacterium found in seawater (190). Ammonia-
oxidizing bacteria are part of the nitrification process within the nitrogen cycle. The first 
step converts ammonia (NH3) or ammonium (NH4+) into nitrite (NO2-) and the second 
step converts the nitrite into nitrate (NO3-). Within this process there is an intermediate, 
nitrous oxide (N2O), that is known to be a greenhouse gas (191). Therefore, N. oceani is 
indirectly related to the greenhouse effect and is why the whole genome was sequenced 
(190). The sequencing of this bacterium’s genome enabled the discovery, through 
bioinformatics that there is a gene that encodes for a human-like SQOR the directly 
upstream. These genes are part of the same regulon, a gene cluster that is controlled by a 
regulatory protein. The fact that a human-like SQOR protein and the SDO-TSTD1 fusion 
are so close together suggests that at least some bacteria and mammals exhibit a similar 
pathway to metabolize H2S.  
SSO3-2 + O2 + H2O             2SO3-2  + 2H+ (eq. 12)GS- 
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 The goal of this chapter is to expand upon the phylogenetic evidence obtained in 
Chapter 3 by characterizing the SDO-TSTD1 fusion enzyme from N. oceani (186). 
Furthermore, we wanted to determine whether the reaction of the fusion protein with 
GSS- results in the consumption of a stoichiometric amount of oxygen (see eq. 11). 
Libiad et al. postulated that human TSTD1 could function in the reverse direction (eq. 13) 
(192). If a similar reaction occurred with the fusion protein, the TSTD1 domain would 
"compete" with the SDO domain for GSS- by using the sulfite produced by the SDO 
domain to consume the GSS- (eq. 13). 
SO3-2 + GSS- ! GS- + SSO3-2 (eq. 13) 
 Our studies support the hypothesis that the N. oceani gene, Noc_2007, encodes 
for a fusion protein of SDO and TSTD1 and catalyzes the TSDO reaction. Additionally, 
the TSTD1 domain of the fusion enzyme does not compete with the SDO domain for 
GSS-. Lastly, the TST reaction is the apparent rate-limiting step in the TSDO reaction.  
4.2 Experimental procedure  
4.2.1 Materials 
 Sodium sulfide was obtained from Alfa Aesar. Sodium thiosulfate pentahydrate 
was purchased from Sigma-Aldrich. Glutathione was obtained from Acros. Isopropyl-β-
D-thiogalactopyranoside (IPTG) was purchased from Gold Biotechnology. Restriction 
enzymes and T4 DNA ligase were obtained from New England Biolabs. PFU turbo was 
obtained from Agilent Technologies. Polymerase chain reaction mixture and oxidized 
glutathione (GSSG) were purchased from Amresco. A 35 ± 2% oxygen (balanced with 
N2) tank was obtained from Airgas.  
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4.2.2 Expression of wild type and mutant Noc_2007 
 A synthetic version of the N. oceani Noc_2007 gene was obtained from 
GENEWIZ (South Plainfield, NJ) (see Appendix 3 figure 1). The synthetic version was 
optimized for expression in E.coli and was flanked by NdeI and XhoI sites. The synthetic 
gene was subcloned between the NdeI and XhoI sites in the pET23a plasmid to produce 
plasmid pET23a_opzNoc_2007. The resulting construct was use to transform E. coli 
BL21(DE3) cells to ampicillin resistance and sequenced across the insert (GENEWIZ, 
Inc.). 
  Mutant constructs of Noc_2007 were produced using PCR site-directed 
mutagenesis. An alignment with the N-terminus of the fusion protein and human SDO 
was performed to identify the iron-binding site residues for mutagenesis. An alignment 
with the C-terminus of the fusion protein and human TSTD1 was performed to identify 
the cysteine of the fusion protein required for TST activity. The amino acid sequence 
alignments with human SDO and TSTD1 to the N-terminus and C-terminus of Noc_2007 
respectively are shown in figure 4.1. PCRs were conducted using pET23a_opzNoc_2007 
as a template, PCR Mixture (Amresco), Pfu turbo DNA polymerase (Agilent 
Technologies), and the primers listed in Table 4.1. After treatment with DpnI (New 
England Bio Laboratories) to remove the template DNA, the PCR products were used to 
transform E. coli BL21(DE3) cells to ampicillin resistance and sequenced across the 
insert (Genewiz, Inc.). The constructs containing the SDO domain mutant plasmids were 
labeled as follows: pET23a_opzNoc_2007 His57Ala, pET23a_opzNoc_2007 His114Ala, 
and pET23a_opzNoc_2007 Asp131Ala. The constructs for the TSTD1 domain mutant 
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plasmids were labeled as follows: pET23a_opzNoc_2007 Cys322Ala and 
pET23a_opzNoc_2007 Cys322Ser.  
 For the expression of the wild type (WT) protein, a starter culture of E.coli 
BL21(DE3)/ pET23a_opzNoc_2007 cells was prepared by an overnight growth in LB 
medium at 37 °C containing ampicillin (200 μg/mL) and used to inoculate 2 L flasks 
containing 1 L of TB medium and ampicillin (100 μg/mL). Cells were grown with 
shaking at 25 °C. Iron(III)chloride (4 μM) was added to the medium 1 h prior to 
induction. Expression of the enzyme was induced with 0.1 mM IPTG when the cell 
density reached A595  ~1.7. Cells were harvested 18 h post induction (~10 g of cells from 
1 L) and stored at –80 °C. The same method was used for the mutant constructs. 
Noteworthy, cells were not stored at –80 °C but used the same day when measuring the 
WT’s SDO domain’s activity.  
4.2.3 Purification of recombinant wild type and mutant fusion protein  
 All steps were done at 4 °C. The protocol was modified from a previously 
described method (186). The same procedure was used to purify each construct, except as 
noted. 5 g of cells were suspended in 7.5 mL of buffer A [25 mM Tris-HCl (pH 8.0) 
containing 500 mM NaCl and 10 % (w/v) glycerol]. The cell suspension was mixed with 
a nuclease/protease inhibitor cocktail: 20 μg/mL DNAase, 20 μg/mL RNAase, 5 mM 
magnesium sulfate, 12.6 μg/mL soybean trypsin inhibitor, 2 μg/mL aprotinin, 25 μg/mL 
phenyl-methanesulfonyl fluoride, and 3 μg/mL tosyllysine chloromethyl ketone. The 
cells were disrupted by sonication. Cell debris was removed by centrifugation (10000 g 
for 10 min). The supernatant was loaded onto a 5 mL HisTrap IMAC column (GE 
Healthcare), previously equilibrated with buffer A. 
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 Next, the column was washed with 5 column volumes of buffer B [25 mM Tris-
HCl (pH 8.0) containing 500 mM NaCl, 10 % (w/v) glycerol, and 10 mM imidazole-
HCl]. The fusion protein was eluted with a 90 mL linear gradient from 10-250 mM 
imidazole that was formed using buffer B and buffer C [25 mM Tris-HCl (pH 8.0) 
containing 500 mM NaCl, 10 % (w/v) glycerol, and 250 mM imidazole-HCl]. The eluate 
was dialyzed against 50 mM Tris-HCl (pH 8.0) containing 50 mM NaCl, and 5% (w/v) 
glycerol. Dialysis buffer for mutants His57Ala, His114Ala, Asp131Ala, and Cys322Ala 
was 25 mM Tris-HCl (pH 8.0) containing 10 % glycerol (w/v) and 125 mM imidazole-
HCl. The sample was clarified (30000 g for 10 min) and the supernatant was stored in 
aliquots at -80 °C.  
4.2.4 Protein assay  
 The protein concentration during enzyme purification was assessed by using a 
Nano Drop 2000 spectrometer (Thermo Scientific). The concentration of purified 
Noc_2007 (ε280 = 42860 M-1 cm-1) was determined using an extinction coefficient 
calculated using the ProParam tool (http://web.expasy.org/protparam/). 
4.2.5 Iron analysis  
 Determination of the iron concentration was similar to, which was previously 
described (22, 193). First the sample was mixed with a final concentration of 5.94 mM 
sulfuric acid for a final ratio of 2:1 sample to sulfuric acid and boiled for 40 minutes. 
Afterwards, solutions were added to 75 μL of boiled sample, in the following order at 
these final concentrations: (i) 968 mM sodium acetate (pH 7.5), (ii) 0.129 % 
hydroxylamine, and (iii) 0.039 % (w/v) bathophenanthroline disulfonic acid in a final 
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volume of 775 μL. The color reaction went for 30 minutes at room temp. The color was 
read at 535 nm (ε535 = 22100 M-1 cm-1). 
4.2.6 Producing glutathione persulfide  
 GSS- was made via a reaction with sodium sulfide and GSSG in a quartz cuvette 
(Spectrocell) with a screw-cap equipped with a Teflon-silicon membrane. A stock 
solution of GSSG was made up with a pH of ~8.0 and was stored in aliquots at -35 °C. 
An aliquot was diluted to 30 mM in 50 mM Tris-Acetate buffer (pH 7.5) and bubbled 
with argon for 30 min. Stock solutions of sodium sulfide were prepared as stated 
previously (158). 45 mM sodium sulfide was added to the 30 mM GSSG with an argon-
purged gastight Hamilton syringe. Sodium sulfide was incubated with GSSG for 30 min. 
The GSS- concentration was measured using a cold cyanolysis method as previously 
described (133). A typical final concentration of GSS- was ~15 mM.  
4.2.7 Catalytic assays of Noc_2007 using an oxygen electrode  
 Assays were conducted at 25 °C using an Oxygraph (Hansatech) with continuous 
monitoring of oxygen consumption. Except where indicated, reactions were conducted in 
air-saturated buffer. Reaction rates were determined by monitoring the consumption of 
oxygen and were corrected for the corresponding blank rate observed in the absence of 
the enzyme.  
 TSDO activity was monitored using an assay that contained 50 mM 
sodium/potassium phosphate buffer (pH 8.0), 20 mM thiosulfate, and 20 mM glutathione 
and was initiated by the addition of the enzyme using a Hamilton syringe. To measure 
SDO activity, GSS- was added to the above assay buffer using an argon-purged gastight 
Hamilton syringe at a final concentration of 280 μM or 292 μM, as indicated. For 
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reactions that required 35 % (450 μM) oxygen, the oxygen was bubbled for 30 min prior 
to the addition of GSS-. It is noteworthy, that the maximal detectable limit of the oxygen 
electrode is 40 % oxygen. To be within the measurable range 35 % oxygen was chosen. 
 For some experiments, control studies using the oxygen electrode were conducted 
with human SDO. Recombinant human SDO was expressed in E. coli 
BL21(DE3)/pMW172ETHE and purified as previously described (22). Plasmid 
pMW172ETHE was obtained as a gift from V. Tiranti. 
4.2.8 TST catalytic assay of Noc_2007 mutants using a sulfite discontinuous assay  
 For mutants to the SDO domain (His57Ala, His 114Ala, and Asp131Ala) the TST 
activity of the TSTD1 domain was measured using a sulfite end point assay as previously 
described (163, 186). An assay containing 50 mM sodium/potassium phosphate buffer 
(pH 8.0), 20 mM thiosulfate, and enzyme were initiated by adding 20 mM glutathione 
(pH 8.0) at 25 °C in a final volume of 0.5 mL. Assays were quenched after 2 min by the 
addition of mercuric chloride to a final concentration of 115 mM and centrifuged. The 
supernatant was assayed for sulfite by using a pararosaniline colorimetric assay (ε570 = 
35300 M-1 L-1). 
4.3 Results 
4.3.1 Purification and iron analysis of recombinant Nitrosococcus oceani SDO-
TSTD1 fusion protein  
 N. oceani gene Noc_2007 was identified from a BLASTp search as a possible 
gene to encode for a fusion protein containing TSTD1-like and SDO-like domains 
connected with a linker region (Chapter 3) (186). We obtained a synthetic version of the 
DNA that was codon optimized for expression in E.coli and subcloned into a pET23a 
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expression vector that introduced a C-terminus (His)6 tag. The resulting construct was use 
to transform E.coli BL21(DE3) cells. The purification strategy was modified from the 
purification for SUMO-TSTD1 (Chapter 3). The WT fusion protein was purified to 
greater than 95% homogeneity; a typical preparation yields approximately 70 mg of 
purified enzyme from 5 g of cells (figure 4.2).  
 Human SDO belongs to a superfamily of enzymes called dioxygen-activating 
mononuclear non-heme iron(II) enzymes that require a 2-His-1-carboxylate facial triad 
for iron binding (23, 24). The growth medium was supplemented with iron to ensure its 
incorporation into the SDO domain of the fusion enzyme. The mole ratio of iron to 
protein was 0.45 ± 0.04 for the WT fusion enzyme (table 4.2).  
 The overall TSDO reaction (eq. 12) involves two consecutive reactions. The first 
step is a TST reaction, catalyzed by the TSTD1 domain, which requires thiosulfate and 
glutathione, producing sulfite and GSS- (eq. 10). The second step is a SDO reaction, 
catalyzed by the SDO domain requiring oxygen. This step consumes the GSS- formed in 
the first step, producing a second molecule of sulfite and regenerating glutathione (eq. 
11). The WT enzyme is postulated to catalyze the formation of two moles of sulfite from 
one mole of thiosulfate and oxygen requires a catalytic amount of glutathione (eq. 12). 
For the WT enzyme, TSDO and SDO activity were determined by measuring oxygen 
consumption according to the assays described in the methods section (section 4.2.7). 
However, the TST activity with the WT enzyme could not be determined because sulfite 
is the product measured in determining TST activity, and both the TST and SDO 
reactions produce sulfite. As summarized in table 4.3, the TSDO activity of the WT 
fusion protein, is 15-fold slower than its SDO activity (kcat,app of  0.53 ± 0.01 s-1 versus 8.2 
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± 0.5 s-1). Because the SDO reaction is significantly faster than the TSDO reaction, we 
hypothesize that the TST reaction is the rate-limiting step. For comparison, the human 
SDO activity (20.4 ± 0.6 s-1) is 2.4-fold higher than the SDO activity of the WT fusion 
protein (table 4.3). 
4.3.2 Mutagenesis of the TSTD1 Domain  
 We hypothesized that the TST activity of the WT enzyme required a catalytic 
cysteine. A sequence alignment of the C-terminus of the Noc_2007 with human TSTD1 
suggested that Cys322 is the catalytic cysteine residue in the fusion protein. Alanine and 
serine Cys322 mutant constructs were expressed, purified, and tested for SDO catalytic 
activity. Both mutations affected protein expression. The Cys322Ala mutant was purified 
to greater than 95% homogeneity; a typical preparation yields 8 mg of protein, which is 
significantly lower than the WT enzyme’s yield (70 mg). The Cys322Ser mutant was 
purified to greater than 95% homogeneity; a typical preparation yields 173 mg of protein, 
which is 2.5-fold higher than the WT enzyme’s yield (70 mg).  
 The mutation of Cys322 is not expected to affect the mole ratio of iron to protein 
because the binding site of iron is located in the SDO domain. This ratio was determined 
for the serine mutant only due to the low amount of purified alanine mutant. As expected, 
the ratio of 0.62 ± 0.04 for the Cys322Ser mutant was similar to the 0.45 ± 0.04 obtained 
for the WT enzyme (table 4.2). Both mutations were found to be catalytically inactive in 
the TSDO assay. As expected the SDO domain was still active. However, the observed 
SDO activity for the alanine and serine mutants was 0.44 ± 0.01 s-1 and 0.71 ± 0.03 s-1 
respectively, and 19- and 12-fold slower respectively than the reaction catalyzed by the 
WT SDO domain (8.5 ± 0.1 s-1) (table 4.3). The slower rate with the mutants suggests 
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that the mutations affected the SDO domain’s catalytic function. These results show that 
Cys322 is catalytically essential for the TST and TSDO reactions. 
4.3.3 Mutagenesis of the SDO Domain 
 We hypothesized that the TST reaction in the TSDO reaction is the rate-limiting 
step, because with the WT enzyme the reaction catalyzed by the SDO domain is 15-fold 
faster than the rate of the overall TSDO reaction. With human SDO, iron is required to 
facilitate the catalytic formation of sulfite from GSS- and oxygen (21). The iron is bound 
to a facial triad composed of two histidines and an aspartate. We expected that mutations 
of these amino acids would cause a decrease in the iron to protein ratio and render the 
SDO domain inactive. A sequence alignment of human SDO and the N-terminus of 
Noc_2007 suggested that His57, His114, and Asp131, are the three residues that 
comprise the iron-binding site. All three mutants were purified to greater than 95% 
homogeneity. A typical preparation yielded, 93 mg, 23 mg, and 26 mg of protein for the 
His114Ala, His57Ala, and Asp131Ala mutations respectively. Compared to the amount 
of the WT enzyme (70 mg) the His114Ala mutant total protein was similar and the other 
two were significantly lower. All three mutants caused a greater than 50% decrease in 
bound iron (table 4.2). Neither TSDO nor SDO activity was detected with any of the 
three mutants (table 4.3).  
 To test the hypothesis that the loss of iron would not affect the TST reaction, we 
performed a TST assay by measuring the production of sulfite by each mutant. The 
results show that all three alanine mutants catalyzed the formation of sulfite with similar 
rates: 0.44 ± 0.00, 0.49 ± 0.06, and 0.46 ± 0.03 s-1 for His57Ala, His 114Ala and 
Asp131Ala respectively (table 4.3). The TST activity of the mutants was similar to the 
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WT’s TSDO activity, which was 0.53 ± 0.01 s-1 by measuring oxygen consumption. The 
TST catalytic activity of the three mutations was approximately 17-fold lower than the 
WT SDO activity. These results in conjunction with the SDO reaction being significantly 
faster than the TSDO reaction of the WT fusion protein, strongly suggests that the TST 
step is the rate-limiting step in the TSDO reaction.  
4.3.4 Is the TSTD1 domain of the fusion protein bidirectional?  
 From our previous work (Chapter 3), we hypothesized that the TSTD1 domain 
functions in a single direction requiring glutathione and thiosulfate to produce GSS- and 
sulfite (eq. 10). However, Libiad et al. postulated that human TSTD1 is a bidirectional 
enzyme that would also function in the reverse direction, requiring GSS- and sulfite to 
produce glutathione and thiosulfate (eq. 13). If a similar reaction occurred with the fusion 
protein, the TSTD1 domain would "compete" with the SDO domain for GSS- by 
consuming it and using the sulfite produced by the SDO domain.  
 If the TSTD1 domain functions bidirectionally, this would alter the mole ratio of 
oxygen consumed to the concentration of GSS- in the SDO reaction. We would expect, 
for the SDO reaction that for every mole of oxygen consumed, an equal amount of GSS- 
would be consumed for a ratio of one. However, if the TSTD1 domain does function in 
two directions, then the ratio of oxygen consumed to GSS- would be less than one for the 
SDO reaction. We conducted the experiment with 35% oxygen (450 µM) and 292 µM 
GSS-, with the enzyme in excess.  
 Prior to testing the fusion enzyme, experiments were conducted with human SDO, 
as a control reaction. This would allow for the comparison of a known SDO to the human 
SDO-like domain in the fusion enzyme. The calculated mole ratio with human SDO was 
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not one as expected but 0.37 ± 0.1 (table 4.4). The WT fusion enzyme’s value was similar 
to that obtained with human SDO (0.39 ± 0.01 compared to 0.37 ± 0.1) (table 4.4). The 
inactive TSTD1 domain (Cys332Ser mutant) had nearly an identical mole ratio of 0.39 ± 
0.05, to the WT enzyme (table 4.4). These results provide definitive evidence that the 
TSTD1 domain within the fusion protein works in the single direction stated in eq. 1. A 
possibility for the ratio value being below one is that the reaction with oxidized 
glutathione and H2S produces GSS- (as described in section 4.2.6) along with polysulfides 
(ie. GSSn- or GSSnSG). These polysulfides along with GSS- will react with cyanide 
forming thiocyanate, which is measured to determine the stock concentration of GSS-
(133). Human SDO and the human SDO-like domain of the fusion protein would 
consume only the GSS-.  
4.4 Discussion  
 In Chapter 3, we presented phylogenetic evidence for the existence of bacterial 
fusion enzymes with a SDO-like and a TSTD1-like domain. In this chapter, we provide 
biochemical data to corroborate the phylogenetic evidence. The SDO-TSTD1 fusion 
enzyme from N. oceani was expressed in E.coli and purified using an immobilized metal 
ion affinity chromatography (IMAC) column. The SDO domain within the WT fusion 
protein is a mononuclear non-heme iron(II) enzyme. The ratio of iron to the WT fusion 
protein was similar to what was determined for human SDO (0.5) (22). Mutations that 
were introduced to the iron-binding center significantly deceased this ratio. A serine 
mutation to the catalytic cysteine (Cys322) in the fusion protein’s TSTD1 domain did not 
affect this ratio.  
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 The overall reaction catalyzed by the WT enzyme is a glutathione-dependent 
conversion of thiosulfate and oxygen to two moles of sulfite. The TSDO reaction consists 
of two steps: a TST reaction followed by a SDO reaction. We hypothesized that the TST 
reaction is the rate-limiting step. With the WT enzyme, the kcat,app of the TSDO reaction 
was 15-fold slower than the kcat,app for the SDO domain. The SDO domain mutants 
exhibited no TSDO or SDO activity. The kcat,app for the TST reaction determined with the 
SDO domain mutants was similar to the kcat,app for the WT enzyme’s TSDO reaction. 
These results provide compelling evidence that the TST reaction is the rate-limiting step 
in the TSDO reaction.  
 To further support this conclusion, we wanted to test the SDO reaction catalyzed 
by the SDO domain with an inactive TSTD1 domain. To evaluate this hypothesis a 
sequence alignment identified Cys322 as the catalytic cysteine, which was subsequently 
mutated to alanine and serine. Instead of observing a rate for the SDO reaction similar to 
what was obtained with the WT enzyme, the kcat,app for the alanine and serine mutants 
were 19- and 12-fold slower respectively. There are two possible explanations for this 
result: (i) mutation to the TSTD1 domain caused a conformational change to the SDO 
domain or the whole protein or (ii) the SDO domain is intrinsically unstable. Evidence 
that the SDO domain is unstable apart from its lower kcat,app with the TSTD1 domain 
mutations, is that the kcat,app obtained for the SDO activity of the WT enzyme was from 
unfrozen cells.  
 What is the overall importance of the H2S metabolic pathway within N. oceani?  
N. oceani is an ammonia-oxidizing bacterium that produces all its energy from the 
oxidization of ammonia to nitrite (194). H2S may regulate the nitrification process, 
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because studies have shown that H2S can inhibit nitrification (195-197). This may explain 
why the genes that encode for the fusion and the human-like SQOR enzyme are located 
on the same regulon cluster. Further studies observing the role of H2S in N. oceani are 
required to better understand how it affects the organism. In turn, this could shed light on 
part of H2S’s environmental impact, because ammonia-oxidizing bacteria are the rate-
limiting step in the overall nitrification process (194).  
 In summary, we have described a novel TSDO fusion enzyme that contains SDO-
like and TSTD1-like domains encoded by the gene, Noc_2007 in N. oceani. The TSTD1 
domain catalyzes a TST reaction, consuming thiosulfate and glutathione and producing 
sulfite and GSS-. The SDO domain catalyzes a SDO reaction, consuming oxygen and the 
GSS- from the TST reaction to produce a second molecule of sulfite and regenerate 
glutathione. Lastly, we observed that the TSTD1 domain does not “compete” with the 
SDO domain for GSS- but rather functions only in the direction previously stated. In 
conclusion, these experiments support the functional interaction that was observed in 
Chapter 3 with human TSTD1 and SDO.  
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Table 4.1 Primers Used for Mutagenesis of Noc_2007 
Fusion 
Protein 
Mutant 
Primer Sequence 5' to 3' 
His57Ala 
Forward GAAATACAGCCTGGAGACCGCCGCCCATGCCGATC 
Reverse GATCGGCATGGGCGGCGGTCTCCAGGCTGTATTTC 
His114Ala 
Forward GCCACACCGGGCGCCACCCCGGGTAGC 
Reverse GCTACCCGGGGTGGCGCCCGGTGTGGC 
Asp131Ala 
Forward CGTGTGTTTACCGGTGCAGCCCTGCTGATTAAC 
Reverse GTTAATCAGCAGGGCTGCACCGGTAAACACACG 
Cys322Ala 
Forward CCGATTATTCTGTACGCCCAGACAGGTGGC 
Reverse GCCACCTGTCTGGGCGTACAGAATAATCGG 
Cys322Ser 
Forward CCGATTATTCTGTACAGCCAGACAGGTGGC 
Reverse GCCACCTGTCTGGCTGTACAGAATAATCGG 
 
 
 
 
 
Table 4.2 Ratio of Iron to Enzyme  
Sample Ratio (iron: enzyme) 
WT 0.45 ± 0.04 
His57Ala 0.18 ± 0.01 
His114Ala 0.16 ± 0.02 
Asp131Ala 0.21 ± 0.01 
Cys322Ser 0.62 ± 0.04 
Enzyme and iron concentrations were 
determined as described in Experimental 
Procedures. 
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Table 4.3 Rate of Wild Type and Mutant Noc_2007 Compared to Human TSTD1 
and SDO Enzymes 
Sample 
k
cat,app
 (s-1) 
TSDO TST SDO 
Wild Type 0.53 ± 0.01 ND 8.2 ± 0.5  
His57Ala 0 0.44 ± 0.00* 0 
His114Ala 0 0.49 ± 0.06 0 
Asp131Ala 0 0.46 ± 0.03 0 
Cys322Ala 0 0 0.44 ± 0.01 
Cys322Ser 0 0 0.71 ± 0.03 
Human TSTD1 0 0.48 ± 0.04 0 
Human SDO 0 0 20.4 ± 0.6 
Reactions were conducted as described in the Experimental Procedures. Values for 
kcat,app are determined on the basis of the rate of oxygen consumption for the TSDO 
and SDO reactions and sulfite formation for the TST reactions. For the SDO 
reactions the GSS- was at a final concentration of 280 μM.  
*Reaction was done in duplicate with an identical value 
 
 
 
 
Table 4.4 SDO Reaction: Determining the Mole Ratio of a Mole of Oxygen Consumed 
to a Mole of Glutathione Persulfide for Human SDO and Wild Type and Cys322Ser of 
Noc_2007 
Enzyme [GSS
-] 
(µM) 
[Oxygen Consumed] 
(µM) 
mol O2 consumed/ 
mol of GSS- 
Human SDO 292 ± 0 108 ± 28 0.37 ± 0.1 
WT Fusion Protein 292 ± 0 114 ± 2 0.39 ± 0.01 
Cys322Ser Fusion Protein 292 ± 0 114 ± 16 0.39 ± 0.05 
Reactions were initiated with an excess amount of enzyme and went to completion 
within 60 sec. Set up was conducted as described in the Experimental Procedures. 
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Figure 4.1 Sequence alignment of human SDO or human TSTD1 with the N-terminal 
SDO-like or the C-terminal TSTD1-like domain, respectively, in Noc_2007. Panel A: 
Mutations made in Noc_2007 are in bold and a larger font size corresponding to the iron-
binding site, His57, His114, and Asp131. Panel B: Active site cysteine, Cys322, which 
was mutated in Noc_2007, is bolded and a large font size. 
 
A) N-terminal of SDO-like Domain 
 
N. oceani          ----------------------MIFRQLFDPESSTYTYLIGDPATKEAVFIDPVNTRVDE 38 
ETHE1              MAEAVLRVARRQLSQRGGSGAPILLRQMFEPVSCTFTYLLGDRESREAVLIDPVLETAPR 60 
 
N. oceani          YLNLLNKYALKLKYSLETHAHADHITASGLLRQRT-GAKTGIGQACGAQYADYQLKDGVV 97 
ETHE1              DAQLIKELGLRLLYAVNTHCHADHITGSGLLRSLLPGCQSVISRLSGAQ-ADLHIEDGDS 119 
 
N. oceani          LAFGQGEEIKVLATPGHTPGSVSYLWRDR--VFTGDALLINGCGRTDFQGGDPGVLYDSI 155 
ETHE1              IRFGR-FALETRASPGHTPGCVTFVLNDHSMAFTGDALLIRGCGRTDFQQGCAKTLYHSV 178 
   
 
N. oceani          TQKLFTLPGETIVYPGHDYNGRWVSSIEQERTRNGRLAGK-TRSEFIEIMNNLNLPKPQR 214 
ETHE1              HEKIFTLPGDCLIYPAHDYHGFTVSTVEEERTLNPRL--TLSCEEFVKIMGNLNLPKPQQ 236 
 
N. oceani          IDEAVPANRRCG------ 226 
ETHE1              IDFAVPANMRCGVQTPTA 254 
 
 
B) C-terminal of TSTD1-like Domain 
 
N. oceani         -----EIDVATVKQRLGDGKTAIIDVREPEEFAAGHLPGAINVPRGVLEFRLGNTA-- 310 
TSTD1               MAGAPTVSLPELRSLLASGRARLFDVRSREEAAAGTIPGALNIPVSELESALQMEPAA 58 
 
N. oceani           --------ELADPNVPIMLYCQTGGRAALAAWSLKCLGYTDAVLIAGGYDAWRAAEQNAN 362 
TSTD1               FQALYSAEKPKLEDEHLVFFCQMGKRGLQATQLARSLGYTGARNYAGAYREWLEKES--- 115 
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Figure 4.2 Expression of recombinant Nitrosococcus oceani SDO-TSTD1 fusion protein. 
The SDS-12% polyacrylamide gel was stained for protein with ProSieve Blue Protein 
Staining Solution (Lonza); lane M, molecular markers; lane 1, whole cell lysate; lane 2, 
low-speed supernatant; lane 3, IMAC flow-through; lane 4 IMAC wash; lane 5, IMAC 
eluate; lane 6, dialyzed IMAC eluate from lane 5. 
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  Chapter 5: Conclusions and Future Directions 
 
 Hydrogen sulfide (H2S) is the newest member of the gasotransmitter family that 
includes nitric oxide and carbon monoxide. Although originally believed to be toxic to 
animals it is now understood that within a small concentration window it plays an 
important role within mammals ranging from high blood pressure to a neuroprotectant 
and modulator (93-95, 103). Outside of this range, H2S is associated with pathological 
conditions, including hypertension, ethylmalonic encephalopathy, Down syndrome, 
ulcerative colitis, Alzheimer’s disease, and Parkinson’s disease (22, 25, 81, 90, 91, 95, 
198). Importantly, H2S is the only gasotransmitter that is enzymatically degraded. Studies 
involving the metabolic pathway of H2S were lacking prior to our work. The goal of this 
thesis work was to improve the field’s understanding of this pathway. 
 Prior to our work, Hildebrandt and Grieshaber proposed a pathway for the 
metabolism of H2S to thiosulfate in mammals and invertebrates (14). The first enzyme in 
the proposed pathway is a membrane-associated enzyme called sulfide:quinone 
oxidoreductase (SQOR). They proposed that SQOR would catalyze the two-electron 
oxidation of H2S to sulfane sulfur (S0) using coenzyme Q as the electron acceptor and 
glutathione as the physiological acceptor of the sulfane sulfur (S0) producing glutathione 
persulfide (GSS-). It is note worthy, that at that time the physiological acceptor of the 
sulfane sulfur was unknown.  In Chapter 2, we successfully purified and characterized 
human SQOR. Importantly, we determined that glutathione was not the physiological 
acceptor of the sulfane sulfur but rather sulfite, producing thiosulfate. The discovery of 
thiosulfate as the product was important, because thiosulfate is a known intermediate and 
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byproduct of H2S metabolism. Latter, Libiad et al. also showed that sulfite was an 
acceptor however, but they stated that glutathione would be the predominant acceptor 
within the cell (192). They reported a Km of 22 mM for glutathione, which is higher than 
the 1-8 mM concentration of glutathione found inside cells (180, 192). We have recently 
shown in assays with SQOR that Michaelis-Menten Kinetics are not observed at 
glutathione concentrations as high as 40 mM (199). The rate observed at glutathione 
concentrations found in cells is ≤ 2-fold faster than the slow rate of H2S oxidation 
observed in assays containing only sulfide and CoQ1. 
 A future experiment would be to determine the physiological concentration of 
sulfite within tissues and compare it to sulfite’s Km (174 μM). If the tissue concentration 
of sulfite is close to its Km, it will provide further evidence supporting that sulfite is the 
predominant acceptor of the sulfane sulfur. Although, the concentration of sulfite in 
serum has been determined, it is important to determine the concentration in tissue, as 
SQOR is located in the mitochondria and is not present in serum (200, 201). 
 Another future experiment with SQOR would be to solve the crystal structure of 
the enzyme with and without a quinone. If solved, to our knowledge it would be the first 
structure of a Type II SQOR. This would allow us to compare it to the other known 
structures: (i) A. aeolicus SQOR (Type I), (ii) A. ferrooxidans SQOR (Type I), and (iii) A. 
ambivalens SQOR (Type V) and to our homology model (32-34, 202).  Additionally, we 
could confirm that Cys201 and Cys379 comprise the redox-active disulfide bridge that is 
near the FAD. Moreover, the structure could provide insight to confirming our postulated 
catalytic mechanism for SQOR (Scheme 2.2). In conjunction to solving a crystal 
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structure, stopped-flow experiments could also be conducted to provide a detailed 
understanding of the mechanism.    
 Hildebrandt and Grieshaber postulated that the second enzyme in the metabolism 
of H2S is sulfur dioxygenase (SDO). SDO is a mitochondrial matrix enzyme, requiring 
oxygen to catalyze the four-electron oxidation of the sulfane sulfur in glutathione 
persulfide (GSS-) to produce sulfite and glutathione (14, 21, 22). In an alternate scenario, 
it has been suggested that SDO might directly oxidize the sulfane sulfur in the SQOR 
persulfide intermediate (E-CysSS- + O2 + H2O ⇒ E-CysS- + SO3-2 + 2H+) (199). 
However, addition of human SDO to assays containing sulfide and CoQ1 did not 
accelerate the rate of H2S oxidation (199). This result and the results obtained in Chapter 
2 lead us to postulate a role for a thiosulfate sulfurtransferase (TST) in H2S metabolism. 
A TST requires thiosulfate and glutathione to produce GSS- and sulfite.  We postulated 
that the TST reaction is the intermediate step that would consume the thiosulfate from the 
SQOR reaction and produce GSS-, a substrate required for the SDO reaction, linking the 
SQOR and SDO steps in H2S metabolism (Scheme 3.1).  
  Using bioinformatics in Chapter 3, we identified the yeast and human genes 
RDL1 and TSTD1 that encode for their respective TSTs. We discovered that GSS− was 
produced by both enzymes, released into solution, and a potent competitive inhibitor of 
the enzymes with respect to glutathione. The TST reaction is thermodynamically 
unfavorable because it produces GSS−, which is a highly reactive compound, compared to 
thiosulfate. On the other hand, the SDO reaction is thermodynamically favorable. We 
hypothesized that there is thermodynamic coupling between the enzymes. To test this we 
performed a continuous assay containing p-toluenethiosulfonate, a chromogenic substrate 
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that is a more reactive sulfane sulfur donor than thiosulfate. In assays containing only 
TST, the observed reaction reached an apparent equilibrium position when only 
approximately 50 % of the p-toluenethiosulfonate had been consumed. In the presence of 
excess SDO, GSS− is oxidatively decomposed and 100 % of the p-toluenethiosulfonate 
was consumed. The observed ability of SDO to drive the TST reaction to completion 
provides a paradigm for proposed thermodynamic coupling of these reactions in cells. 
Additionally, this supports our hypothesis that the TST reaction is the missing link 
between the SQOR and SDO reactions in the H2S metabolic pathway.  
 To confirm the roles of SQOR and TSTD1 in H2S metabolism, it would be 
beneficial to perform protein knockdown experiments using clustered regularly 
interspaced short palindromic repeats-interference (CRISPRi) mediated transcriptional 
repression. A common method usually used to knockdown protein levels in cells is short 
hairpin RNA (shRNA). However, CRISPRi mediated transcriptional repression is a 
newer, more effective technique. This method decreases protein levels in a cell by 
affecting transcription instead of translation with shRNA (203). An expected result from 
SQOR knockdown would be an increase in the levels of H2S. This increase would also be 
expected in experiments with TSTD1 knockdown. With either enzyme being knockdown 
sulfite would not be detected. SDO would not be able produce to sulfite because GSS-, a 
substrate for the reaction would not be produced (see Scheme 3.1 for proposed metabolic 
pathway of H2S). Our assumption that sulfite will not be detected is from the results 
obtained by Tiranti et al. that showed in ETHE1-/- (gene that encodes for human SDO) 
mice or individuals with ethylmalonic encephalopathy (disease associated with inactive 
SDO), that sulfite was undetectable (22).   
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 The thermodynamic coupling of human TSTD1 and SDO observed in Chapter 3 
led us to inquire if there is phylogenetic evidence to support their interaction. From 
bioinformatic approaches we identified fusion proteins within bacteria that contain a 
human SDO-like and human TSTD1-like domain at the C- and N- terminal respectively 
connected with a variable-length linker region. Operationally, the fusion is a glutathione-
dependent thiosulfate dioxygenase (TSDO), which has the combined functions, of a TST 
reaction followed by the SDO reaction. The net reaction requires a catalytic amount of 
glutathione to facilitate the oxidation of one mole of thiosulfate in the presence of 
oxygen, to two moles of sulfite. To confirm the results obtained from bioinformatics a 
fusion protein was expressed from N. oceani that was encoded by the Noc_2007 gene 
(see Chapter 4). We determined that it is indeed a fusion of both enzymes and that the 
TST reaction is the apparent rate-limiting step in the TSDO reaction.  
 Libiad et al. postulated that human TSTD1 could function in the reverse direction 
(192). If a similar reaction occurred with the fusion protein, the TSTD1 domain would 
"compete" with the SDO domain for GSS− by using the sulfite produced from the SDO 
reaction to consume GSS−.  We observed that the TSTD1 domain does not “compete” 
with the SDO domain for GSS− and thus functions in one direction. A future experiment 
would be to obtain the crystal structure of the N. oceani fusion protein. The structure 
would provide insight regarding the mechanism of catalysis by the fusion protein, 
including the possibility of substrate (GSS-) channeling between the two domains.  
 From our work we propose a newer model (Scheme 3.1) for the metabolic 
pathway of H2S than previously described by Hildebrandt and Grieshaber (14). As the 
field of H2S keeps expanding it is important that the metabolism of this gasotransmitter 
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continues to be studied. Furthermore, understanding how this pathway is regulated could 
uncover key aspects related directly to H2S signaling.  
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Appendices 
 
 
Appendix 1: Supplemental Figures for Chapter 2 
 
 
 
 
 
Appendix 1 Figure 1 The nucleotide sequence of the synthetic gene used to express 
recombinant SQOR (upper case) is compared with the original gene sequence (lower 
case). The synthetic gene contains a single Met in place of an N-terminal mitochondrial 
targeting presequence (41 amino acids). The amino acid sequence (top line) is numbered 
according to the precursor sequence. 
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Appendix 1 Figure 2 Spectral course of sulfide oxidation by SQOR in the presence of 
cyanide and CoQ1.  The reaction was conducted at 25 ̊C in 100 mM potassium phosphate, 
pH 8.0, containing 0.5 mM EDTA.  The dotted black line was recorded before addition of 
300 μM sulfide to an assay mixture containing 158 μM CoQ1, 1.0 mM cyanide, and 9.3 
nM SQOR.  Curves 2 to 7 were recorded 1.4, 22, 42, 62, 82, 102, and 831 s, respectively, 
after sulfide addition.  The inset shows the time course of absorbance changes at 272 and 
317 nm plotted according to the left and right y-axes, respectively. 
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Appendix 1 Figure 3 Reaction of dithiothreitol (DTT) with the sulfur oxidation product 
formed during the apparent “acceptor-free” oxidation of sulfide by SQOR.  Reactions 
were conducted in 100 mM potassium phosphate, pH 8.0, containing 0.5 mM EDTA at 
25 ̊C.  The dotted black line was recorded after maximal formation of the sulfur oxidation 
product in an assay mixture containing 300 μM sulfide, 158 μM CoQ1 and 32.5 nM 
SQOR.  Curves 1 to 5 were recorded 1.4, 17, 37, 117, and 831 s, respectively, after 
addition of 1.0 mM DTT.  The inset shows a difference spectrum calculated by 
subtracting the spectrum observed at the end of the DTT reaction from the spectrum 
observed before DTT addition.  
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Appendix 1 Figure 4 Spectral course of sulfide oxidation by SQOR in the presence of 
glutathione and CoQ1.  The assay was conducted at 25 ̊C in 100 mM potassium phosphate 
buffer, pH 8.0, containing 0.5 mM EDTA, 200 μM sulfide, 83 μM CoQ1, 1.0 mM 
glutathione, and 36.2 nM SQOR.  Curves 1 to 9 were recorded 1.4, 10, 20, 30, 40, 50, 60, 
70, and 120 s, respectively, after sulfide addition.   
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Appendix 1 Figure 5  Effect of sulfide concentration on the observed rate of reduction of 
CoQ1.  Measurements were made at saturating CoQ1 (66.2 μM) in 100 mM potassium 
phosphate buffer, pH 7.0, containing 0.5 mM EDTA  at 25 ̊C.   The red line was obtained 
by fitting a hyperbolic equation (kcat app = kcat[sulfide]/(Km +[sulfide]) to the data (black 
circles).  The inset shows the corresponding double reciprocal plot.  The red line was 
generated by linear regression analysis of the data (r2 = 0.9443) 
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Appendix 2:  Supplemental Figures and Tables for Chapter 3 
 
 
 
 
 
 
 
 
 
 
  
 
 
Appendix 2 Table 1 Primers used for PCR reactions 
Reaction Primers 
Amplification of the RDL1 gene 
from S. cerevisiae genomic DNA  
5’- GCTAGCCATATGTGGAAGGCCGTGATGAATG-3’ 
5’-
CCTAGAGTATACACTCGAGTAAGTCAAGTTTATCACCC-3’ 
Ligation-independent cloning of an 
optimized synthetic gene encoding 
human TSTD1 isoform 1   
5’-AGATTGGTGGCATGGCCGGGGCGCCG-3’ 
5’-GAGGAGAGTTTAGACTCACGACTCCTTCTCCAG-3’ 
Ligation-independent cloning of an 
optimized synthetic gene encoding 
human TSTD1 isoform 2  
5'-AGATTGGTGGCATGGCAGGTGTTAGTG-3' 
5'-GAGGAGAGTTTAGACTCAGGATTCTTTTTCTAACC-3' 
Ligation-independent cloning of an 
optimized synthetic gene encoding 
human TSTD1 isoform 3  
5’-AGATTGGTGGCATGGCCGGAGCCCC-3’ 
5'-GAGGAGAGTTTAGACTCAGCGACCTGCTAATAAC-3' 
Mutation of Cys98 to Ala in yeast 
RDL1 
5'-GGAGCTAATATTTTATGCTGCTTCTGGCAAACGCG-3’ 
5’-GCGGTTTGCCAGAAGCAGCATAAAATATTAGCTCC-3’ 
Mutation of Cys98 to Ser in yeast 
RDL1 
5’-GGAGCTAATATTTTATTGTGCTTCTGGCAAACGCG -3’ 
5’- CGCGYYYGCCAGAAGCACAATAAAATATTAGCTCC-3’ 
Mutation of Cys79 to Ala in 
human TSTD1 isoform 1  
5’- CATCTGGTTTTTTTCGCACAGATGGGTAAACGC-3’ 
5’-GCGTTTACCCATCTGTGCGAAAAAAACCAGATG-3’ 
Mutation of Cys79 to Ser in human 
TSTD1 isoform 1 
5’- CATCTGGTTTTTTTCTCTCAGATGGGTAAACGC-3’ 
5’- GCGTTTACCCATCTGAGAGAAAAAAACCAGATG-3’ 
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Appendix 2 Table 2 BLASTp Search of the Bacterial Proteomes that Contain SDO-TSTD1 Fusion 
Proteins Using Human SQOR as the Query Sequence 
 
Organism (Taxonomy ID) 
Highest Scoring Blast Hit 
GenBank accession 
number (remarks) 
Query 
Cover 
(%) 
E Value Identity (%) 
Distance 
(nucleotides)a 
1 Nitrosococcus oceani 
(1229) 
YP_343998.1 88 4e-144 42 73 
2 Nitrosococcus watsonii 
(473531) 
YP_003760988.1 88 5e-111 42 73 
3 Methylocella silvestris 
(199596) 
(no hit obtained)  -  - - - 
4 Methylobacter 
tundripaludum (173365) 
WP_006892758.1 87 1e-114 42 21 
5 Methylomicrobium 
album (39775) 
WP_005371245.1 87 4e-111 41 45 
6 Methyloglobulus 
morosus (1410681) 
WP_023495229.1 86 5e-115 42 113 
7 Methylocystis rosea 
(173366) 
WP_018406351.1 51 1e-10 27 nd 
8 Methylosarcina fibrata 
(105972) 
WP_020565271.1 87 7e-112 41 246 
9 Bradyrhizobiaceae 
bacterium (709797) 
WP_009735658.1 67 0.001 22 nd 
10 Afipia broomeae 
(56946) 
WP_006019594.1 65 3e-6 22 nd 
11 γ-proteobacterium 
HTCC2148 (247634) 
(bacterial proteome 
unavailable) 
  -   -   - - 
12 Rhizobium giardinii 
(56731) 
WP_018327723.1 86 5e-90 35 nd 
13 Mesorhizobium 
amorphae (71433) 
WP_006203294.1 79 2e-23 26 nd 
aThe indicated distance is determined based on the number of intervening nucleotides between the human 
SQOR homolog gene and the SDO-TSTD1 fusion protein gene in the bacterial chromosome. Complete 
genomic data are available only for N. oceani and N. watsonii.  Genomic distances in other bacteria, where 
whole-genome shotgun contigs are available, could be determined when the genes for the SQOR homolog 
and the SDO-TSTD1 fusion protein were found in the same contig but not when the genes were located in 
different contigs (nd).  
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Appendix 2 Figure 1 The nucleotide sequence of the synthetic gene used to express 
recombinant TSTD1 isoform 1 (upper case) is compared with the original gene sequence 
(lower case). The top line shows the amino acid sequence of isoform 1. 
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Appendix 2 Figure 2 The nucleotide sequence of the synthetic gene used to express 
recombinant TSTD1 isoform 2 (upper case) is compared with the original gene sequence 
(lower case). The top line shows the amino acid sequence of isoform 2. 
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Appendix 2 Figure 3 The nucleotide sequence of the synthetic gene used to express 
recombinant TSTD1 isoform 3 (upper case) is compared with the original gene sequence 
(lower case). The top line shows the amino acid sequence of isoform 3. 
 
 
 
 
 
 
 
 
 
 
 
  
154!
 
Appendix 2 Figure 4 Alignment of human TSTD1 isoforms. Amino acids encoded 
across a splice junction and cysteines are highlighted in yellow and red, respectively. All 
isoforms contain a tripeptide at the N-terminus and a central core of 55 amino acids that 
are encoded by exons 1 and 3, respectively. The N-terminal tripeptide in isoforms 1 and 3 
is followed by a stretch of 41 amino acids (encoded by exon 2) that is absent in isoform 
2. The 16 amino acids at the C-terminus of isoforms 1 and 2 (encoded by exon 4) are 
replaced by a decapeptide in isoform 3 (encoded by retained intron 3). 
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Appendix 2 Figure 5 Purification of recombinant human TSTD1 isoform 2 with a 
cleavable N-terminal His-SUMO tag. The SDS 15% polyacrylamide gel was stained for 
protein with ProSieve Blue Protein Staining Solution (Lonza); lane M, molecular 
markers; lane 1, whole cell lysate; lane 2, low speed supernatant; lane 3, Ni affinity 
column flow-through; lane 4, Ni affinity column wash; lane 5, Ni affinity column eluate; 
lane 6, Ni affinity column eluate after cleavage with SUMO hydrolase; lane 7, SUMO 
hydrolase-treated sample after dialysis; lane 8, second Ni affinity column flow-through; 
lane 9, second Ni affinity column eluate; lane 10, dialyzed sample from lane 8. 
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Appendix 2 Figure 6 Purification of recombinant human TSTD1 isoform 3 with a 
cleavable N-terminal His- SUMO tag. The SDS 15% polyacrylamide gel was stained for 
protein with ProSieve Blue Protein Staining Solution (Lonza); lane M, molecular 
markers; lane 1, whole cell lysate; lane 2, low speed supernatant; lane 3, Ni affinity 
column flow-through; lane 4, Ni affinity column wash; lane 5, Ni affinity column eluate; 
lane 6, Ni affinity column eluate after cleavage with SUMO hydrolase; lane 7, SUMO 
hydrolase-treated sample after dialysis; lane 8, second Ni affinity column flow-through; 
lane 9, second Ni affinity column eluate; lane 10, dialyzed sample from lane 8.  
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Appendix 2 Figure 7 Spectral properties of p-toluenethiosulfonate (p-Tol-SO2S-) and p-
toluenesulfonite (p- Tol-SO2-). Spectra were recorded at 25 EC using a 2 mm cuvette. 
Curve 1 is the absorption spectrum of p-Tol-SO2S- in 50 mM potassium/sodium 
phosphate buffer, pH 8.0, recorded 2 s after addition of 1.6 mM potassium cyanide. 
Curve 2 is the absorption spectrum of p-Tol-SO2- in the same buffer, recorded 190 s after 
addition of 60 nM human rhodanese, an enzyme previously show to catalyze the transfer 
of the sulfane sulfur from p-Tol-SO2S- to cyanide (Sorbo, B. (1953) Acta Chem. Scand. 
7, 32-37). 
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Appendix 2 Figure 8 Multiple sequence alignment of selected SDO-TSTD1 bacterial 
fusion proteins. The black box marks a poorly conserved, variable length linker (9 to 52 
amino acids) between the N-terminal SDO-like domain (230 or 231 amino acids) and the 
C-terminal TSTD1-like domain (96 to 105 amino acids). GenBank accession numbers: 
Nitrosococcus oceani (WP_013220760.1); Methylocella silvestris (WP_012591638.1); 
Methylobacter tundripaludum (WP_006892756.1); Methylomicrobium album 
(WP_005371248.1); Methyloglobulus morosus (WP_023495230.1). 
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Appendix 2 Figure 9 Multiple sequence alignment of human SDO or human TSTD1 
with the N-terminal SDO-like or the C-terminal TSTD1-like domain, respectively, in 
selected bacterial SDO-TSTD1 fusion proteins. Panel A: The black box marks a β-
lactamase signature motif. Conserved metal binding and glutathione binding sites, 
identified in previous studies (Zhang et al. (2013) PLOS ONE, 8, e81885), are 
highlighted in yellow and magenta, respectively. Panel B: The black boxes mark a six 
amino acid active site loop and a rhodanese homology domain signature motif. GenBank 
accession numbers: Nitrosococcus oceani (WP_013220760.1); Methylocella silvestris 
(WP_012591638.1); Methylobacter tundripaludum (WP_006892756.1); 
Methylomicrobium album (WP_005371248.1); Methyloglobulus morosus 
(WP_023495230.1). 
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Appendix 3: Supplemental Figures for Chapter 4 
 
 
 
 
 
 
M  I  F  R  Q  L  F  D  P  E  S  S  T  Y  T  Y  L  I  G  D       60 
atgatctttcggcagctatttgaccctgaatcctcgacctatacttatcttattggtgat   
||||||||.||.|||||.||.||.||.|||..|...||||||||.|||||.||||||||. 
ATGATCTTCCGCCAGCTGTTCGATCCGGAAAGCAGCACCTATACCTATCTGATTGGTGAC   
 
P  A  T  K  E  A  V  F  I  D  P  V  N  T  R  V  D  E  Y  L       120 
ccggctactaaagaagcagtatttattgatccagtgaatacccgtgttgatgagtatcta   
||.||.||.|||||.||.||.|||||.||.||.|||||||||||.||.||||||||.||. 
CCTGCCACCAAAGAGGCCGTGTTTATCGACCCGGTGAATACCCGCGTGGATGAGTACCTG   
 
N  L  L  N  K  Y  N  L  K  L  K  Y  S  L  E  T  H  A  H  A       180 
aatctacttaataagtacaatcttaaactgaaatattctttggaaacccacgcccacgct   
|||||.||.||||||||.||.||.|||||||||||.....||||.|||||.|||||.||. 
AATCTGCTGAATAAGTATAACCTGAAACTGAAATACAGCCTGGAGACCCATGCCCATGCC   
 
D  H  I  T  A  S  G  L  L  R  Q  H  T  G  A  K  T  G  I  G       240 
gatcatatcaccgctagtggtttgctgcgccagcacaccggggccaagacaggaattggg   
||||||||.|||||.||.||..|||||||.|||||.|||||.|||||.||.||.|||||. 
GATCATATTACCGCCAGCGGCCTGCTGCGTCAGCATACCGGCGCCAAAACCGGCATTGGC   
 
Q  A  C  G  A  Q  Y  A  D  Y  Q  L  K  D  G  V  V  L  A  F       300 
caagcttgcggcgcgcaatatgctgactatcagctcaaagatggcgttgtgttagctttt   
||.||.|||||.||.||.|||||.|||||||||||.|||||.||.||||||.|.||.||| 
CAGGCCTGCGGTGCACAGTATGCCGACTATCAGCTGAAAGACGGTGTTGTGCTGGCCTTT   
 
G  Q  G  E  E  I  K  V  L  A  T  P  G  H  T  P  G  S  I  S       360 
ggccagggcgaggagattaaggtgcttgccacccctggccatacgcctgggagtatctcc   
||||||||.|||||||||||.||.||.|||||.||.||||||||.||.||.||.||...| 
GGCCAGGGTGAGGAGATTAAAGTTCTGGCCACACCGGGCCATACCCCGGGTAGCATTAGC   
 
Y  L  W  R  D  R  V  F  T  G  D  A  L  L  I  N  G  C  G  R       420 
tatctgtggcgtgatcgggtgtttaccggcgatgcgctgcttatcaacggttgcgggcgc   
||.|||||||||||.||.|||||||||||.||.||.|||||.||.|||||.|||||.||| 
TACCTGTGGCGTGACCGTGTGTTTACCGGTGACGCCCTGCTGATTAACGGCTGCGGTCGC   
 
T  D  F  Q  G  G  D  P  G  T  L  Y  D  S  V  T  Q  K  L  F       480 
accgattttcaaggtggcgatccggggacattatacgattcggttactcagaaactattc   
|||||||||||.|||||.||||||||.||..|.||||||...||.||.||||||||.||. 
ACCGATTTTCAGGGTGGTGATCCGGGCACCCTGTACGATAGCGTGACCCAGAAACTGTTT   
 
T  L  P  G  E  T  I  V  Y  P  G  H  D  Y  N  G  R  W  V  S       540 
accttgcctggcgaaaccatcgtttatccggggcacgattataatggtcgctgggtcagt   
|||.||||.||.||.|||||||||||||||||.|||||.|||||.|||||.|||||.||. 
ACCCTGCCGGGTGAGACCATCGTTTATCCGGGCCACGACTATAACGGTCGTTGGGTGAGC  
 
S  V  E  Q  E  R  T  G  N  G  R  L  A  G  K  T  R  A  E  F       600 
tcagttgaacaggagcgtaccgggaacggacggcttgcgggcaaaacccgcgctgagttc   
...||.|||||.||.||.||.||.||.||.||.||.||.||.||.||||||||.||.||. 
AGCGTGGAACAAGAACGCACAGGCAATGGTCGCCTGGCCGGTAAGACCCGCGCAGAATTT   
 
I  E  I  M  N  N  L  N  L  P  K  P  R  L  I  D  E  A  V  P       660 
attgaaattatgaataatttaaatttgcccaagccccggcttatcgatgaagctgttcca   
|||||.||||||||.||..|.|||||.||.||.||.||.||.|||||||||||.||.||. 
ATTGAGATTATGAACAACCTGAATTTACCGAAACCGCGCCTGATCGATGAAGCCGTGCCG   
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Appendix 3 Figure 1 The nucleotide sequence of the synthetic gene used to express 
recombinant Noc_2007 (upper case) is compared with the original gene sequence (lower 
case). The top line shows the amino acid sequence of Noc_2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A  N  R  R  C  G  L  T  E  E  E  I  R  Q  D  T  M  M  G  E       720 
gcaaataggcgctgtggcttaaccgaggaagaaattcgccaggatactatgatgggcgag   
||||||.|.||.||.||..|.|||||.|||||.|||||||||||.||.|||||||||||. 
GCAAATCGCCGTTGCGGTCTGACCGAAGAAGAGATTCGCCAGGACACCATGATGGGCGAA   
 
K  R  V  S  T  P  Q  D  L  V  Q  E  A  R  K  Q  V  R  E  I       780 
aaacgcgtcagcacgccacaggatttagtacaggaggccaggaagcaggtccgtgaaatt   
||||||||.||.||.||.||||||.|.||.|||||.||..|.||.||.||.|||||.||. 
AAACGCGTTAGTACCCCGCAGGATCTGGTGCAGGAAGCACGCAAACAAGTGCGTGAGATC   
 
D  V  A  T  V  K  Q  R  L  G  D  G  K  T  A  I  I  D  V  R       840 
gacgttgccaccgtgaagcaaaggttgggcgatggtaaaacagccatcattgatgtgcgg   
||.||||||||||||||.||..|..||||.|||||.|||||.|||||.||.||.|||||. 
GATGTTGCCACCGTGAAACAGCGTCTGGGTGATGGCAAAACCGCCATTATCGACGTGCGT   
 
E  P  E  E  F  A  A  G  H  L  P  G  A  I  N  V  P  R  G  V       900 
gagccggaagaattcgcggcgggtcatctgcctggcgctatcaatgtaccacgtggtgtt    
||||||||||||||.||.||.||.||||||||.||.||.||.|||||.||.||||||||| 
GAGCCGGAAGAATTTGCCGCAGGCCATCTGCCGGGTGCCATTAATGTGCCGCGTGGTGTT   
 
L  E  F  R  L  G  N  T  A  E  L  A  D  P  N  I  P  I  I  L       960 
ttagagtttcgcttaggtaatactgcggagctggctgatcctaatatccctattattctg   
.|.||.||||||.|.||.||.||.||.||.|||||.|||||.|||||.||.||||||||| 
CTGGAATTTCGCCTGGGCAACACCGCCGAACTGGCCGATCCGAATATTCCGATTATTCTG   
 
Y  C  Q  T  G  G  R  A  A  L  A  A  W  S  L  K  C  L  G  Y      1020 
tactgccaaacaggtgggcgcgcagcattggctgcctggtcgctcaaatgccttggttat   
||||||||.||||||||.|||||.|||||.||.||||||...||.||||||.|.||.||| 
TACTGCCAGACAGGTGGCCGCGCCGCATTAGCAGCCTGGAGCCTGAAATGCTTAGGCTAT   
 
T  D  A  T  L  I  A  G  G  Y  D  A  W  R  A  A  K  Q  N  A   D  1083 
actgatgcaacgctaatagcgggcggttatgacgcatggcgagcagccaagcagaacgctgat   
||.|||||.||.||.||.||.|||||||||||.||.|||||.||.||.||.|||||.||.||| 
ACCGATGCCACCCTGATTGCAGGCGGTTATGATGCCTGGCGTGCCGCAAAACAGAATGCCGAT  
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